10-Q

0000950170-23-040621.txt : 20230809 0000950170-23-040621.hdr.sgml : 20230809 20230809161745 ACCESSION NUMBER: 0000950170-23-040621 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINOVA INC CENTRAL INDEX KEY: 0001226616 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330927979 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33185 FILM NUMBER: 231155426 BUSINESS ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-373-1500 MAIL ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE STREET 2: SUITE 300 CITY: LA JOLLA STATE: CA ZIP: 92037 10-Q 1 mnov-20230630.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED June 30, 2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-33185

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)


Delaware		33-0927979
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

4275 Executive Square, Suite 300 La Jolla, CA		92037
(Address of Principal Executive Offices)		(Zip Code)

(858) 373-1500

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:


Common Stock, $0.001 par value	MNOV	The Nasdaq Stock Market LLC
(Title of each class)	(Trading symbol(s))	(Name of each exchange on which registered)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:


Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 7, 2023, the registrant had 49,046,246 shares of Common Stock ($0.001 par value) outstanding.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q, in particular "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations," and the information incorporated by reference herein contains “forward-looking statements”. The forward-looking statements are contained principally in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” but are also contained elsewhere in this report. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or the negative version of these words and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those described in "Risk Factors" and elsewhere in this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our beliefs and assumptions only as of the date of this report. Considering the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should read this report completely and with the understanding that our actual future results may be materially different from what we expect.

The following factors are among those that may cause actual results to differ materially from our forward-looking statements:

•

Inability to raise additional capital if needed;

•

Inability to generate revenues from product sales to continue business operations;

•

Inability to develop and commercialize our product candidates;

•

Failure or delay in completing clinical trials or obtaining Food and Drug Administration or foreign regulatory approval for our product candidates in a timely manner;

•

Unsuccessful clinical trials stemming from clinical trial designs, failure to enroll a sufficient number of patients, undesirable side effects and other safety concerns;

•

Inability to demonstrate sufficient efficacy of product candidates;

•

Reliance on the success of our MN-166 (ibudilast) and MN-001 (tipelukast) product candidates;

•

Delays in commencement or completion of clinical trials or suspension or termination of clinical trials;

•

Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;

•

Competitors may develop products rendering our product candidates obsolete and noncompetitive;

•

The widespread outbreak of an illness or any other communicable disease, such as COVID-19, which would lead key employees becoming ill for a period of time;

•

Inability to successfully attract partners and enter into collaborations on acceptable terms;

•

Dependence on third parties to conduct clinical trials and to manufacture product candidates;

•

Dependence on third parties to market and distribute products;

•

Our product candidates, if approved, may not gain market acceptance or obtain adequate coverage for third party reimbursement;

•

Disputes or other developments concerning our intellectual property rights;

•

Actual and anticipated fluctuations in our quarterly or annual operating results;

•

Price and volume fluctuations in the overall stock markets;

•

Litigation or public concern about the safety of our potential products;

•

International trade or foreign exchange restrictions, increased tariffs, foreign currency exchange;

•

High quality material for our products may become difficult to obtain or expensive;

•

Strict government regulations on our business;

•

Regulations governing the production or marketing of our product candidates;

•

Loss of, or inability to attract, key personnel; and

•

Economic, political, foreign exchange and other risks associated with international operations.

MEDICINOVA, INC.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION		5

ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	16
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	20
ITEM 4.	CONTROLS AND PROCEDURES	20

PART II. OTHER INFORMATION		21

ITEM 1.	LEGAL PROCEEDINGS	21
ITEM 1A.	RISK FACTORS	21
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	21
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	21
ITEM 4.	MINE SAFETY DISCLOSURES	21
ITEM 5.	OTHER INFORMATION	21
ITEM 6.	EXHIBITS	22

SIGNATURES		23

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	June 30,			December 31,
	2023			2022
Assets
Current assets:
Cash and cash equivalents	$	52,876,271		$	18,505,493
Prepaid expenses and other current assets		645,464			499,403
Investments		—			39,982,213
Total current assets		53,521,735			58,987,109
Goodwill		9,600,240			9,600,240
In-process research and development		4,800,000			4,800,000
Property and equipment, net		54,562			45,269
Right-of-use asset		669,314			629,495
Other non-current assets		72,791			92,792
Total assets	$	68,718,642		$	74,154,905
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	548,221		$	424,646
Accrued liabilities and other current liabilities		2,071,738			2,605,308
Operating lease liability		201,277			157,505
Total current liabilities		2,821,236			3,187,459
Deferred tax liability		201,792			201,792
Other non-current liabilities		519,685			523,619
Total liabilities		3,542,713			3,912,870
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 49,046,246 and 49,046,246 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		49,046			49,046
Additional paid-in capital		478,167,424			477,438,451
Accumulated other comprehensive loss		(121,040	)		(115,285	)
Accumulated deficit		(412,919,501	)		(407,130,177	)
Total stockholders’ equity		65,175,929			70,242,035
Total liabilities and stockholders' equity	$	68,718,642		$	74,154,905

See accompanying notes.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)


	Three months ended						Six months ended
	June 30,						June 30,
	2023			2022			2023			2022
Operating expenses:
Research, development and patents	$	1,735,735		$	2,564,969			3,212,411			4,676,965
General and administrative		1,564,295			1,524,966			3,050,862			2,822,982
Total operating expenses		3,300,030			4,089,935			6,263,273			7,499,947
Operating loss		(3,300,030	)		(4,089,935	)		(6,263,273	)		(7,499,947	)
Interest income		451,420			91,275			960,466			128,614
Other expense		(23,210	)		(30,338	)		(486,517	)		(44,082	)
Net loss applicable to common stockholders	$	(2,871,820	)	$	(4,028,998	)	$	(5,789,324	)	$	(7,415,415	)
Basic and diluted net loss per common share	$	(0.06	)	$	(0.08	)	$	(0.12	)	$	(0.15	)
Shares used to compute basic and diluted net loss per common share		49,046,246			49,045,587			49,046,246			49,044,423
Net loss applicable to common stockholders	$	(2,871,820	)	$	(4,028,998	)	$	(5,789,324	)	$	(7,415,415	)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments		(4,213	)		(11,980	)		(5,755	)		(19,415	)
Comprehensive loss	$	(2,876,033	)	$	(4,040,978	)	$	(5,795,079	)	$	(7,434,830	)

See accompanying notes.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


	Six Months Ended June 30, 2023
	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Shares		Amount		capital		loss			deficit			equity
Balance at December 31, 2022		49,046,246	$	49,046	$	477,438,451	$	(115,285	)	$	(407,130,177	)	$	70,242,035
Share-based compensation	—		—			403,263	—			—				403,263
Net loss	—		—		—		—				(2,917,504	)		(2,917,504	)
Foreign currency translation adjustments	—		—		—			(1,542	)	—				(1,542	)
Balance at March 31, 2023		49,046,246		49,046		477,841,714		(116,827	)		(410,047,681	)		67,726,252
Share-based compensation		—		—		325,710		—			—			325,710
Net loss		—		—		—		—			(2,871,820	)		(2,871,820	)
Foreign currency translation adjustments		—		—		—		(4,213	)		—			(4,213	)
Balance at June 30, 2023		49,046,246	$	49,046	$	478,167,424	$	(121,040	)	$	(412,919,501	)	$	65,175,929


	Six Months Ended June 30, 2022
	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Shares		Amount		capital		loss			deficit			equity
Balance at December 31, 2021		49,043,246	$	49,043	$	476,788,012	$	(98,877	)	$	(393,061,094	)	$	83,677,084
Share-based compensation	—		—			81,053	—			—				81,053
Net loss	—		—		—		—				(3,386,417	)		(3,386,417	)
Foreign currency translation adjustments	—		—		—			(7,435	)	—				(7,435	)
Balance at March 31, 2022		49,043,246		49,043		476,869,065		(106,312	)		(396,447,511	)		80,364,285
Share-based compensation		—		—		274,502		—			—			274,502
Issuance of common stock for option exercises		3,000		3		7,917	—			—				7,920
Net loss		—		—		—		—			(4,028,998	)		(4,028,998	)
Foreign currency translation adjustments		—		—		—		(11,980	)		—			(11,980	)
Balance at June 30, 2022		49,046,246	$	49,046	$	477,151,484	$	(118,292	)	$	(400,476,509	)	$	76,605,729

See accompanying notes.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six months ended
	June 30,
	2023			2022
Operating activities:
Net loss	$	(5,789,324	)	$	(7,415,415	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation		728,973			355,555
Depreciation and amortization		9,100			8,917
Loss on disposal of investments		102,513			—
Change in carrying amount of right-of-use asset		98,643			101,394
Changes in assets and liabilities:
Prepaid expenses and other assets		(182,896	)		(135,311	)
Accounts payable, accrued liabilities and other liabilities		(428,876	)		956,112
Operating lease liabilities		(98,562	)		(55,620	)
Net cash used in operating activities		(5,560,429	)		(6,184,368	)
Investing activities:
Proceeds from disposal of investments		39,929,015			—
Acquisitions of property and equipment		(18,577	)		—
Net cash provided by investing activities		39,910,438			—
Financing activities:
Proceeds from issuance of common stock and exercise of common stock options		—			7,920
Net cash provided by financing activities		—			7,920
Effect of exchange rate changes on cash and cash equivalents		20,769			(21,238	)
Net change in cash and cash equivalents		34,370,778			(6,197,686	)
Cash and cash equivalents, beginning of period		18,505,493			71,430,954
Cash and cash equivalents, end of period	$	52,876,271		$	65,233,268
Supplemental disclosure of non-cash investing activities:
Right-of-use asset obtained in exchange for operating lease liability	$	139,001		$	—

See accompanying notes.

MEDICINOVA, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Interim Financial Information

Organization and Business

MediciNova, Inc. (the “Company” or “MediciNova”) was incorporated in the state of Delaware in September 2000. The Company’s common stock is listed in both the United States and Japan and trades on the Nasdaq Global Market and the Standard Market of the Tokyo Stock Exchange. The Company is a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs with a commercial focus on the United States market. The Company’s current strategy is to focus its development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Amendment No. 1 to Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2022 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by GAAP for complete financial statements.

Principles of Consolidation

The consolidated financial statements include the accounts of MediciNova, Inc. and its wholly owned subsidiaries, MediciNova Japan, Inc., MediciNova (Europe) Limited, MediciNova Europe GmbH and Avigen Inc. The financial statements of the Company’s foreign subsidiaries are measured using their local currency as the functional currency. The resulting translation adjustments are recorded as a component of other comprehensive income or loss. Intercompany transaction gains or losses at each period end are included as translation adjustments and recorded within other comprehensive income or loss. All intercompany transactions and balances are eliminated in consolidation.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment – the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and other highly liquid investments including money market accounts, with original maturities of three months or less from the date of purchase.

Investments

Investments purchased with an original maturity of greater than three months are classified as investments. Investments are stated at fair value and are classified as current or non-current based on the nature of the securities as well as their stated maturities.

Research, Development and Patents

Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, facilities and depreciation, research and development supplies, licenses and outside services. Such research and development costs totaled $1.6 million and $2.5 million for the three months ended June 30, 2023 and 2022, respectively, and $3.0 million and $4.5 million for the six months ended June 30, 2023 and 2022, respectively.

Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. The Company includes all external costs related to the filing of patents in Research, Development and Patents expenses. Such patent-related expenses totaled $0.1 million for the three months ended June 30, 2023 and 2022, respectively, and $0.2 million for the six months ended June 30, 2023 and 2022, respectively.

Clinical Trial Accruals and Prepaid Expenses

Costs for preclinical studies, clinical studies and manufacturing activities are recognized as research and development expenses based on an evaluation of the progress by Company vendors towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to the Company by such vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. The Company’s estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.

Leases

The Company determines if an arrangement is a lease at inception and if so, determines whether the lease qualifies as an operating or finance lease. The Company does not recognize right-of-use assets and lease liabilities for leases with a term of 12 months or less and does not separate non-lease components from lease components. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease expense is recognized on a straight-line basis over the lease term and is included in general and administrative expenses. As most of the Company’s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments— Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The ASU introduced a new credit loss methodology, the Current Expected Credit Losses (“CECL”) methodology, which requires earlier recognition of credit losses, while also providing additional transparency about credit risk. The CECL methodology utilizes a lifetime “expected credit loss” measurement objective for the recognition of credit losses for loans, held-to maturity debt securities, trade receivables and other receivables measured at amortized cost at the time the financial asset is originated or acquired. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard was effective for the Company on January 1, 2023. There was no impact on the consolidated financial statements upon adoption of this standard on January 1, 2023.

2. Revenue Recognition

Revenue Recognition Policy

Revenues historically have consisted mainly of research and development services performed under a contract with a customer. The Company evaluates the separate performance obligation(s) under each contract, allocates the transaction price to each performance obligation considering the estimated stand-alone selling prices of the services and recognizes revenue upon the satisfaction of such obligations at a point in time or over time dependent on the satisfaction of one of the following criteria: (1) the customer simultaneously receives and consumes the economic benefits provided by the vendor’s performance (2) the vendor creates or enhances an asset controlled by the customer (3) the vendor’s performance does not create an asset for which the vendor has an alternative use, and (4) the vendor has an enforceable right to payment for performance completed to date.

3. Fair Value Measurements

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:


Level 1:	Observable inputs such as quoted prices in active markets;

Level 2:	Inputs are quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active near the measurement date; and

Level 3:	Unobservable inputs due to little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amount and approximate fair value of financial instruments as of June 30, 2023 and December 31, 2022, were as follows:


	June 30, 2023				December 31, 2022
	Carrying Amount		Fair Value		Carrying Amount		Fair Value		Valuation Inputs
Cash and cash equivalents:
Money market funds	$	762,116	$	762,116	$	704,882	$	704,882	Level 1
Investments
Bank certificates of deposit		—		—	$	39,982,213	$	39,982,213	Level 2

Short-term investments consisting of bank certificates of deposit with an original purchased maturity greater than three months are classified as held-to-maturity and are stated at amortized cost, which approximates fair value due to the short-term maturities and market rates of interest of these instruments.

4. Commitments and Contingencies

Lease Commitments

The Company has operating leases primarily for real estate in the United States and Japan. The United States lease is for the Company’s headquarters in San Diego and has a term of five years ending January 31, 2027, with annual escalations. The Company’s lease in Tokyo, Japan has a term of two years ending May 2025 with an auto-renewal, two-year extension. The real estate operating leases are included in "Right-of-use asset” on the Company's balance sheet and represents the Company’s right to use the underlying assets for the lease term. The Company’s obligation to make lease payments are included in "Operating lease liability" and "Other non-current liabilities" on the Company's balance sheet.

Information related to the Company’s right-of-use assets and related lease liabilities are as follows:


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Cash paid for operating lease liabilities	$	64,024	$	34,283	$	127,391	$	68,565
Operating lease costs		64,011		65,170		128,022		115,222


	June 30,			December 31,
	2023			2022
Current operating lease liabilities	$	201,277		$	157,505
Non-current operating lease liabilities		519,685			523,619
Total operating lease liabilities	$	720,962		$	681,124
Weighted-average remaining lease term (in years)		3.28			3.90
Weighted-average discount rate		9.3	%		9.8	%


Maturities of operating lease liabilities as of June 30, 2023 were as follows:
2023 (remaining six months)	$	128,491
2024		263,811
2025		228,686
2026		206,483
2027		17,269
Thereafter		—
Total minimum payments		844,740
Less imputed interest		(123,778	)
Total lease liabilities	$	720,962

Product Liability

The Company’s business exposes it to liability risks from its potential drug products. A successful product liability claim or series of claims brought against the Company could result in the payment of significant amounts of money and divert management’s attention from running the business. The Company may not be able to maintain insurance on acceptable terms, or the insurance may not provide adequate protection in the case of a product liability claim. To the extent that product liability insurance, if available, does not cover potential claims, the Company would be required to self-insure the risks associated with such claims. The Company believes it carries reasonably adequate insurance for product liability.

License and Research Agreements

The Company has entered into in-licensing agreements with various pharmaceutical companies. Under the terms of these agreements, the Company has received licenses to research, know-how and technology claimed in specified patents or patent applications. Under these license agreements, the Company is generally required to make upfront payments and additional payments upon the achievement of milestones and/or royalties on future sales of products until the later of the expiration of the applicable patent or the applicable last date of market exclusivity after the first commercial sale, on a country-by-country basis.

No milestone payments have been made under these agreements during the three and six months ended June 30, 2023 and 2022. For products currently in development, future potential milestone payments based on product development of MN-166 (ibudilast) and MN-001 (tipelukast) are $10 million as of June 30, 2023. For all other products, future potential milestone payments related to development milestones and commercialization milestones totaled $16.5 million as of June 30, 2023. There are no minimum royalties required under any of the license agreements. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments are dependent upon the progress of the Company’s product development programs.

Legal Proceedings

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not aware of any such proceedings or claims that it believes will have, individually or in aggregate, a material adverse effect on its business, financial condition or results of operations.

5. Stock-based Compensation

Stock Incentive Plans

In June 2013, the Company adopted the 2013 Equity Incentive Plan, or 2013 Plan, under which the Company granted equity-based awards, including stock options, stock appreciation rights, restricted stock, and restricted stock units to individuals who were then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. A total of 8,700,000 shares of common stock were reserved for issuance under the 2013 Plan. In addition, “returning shares” that may become available from time to time were added back to the plan. “Returning shares” included shares that were subject to outstanding awards granted under the Company's prior 2004 Equity Incentive Plan that expired or terminated prior to exercise or settlement, were forfeited because of the failure to vest, were repurchased, or were withheld to satisfy tax withholding or purchase price obligations in connection with such awards. Although the Company no longer grants equity awards under the 2013 Plan, all outstanding stock awards granted under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the 2013 Plan.

In June 2023, the Company adopted the 2023 Equity Incentive Plan, or 2023 Plan, under which the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The 2023 Plan is the successor to the 2013 Plan. A total of 8,700,000 shares of common stock are reserved for issuance under the 2023 Plan. The number of shares of common stock that may be issued under the 2023 Plan is equal to the sum of (a) shares subject to awards granted under the 2013 Plan that were outstanding upon expiration of the 2013 Plan and are subsequently forfeited, expire or lapse unexercised or unsettled and shares issued pursuant to awards granted under the 2013 Plan that were outstanding upon expiration of the 2013 Plan and are subsequently forfeited to or reacquired by the Company and (b) shares reserved under the 2013 Plan that were not issued or subject to outstanding awards under the 2013 Plan upon expiration of the 2013 Plan. While a maximum of 9,934,567 shares may become available for issuance under the 2023 Plan from the 2013 Plan, since this figure assumes that all awards outstanding under the 2013 Plan upon expiration of the 2013 Plan will be forfeited, the Company expects the actual number of shares added to the 2023 Plan to be less. In general, to the extent that awards under the 2023 Plan are forfeited, cancelled or expire for any reason before being exercised or settled in full, the shares subject to such awards will again become available for issuance under the 2023 Plan. If stock appreciation rights are exercised or restricted stock units are settled, then only the number of shares (if any) actually issued to the participant will reduce the number of shares available under the 2023 Plan. If restricted shares or shares issued upon exercise of options are reacquired by the Company pursuant to a forfeiture provision, repurchase right or for any other reason, then such shares shall again become available for issuance under the 2023 Plan. Shares withheld to pay the exercise price of options or satisfy tax withholding obligations related to an award shall again become available for issuance under the 2023 Plan. Further, to the extent an award is settled in cash rather than shares, the cash settlement shall not reduce the number of shares available for issuance under the 2023 Plan.

As of June 30, 2023, 1,648,151 shares remain available for future grants under the 2023 Plan.

Certain of the employee stock options granted contain performance conditions, the vesting of which is based on a determination made by the compensation committee followed by an approval of the board of directors as to the achievement of certain corporate objectives at the end of the performance period. The grant date of such awards is the date on which the board of directors makes its determination. For periods preceding the grant date, the expense related to these awards is measured based on their fair value at each reporting date. The estimated fair value of the performance awards granted and the resulting expense is based upon a certain level of achievement of the corporate objectives and other assumptions in determining fair value. The amount of expense ultimately recognized upon the grant date at completion of the performance period could change from the estimate as a result of various factors, including the level of achievement of the corporate objectives, changes in the assumptions used in the Black-Scholes model in determining fair value or fluctuations in the Company’s stock price during the performance period. As of June 30, 2023, there were a total of 730,350 shares underlying performance options that were subject to vesting based on achievement of corporate objectives for 2023.

Stock Options

Options granted under the 2023 Plan and the 2013 Plan have terms of ten years from the date of grant unless earlier terminated and generally vest over a one or four year period. The exercise price of all options granted through June 30, 2023 and 2022, was equal to the fair market value of the Company’s common stock on the date of grant.

A summary of stock option activity and related information as of June 30, 2023 is as follows:


	Number of Option Shares			Weighted Average Exercise Price
Outstanding at December 31, 2022		7,985,250		$	5.55
Granted		770,350			2.39
Exercised		—			—
Cancelled		(469,184	)		3.99
Outstanding at June 30, 2023		8,286,416		$	5.34
Exercisable at June 30, 2023		7,492,898		$	5.65

Compensation Expense

Stock-based compensation expense for stock option awards are reflected in total operating expenses for each respective period.

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively:


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Research, development and patents	$	120,037	$	96,364	$	261,155	$	138,871
General and administrative		205,673		178,138		467,818		216,684
Total stock-based compensation expense	$	325,710	$	274,502	$	728,973	$	355,555

The Company uses the Black-Scholes valuation model for determining the estimated fair value for stock-based awards granted to employees and considers management’s current expectations of the achievement of the performance objectives for the year. The following table provides the assumptions used in the Black-Scholes valuation model used to estimate the fair value of options granted during the six months ended June 30, 2023 and 2022, and to estimate the fair value of performance-based stock options as of June 30, 2023 and 2022.


	Six months ended
	June 30, 2023	June 30, 2022
Stock Option assumptions:
Risk-free interest rate	3.59 - 4.13%	2.42 - 3.01%
Expected volatility of common stock	75.81 - 77.96%	75.13 - 78.45%
Dividend yield	0.00%	0.00%
Expected term (in years)	5.13 - 5.38	5.12 - 5.77

As of June 30, 2023, there was $0.7 million of unamortized compensation cost related to unvested stock option awards which is expected to be recognized over a remaining weighted-average vesting period of 0.6 years, on a straight-line basis. Such compensation cost will ultimately be adjusted based upon actual performance compared to the corporate objectives as described above.

The weighted-average fair value of each stock option granted during the six months ended June 30, 2023 and 2022, estimated as of the grant date using the Black-Scholes option valuation model, was $1.60 and $1.47, respectively.

6. Stockholders’ Equity

At-The-Market Issuance Sales Agreements and Private Placement Transactions

On August 23, 2019, the Company entered into an at the market issuance sales agreement, which was amended on August 26, 2022 (as amended, the “ATM Agreement”) with B. Riley FBR, Inc. (B. Riley FBR) pursuant to which the Company may sell common stock through B. Riley FBR from time to time up to an aggregate offering price of $75.0 million. Sales of the Company’s common stock through B. Riley FBR, if any, will be made by any method that is deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on Nasdaq, on any other existing trading market for the common stock or through a market maker. B. Riley FBR may also sell the common stock in privately negotiated transactions, subject to the Company’s prior approval. The Company agreed to pay B. Riley FBR an aggregate commission rate of up to 3.5% of the gross proceeds of any common stock sold under this agreement. Proceeds from sales of common stock will depend on the number of shares of common stock sold to B. Riley FBR and the per share purchase price of each transaction.

No shares of common stock were sold under the ATM Agreement in the three and six months ended June 30, 2023 and 2022, respectively.

7. Net Loss Per Share

The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option agreements. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.

Potentially dilutive outstanding stock options excluded from diluted net loss per common share due to their anti-dilutive effect totaled 8,286,416 shares for both the three and six months ended June 30, 2023 and 8,013,920 shares for both the three and six months ended June 30, 2022.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2022 included in our Annual Report on Form 10-K, as amended, as filed with the Securities and Exchange Commission (SEC) on March 28, 2023 (Annual Report on Form 10-K, as amended). Past operating results are not necessarily indicative of results that may occur in future periods.

This Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties, many of which are beyond our control. Our actual results may differ from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II of this Quarterly Report on Form 10-Q under the caption “Item 1A. Risk Factors” and under the caption “Item 1A. Risk Factors” in our Annual Report on Form 10-K, as amended. The differences may be material. Forward-looking statements discuss matters that are not historical facts. Forward-looking statements include, but are not limited to, statements regarding our plans, strategies, objectives, product development programs, clinical trials, industry, financial condition, liquidity and capital resources, future performance and other statements that are not historical facts. Such forward-looking statements include statements preceded by, followed by or that otherwise include the words “may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “estimate,” “anticipate,” “predict,” “potential,” “plan” or similar words. For such statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You should not rely unduly on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Overview

We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). Our pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. We were incorporated in Delaware in September 2000.

We have incurred significant net losses since our inception. As of June 30, 2023, from inception, our accumulated deficit was $412.9 million. We expect to incur substantial net losses for the next several years as we continue to develop certain of our existing product development programs, and over the long-term if we expand our research and development programs and acquire or in-license products, technologies or businesses that are complementary to our own.

Our goal is to build a sustainable biopharmaceutical business through the successful development of differentiated products for the treatment of serious diseases with unmet medical needs in high-value therapeutic areas. Key elements of our strategy are as follows:

•

Pursue the development of MN-166 (ibudilast) for multiple potential indications with the support of non-dilutive financings.

We intend to advance our diverse MN-166 (ibudilast) program through a combination of investigator-sponsored clinical trials, trials funded through government grants or other grants, and trials funded by us. We intend to pursue additional strategic alliances to help support further clinical development of MN-166 (ibudilast).

•

Pursue the development of MN-001 (tipelukast) for fibrotic and other diseases.

We intend to advance development of MN-001 (tipelukast) through a variety of means, which may include investigator-sponsored trials with or without grant funding as well as trials funded by us.

•

Consider strategic partnerships with one or more leading pharmaceutical companies to complete product development and successfully commercialize our products.

We develop and maintain relationships with pharmaceutical companies that are therapeutic category leaders. We intend to discuss strategic alliances with leading pharmaceutical companies who seek product candidates, such as MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine), and MN-029 (denibulin), which could support our clinical development and product commercialization.

Impact of COVID-19 and the Macroeconomic Environment on Our Business

The ongoing COVID-19 pandemic has resulted in significant national and global economic disruption and has, and may continue to adversely affect our business. To date, we have experienced certain adverse effects on our business as well as been provided certain opportunities as a result of the pandemic. The pandemic caused a decrease in the number of patient visits at some clinical trial sites which we believe resulted in slower enrollment in our clinical trials than would have occurred without the pandemic. However, we have seen an increase in the number of patient visits compared to earlier in the pandemic and we continue to enroll patients in clinical trials. Throughout the pandemic, we have continued with routine clinical trial activities including executing new clinical trial agreements, negotiating budgets, institutional review board (IRB) approvals, site training, and other activities related to the initiation of new clinical trials and the opening of new clinical trial sites, although some of these activities took longer to complete than what we experienced prior to the pandemic.

The pandemic created certain opportunities for our clinical development and we have pursued those opportunities. Following the outbreak of the pandemic, we designed a clinical trial to evaluate MN-166 (ibudilast) for prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19. In June 2022, we announced positive top-line results from this Phase 2 clinical trial in which MN-166 (ibudilast) demonstrated large improvements compared to placebo for all four clinical endpoints analyzed. Separately, in August 2022, we announced plans to participate in RECLAIM (Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial), a grant-funded clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19. In February 2023, we announced that Health Canada completed its review of the clinical trial application and granted authorization to commence the RECLAIM trial.

We continue to actively monitor the pandemic situation and the possible effects on our financial condition, liquidity, operations, suppliers, industry, and workforce. To the extent that there is a resurgence in the COVID-19 pandemic, or other health epidemics or outbreaks, our operations could be disrupted and our business adversely impacted.

Further, the COVID-19 pandemic and government responses to the pandemic has resulted in, and may continue to result in, downward pressure, extreme volatility, and disruptions in the capital and credit markets, reducing our ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact our short-term and long-term liquidity, access to capital markets, and our ability to operate in accordance with our operating plan, or at all.

In addition, we may be exposed to credit risk on deposits at financial institutions to the extent our account balances exceed the amount insured by the Federal Deposit Insurance Corporation. We are monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions.

Research, Development and Patents Expenses

Our research, development and patents expenses consist primarily of license fees related to our product candidates, salaries and related employee benefits, costs associated with the preclinical and clinical development of our product development programs, costs associated with non-clinical activities, such as regulatory expenses, and pre-commercialization manufacturing development activities. We use external service providers to manufacture our compounds to be used in clinical trials and for the majority of the services performed in connection with the preclinical and clinical development of our product candidates. Research, development and patents expenses include fees paid to consultants, contract research organizations, contract manufacturers and other external service providers, including professional fees and costs associated with legal services, patents and patent applications for our intellectual property. Internal research and development expenses include costs of compensation and other expenses for research and development personnel, supplies, facility costs and depreciation. Research, development and patents costs are expensed as incurred and we expect to increase such costs through the remainder of 2023 as our development programs progress.

The following table summarizes our research, development and patents expenses for the periods indicated for each of our product development programs. To the extent that costs, including personnel costs, are not tracked to a specific product development program, such costs are included in the “Other R&D expense” category (in thousands):


	Three months ended					Six months ended
	June 30,					June 30,
		2023		2022			2023		2022
External development expense:
MN-221	$	2	$	399		$	12	$	401
MN-166		872		1,538			1,694		3,155
MN-001		221		35			284		42
MN-029		1		1			2		2
Other		—		11			—		11
Total external development expense		1,096		1,984			1,992		3,611
R&D personnel expense		451		429			926		699
R&D facility and depreciation expense		16		11			26		26
Patent expenses		97		142			170		229
Other R&D expense (gain)		75		(1	)		98		112
Total research, development and patent expense	$	1,735	$	2,565		$	3,212	$	4,677

General and Administrative

Our general and administrative costs primarily consist of salaries, stock-based compensation, benefits and consulting and professional fees related to our administrative, finance, human resources, business development, legal, information systems support functions, facilities and insurance costs. General and administrative costs are expensed as incurred.

Our general and administrative expenses may increase in future periods if we are required to expand our infrastructure based on the success of our product development programs and in raising capital to support our product development programs or otherwise in connection with increased business development activities related to partnering, out-licensing or product disposition.

Critical Accounting Policies and Estimates

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which we have prepared in accordance with United States generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting periods. We base our estimates on historical experience and on various other factors and assumptions that we believe are reasonable under the circumstances at the time the estimates are made, the results of which form the basis for making judgments about the book values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We periodically evaluate our estimates and judgments in light of changes in circumstances, facts and experience.

Our critical accounting policies are those accounting principles generally accepted in the United States that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. For a description of our critical accounting policies, please see the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Use of Estimates” contained in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2022. There have not been any material changes to the critical accounting policies discussed therein during the six months ended June 30, 2023.

Results of Operations

Comparison of the three months ended June 30, 2023 and 2022

Research, Development and Patents Expenses

Research, development and patents expenses were $1.7 million and $2.6 million for the three months ended June 30, 2023 and 2022, respectively. The decrease of $0.9 million expense was primarily due to a decrease in MN-221 and MN-166 related manufacturing expenses, partially offset by increased MN-001 related expenses.

General and Administrative Expenses

General and administrative expenses were $1.6 million and $1.5 million for the three months ended June 30, 2023 and 2022, respectively. The increase of $0.1 million was primarily due to an increase in performance-based stock option expense.

Interest Income

Interest income was $0.5 million and $0.1 million for the three months ended June 30, 2023 and 2022, respectively. The increase of $0.4 million was primarily driven by higher interest rates on cash and bank certificates of deposit. Interest income consists of interest earned on our cash and cash equivalents and investments.

Comparison of the six months ended June 30, 2023 and 2022

Research, Development and Patents Expenses

Research, development and patents expenses were $3.2 million and $4.7 million for the six months ended June 30, 2023 and 2022, respectively. The decrease of $1.5 million expense was primarily due to a decrease in MN-221 and MN-166 related manufacturing expenses, partially offset by increased MN-001 related expenses.

General and Administrative Expenses

General and administrative expenses were $3.1 million and $2.8 million for the six months ended June 30, 2023 and 2022, respectively. The increase of $0.3 million was primarily due to an increase in performance-based stock option expense.

Interest Income

Interest income was $1.0 million and $0.1 million for the six months ended June 30, 2023 and 2022, respectively. The increase of $0.9 million was primarily driven by higher interest rates on cash and bank certificates of deposit. Interest income consists of interest earned on our cash and cash equivalents and investments.

Other Expense

Other expense was $0.5 million and $0.0 million for the six months ended June 30, 2023 and 2022, respectively. The increase of $0.5 million was primarily driven by penalties on early disposal of bank certificates of deposit.

Liquidity and Capital Resources

Net cash used in operating activities during the six months ended June 30, 2023 was $5.6 million compared to $6.2 million during the same period in 2022. The $0.6 million change is primarily related to the decreased net loss and changes in operating assets and liabilities for those periods.

Net cash provided by investing activities during the six months ended June 30, 2023 was $39.9 million compared to $0.0 million during the same period in 2022 due to the disposal of certificates of deposit.

As of June 30, 2023, we had available cash and cash equivalents of $52.9 million and working capital of $50.7 million. As of the date of this report, we believe we have working capital sufficient to fund operations at least through the end of 2024. However, we cannot provide assurance that these capital resources will be sufficient to conduct all our research and development programs as planned.

Equity Financing

On August 23, 2019, we entered into an at the market issuance sales agreement, which was amended on August 26, 2022 (as amended, the “ATM Agreement”) with B. Riley FBR, Inc. (B. Riley FBR) pursuant to which we may sell common stock through B. Riley FBR from time to time up to an aggregate offering price of $75.0 million. Sales of our common stock through B. Riley FBR, if any, will be made by any method that is deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on Nasdaq, on any other existing trading market for the common stock or through a market maker. B. Riley FBR may also sell the common stock in privately negotiated transactions, subject to our prior approval. We agreed to pay B. Riley FBR an aggregate commission rate of up to 3.5% of the gross proceeds of any common stock sold under this agreement. Proceeds from sales of common stock will depend on the number of shares of common stock sold to B. Riley FBR and the per share purchase price of each transaction.

No shares of common stock were sold under the ATM Agreement in the three and six months ended June 30, 2023 and 2022.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that the information required to be disclosed in our filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is (1) recorded, processed, summarized and reported within the time periods specified in SEC’s rules and forms, and (2) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our procedures or our internal controls will prevent or detect all errors and all fraud. Any internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of our controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We are not involved in any material legal proceedings as of June 30, 2023. We may become involved in various disputes and legal proceedings which arise in the ordinary course of business or otherwise. While it is not possible to accurately predict or determine the outcome of these matters, an adverse result in any litigation matter may occur which could harm our business.

ITEM 1A. RISK FACTORS.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2022, which are incorporated herein by reference and which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as amended, are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. We do not believe that there have been any material changes from the risk factors previously disclosed in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2022.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable

ITEM 5. OTHER INFORMATION.

None

ITEM 6. EXHIBITS.


Exhibit Number		Description

3.1		Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2012 (File No. 001-33185)).

3.2		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the SEC on April 25, 2019 (File No. 001-33185)).

31.1(1)		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2(1)		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1(1)*		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).

32.2(1)*		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).

101.INS(1)		Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

101.SCH(1)		Inline XBRL Taxonomy Extension Schema Document.

101.CAL(1)		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF(1)		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB(1)		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE(1)		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104(1)		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

(1)

Filed Herewith

The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of MediciNova, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	MEDICINOVA, INC.

Date: August 9, 2023	By:	/s/ YUICHI IWAKI
		Yuichi Iwaki, M.D., Ph.D.
		President and Chief Executive Officer
		(on behalf of the registrant and
		as the registrant’s Principal Executive Officer)

	By:	/s/ JASON KRUGER
		Jason Kruger
		Chief Financial Officer
		(on behalf of the registrant and
		as the registrant’s Principal Financial Officer)

EX-31.1 2 mnov-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

MEDICINOVA, INC.

Certification of the Principal Executive Officer Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Yuichi Iwaki, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 of MediciNova, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 9, 2023

By:		/s/ YUICHI IWAKI
		Yuichi Iwaki, M.D., Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 mnov-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

MEDICINOVA, INC.

Certification of the Principal Financial Officer Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Jason Kruger, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 of MediciNova, Inc.;

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 9, 2023

By:		/s/ JASON KRUGER
		Jason Kruger
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 mnov-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of MediciNova, Inc. (the “Company”) for the quarter ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yuichi Iwaki, as President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 9, 2023

By:		/s/ Yuichi Iwaki
		Yuichi Iwaki, M.D., Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and such certification is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 mnov-ex32_2.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of MediciNova, Inc. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jason Kruger, as Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 9, 2023

By:		/s/ JASON KRUGER
		Jason Kruger
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-101.PRE 6 mnov-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 7 mnov-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.CAL 8 mnov-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 9 mnov-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100060 - Disclosure - Interim Financial Information link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Interim Financial Information (Policies) link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Interim Financial Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Revenue Recognition - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Fair Value Measurements - Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Commitments and Contingencies - Schedule of Right-of-Use Assets and Related Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Summary of Stock Option Activity and Related Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Summary of Stock-based Compensation Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Net Loss Per Share - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 10 mnov-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address City Or Town Entity Address, City or Town Fair Value Disclosures [Abstract] Earnings Per Share [Abstract] Fair Value Inputs Level1 [Member] Level 1 Commercialization milestone. Commercialization Milestone [Member] Commercialization Milestone Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Dividend yield Lessee Operating Lease Discount Rate Weighted-average discount rate License Agreement Terms [Member] Licensing Agreements Amendment Flag Amendment Flag Gain (Loss) on Sale of Investments, Total Gain (Loss) on Sale of Investments Loss on disposal of investments Goodwill Goodwill Goodwill, Total Goodwill, Beginning Balance Goodwill, Ending Balance Operating Lease Right Of Use Asset Right-of-use asset Document Quarterly Report Document Quarterly Report Lessee Operating Lease Liability Undiscounted Excess Amount Less imputed interest Proceeds from disposal of investments. Proceeds From Disposal Of Investments Proceeds from disposal of investments Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash and Cash Equivalents Statement [Table] Statement [Table] Operating Lease Liability Noncurrent Non-current operating lease liabilities Annual increase in shares reserved for issuance as percentage of outstanding shares of common stock. Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Shares Of Common Stock Increase in shares reserved for issuance as percentage of outstanding shares Operating Lease Payments Cash paid for operating lease liabilities Stock Issued During Period Shares Employee Stock Purchase Plans Issuance of shares under an employee stock purchase plan (ESPP), shares Aggregate shares issued under ESPP Carrying amount as of the balance sheet date, which is the fair value of the acquired in-process technology, adjusted for any amortization recognized after market feasibility has been achieved and for any impairment charges. In Process Research And Development In-process research and development Common Stock Capital Shares Reserved For Future Issuance Common stock reserved for future issuance Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Stock Options, Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Employee Stock [Member] 2007 Employee Stock Purchase Plan Employee Stock Option [Member] Stock Option Operating Lease Weighted Average Remaining Lease Term1 Weighted-average remaining lease term (in years) Liabilities And Stockholders Equity Total liabilities and stockholders' equity Plan Name [Domain] Plan Name Stock issuance limit under employee stock purchase plan description. Stock Issuance Limit Under Employee Stock Purchase Plan Description Shares reserved, description Entity Incorporation State Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Sale Of Stock Name Of Transaction [Domain] Sale of Stock Liabilities Current Total current liabilities Lessee Operating Lease Liability Payments Due Year Three 2026 Fair Value Measurements Recurring [Member] Fair Value Measurements Recurring Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate Percentage of employee compensation for purchase of common stock under ESPP Clinical trial accruals and prepaid expenses policy. Clinical Trial Accruals And Prepaid Expenses Policy Policy [Text Block] Clinical Trial Accruals and Prepaid Expenses Entity Small Business Entity Small Business Revenue Recognition Milestone Method [Table] Revenue Recognition Milestone Method [Table] Assets Current Total current assets Product development. Product Development [Member] Product Development 2023 (remaining six months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Revenue Recognition Milestone Method [Line Items] Revenue Recognition Milestone Method [Line Items] Weighted Average Number Of Shares Outstanding Basic Shares used to compute basic net loss per common share Weighted Average Number of Shares Outstanding, Basic, Total City Area Code City Area Code Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Liabilities Total liabilities Private Placement [Member] Private Placement Document Period End Date Document Period End Date Payments Of Stock Issuance Costs Payments of stock issuance costs Common stock issuance costs Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Weighted-average fair value, per option Lessee Operating Lease Renewal Term Operating lease, auto-renewal term Range [Axis] Statistical Measurement Interest Income Other Interest income Related Party Transactions By Related Party [Axis] Related Party Assets Total assets Earnings Per Share Diluted Diluted net loss per common share Earnings Per Share, Diluted, Total 2019 at-the-market issuance sales agreement Two Thousand Nineteen At Market Issuance Sales Agreement [Member] 2019 at market issuance sales agreement Entity Address Postal Zip Code Entity Address, Postal Zip Code Document Fiscal Period Focus Document Fiscal Period Focus Certificates Of Deposit [Member] Bank Certificates of Deposit Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Repurchase Agreement Counterparty Name [Domain] Counterparty Name Operating Lease Liability Total lease liabilities Total operating lease liabilities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities, Total Statement Of Financial Position [Abstract] Entity File Number Entity File Number Statement Of Cash Flows [Abstract] Lessee Operating Lease Liability Payments Due After Year Five Thereafter Segment Geographical [Domain] Geographical Range [Member] Statistical Measurement Statement Of Stockholders Equity [Abstract] Subsidiary Sale Of Stock [Axis] Sale of Stock Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Common stock fair market value, percentage Proceeds From Issuance Of Common Stock Gross proceeds Deferred Income Tax Liabilities Net Deferred tax liability Revenue From Contract With Customer [Text Block] Revenue Recognition Two thousand thirteen equity incentive plan. Two Thousand Thirteen Equity Incentive Plan [Member] 2013 Plan Weighted Average Number Of Diluted Shares Outstanding Shares used to compute diluted net loss per common share Weighted Average Number of Shares Outstanding, Diluted, Total General And Administrative Expense [Member] General and Administrative Research And Development Arrangement Contract To Perform For Others Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Current Fiscal Year End Date Current Fiscal Year End Date Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Other Assets Noncurrent Other non-current assets Entity Address Address Line1 Entity Address, Address Line One Quarterly Financial Information Disclosure [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental disclosure of non-cash investing activities: Investment Policy [Text Block] Investments Lease Expiration Date1 Operating lease expiration date Increase Decrease In Operating Lease Liability Operating lease liabilities Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Weighted Average Exercise Price, Cancelled Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Stock Issued During Period Shares New Issues Issuance of common stock in a private transaction, net of issuance costs, shares Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Equity [Abstract] Operating Income Loss Operating loss Related Party [Domain] Related Party Additional Paid In Capital Common Stock Additional paid-in capital Impact of the onging COVID-19 pandemic policy. Impact of COVID Nineteen Policy [Policy Text Block] Impact of COVID-19 on the Company’s Business Entity Filer Category Entity Filer Category Operating Expenses Total operating expenses Patents expense. Patents Expense Patent-related expenses Entity Current Reporting Status Entity Current Reporting Status Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Change in carrying amount of right of use asset. Change In Carrying Amount Of Right Of Use Asset Change in carrying amount of right-of-use asset Stockholders Equity Balance Balance Total stockholders’ equity Accumulated Other Comprehensive Income [Member] Accumulated other comprehensive loss Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Entity Tax Identification Number Entity Tax Identification Number Income Statement Location [Axis] Income Statement Location Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 49,046,246 and 49,046,246 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock Value Retained Earnings Accumulated Deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Statement Equity Components [Axis] Equity Components Cash And Cash Equivalents Policy [Text Block] Cash and Cash Equivalents Research and development and patents expense. Research And Development And Patents Expense [Member] Research, Development and Patents Entity Emerging Growth Company Entity Emerging Growth Company Operating Expenses [Abstract] Operating expenses: Revenue Recognition Policy [Text Block] Revenue Recognition Policy Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected term (in years) Expected volatility of common stock, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Document Transition Report Document Transition Report Depreciation Depletion And Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Employee stock purchase plan offering period. Employee Stock Purchase Plan Offering Period Employee stock purchase plan offering period Potential future milestone payments. Potential Future Milestone Payments Future potential milestone payments Sale Of Stock Price Per Share Share price per share Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Net Income Loss Net loss applicable to common stockholders Net loss applicable to common stockholders Net loss Fair Value Measurement Inputs Disclosure [Text Block] Fair Value Measurements Operating Lease Liability Current Current operating lease liabilities Operating lease liability Research, development and patents expense. Research Development And Patents Expense Research, development and patents Additional Paid In Capital [Member] Additional paid-in capital Entity Registrant Name Entity Registrant Name Accrued liabilities and other liabilities current. Accrued Liabilities And Other Liabilities Current Accrued liabilities and other current liabilities Total accrued liabilities and other current liabilities Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Cash And Cash Equivalents At Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Carrying Amount Cash and cash equivalents Earnings Per Share [Text Block] Net Loss Per Share Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options Share Based Compensation Non-cash stock-based compensation Share-Based Payment Arrangement, Noncash Expense, Total Property Plant And Equipment Net Property and equipment, net Property, Plant and Equipment, Net, Total Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Award Type Statement [Line Items] Statement [Line Items] Annual increase in shares reserved for issuance. Annual Increase In Shares Reserved For Issuance Increase in shares reserved for issuance Security12b Title Title of 12(b) Security Share-based compensation arrangement by share-based payment award, number of additional shares issued. Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Issued Shares issued under ESPP Further shares issued under ESPP Common Stock [Member] Common stock Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Options granted expiration term Net Cash Provided By Used In Operating Activities [Abstract] Operating activities: Equity Component [Domain] Equity Component Revenue From Contract With Customer Excluding Assessed Tax Revenues Entity Address State Or Province Entity Address, State or Province Lessee Operating Lease Liability Payments Due Year Four 2027 Statement Geographical [Axis] Geographical Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Net change in cash and cash equivalents Document Type Document Type Percentage of commission on gross proceeds from sale of common stock, maximum. Percentage Of Commission On Gross Proceeds From Sale Of Common Stock Maximum Sales commission as a percentage of gross proceeds UNITED STATES U.S Entity Shell Company Entity Shell Company Allocated Share Based Compensation Expense Total stock-based compensation expense Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Security Exchange Name Security Exchange Name Revenue From Contract With Customer [Abstract] Revenue Recognition [Abstract] Net Cash Provided By Used In Operating Activities Net cash used in operating activities Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Unamortized compensation cost, vesting period Research development and patents expense. Research Development And Patents Expense Policy [Text Block] Research Development and Patents Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive loss, net of tax: Commitments And Contingencies Disclosure [Abstract] Operating Lease Cost Operating lease costs Lessee Operating Lease Liability Maturity Table [Text Block] Schedule of Maturities of Operating Lease Liabilities Consolidation Policy [Text Block] Principles of Consolidation Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Stock Option Activity and Related Information New Accounting Pronouncements Policy Policy [Text Block] Recently Issued Accounting Pronouncements Common Stock Shares Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Fair Value Inputs Level2 [Member] Level 2 Net Cash Provided By Used In Investing Activities [Abstract] Investing activities: Commitments And Contingencies Commitments and contingencies (Note 4) Common Stock Shares Issued Common stock, shares issued Minimum [Member] Minimum Common Stock Shares Subscriptions Stock purchase agreement, aggregate amount of common stock agreed to be purchased Risk-free interest rate, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Lessee Leases Policy [Text Block] Leases Weighted Average Exercise Price, Exercisable at June 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Stockholders Equity [Abstract] Stockholders’ equity: Counterparty Name [Axis] Counterparty Name Entity Address Address Line2 Entity Address, Address Line Two Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Award Type [Axis] Award Type Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Unamortized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Loss Contingencies [Table] Loss Contingencies [Table] Other Nonoperating Income Expense Other expense Other Nonoperating Income (Expense), Total Research And Development Expense Research and development costs Research and Development Expense, Total Research and development expense Lessee Operating Lease Liability Payments Due Total minimum payments Lessee Operating Lease Term Of Contract Operating lease term Entity Central Index Key Entity Central Index Key Short-Term Investments, Total Short-Term Investments Investments Schedule of information related to right-of-use assets and related lease liabilities. Schedule Of Information Related To Right Of Use Assets And Related Lease Liabilities Table [Text Block] Schedule of Information Related to Right-of-Use Assets and Related Lease Liabilities 2023 Plan Two Thousand Twenty Three Equity Incentive Plan [Member] Two thousand twenty three equity incentive plan. Accounting Policies [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] Weighted-average assumptions for stock options and ESPP Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected volatility of common stock Lessee operating lease extended term of contract. Lessee Operating Lease Extended Term Of Contract Operating lease, extension term Fair Value By Measurement Frequency [Axis] Measurement Frequency Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares available for future grant Operating lease expiration date, month and year Operating Lease Expiration Date Month And Year Operating lease expiration date, month and year. Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-based Compensation General And Administrative Expense General and administrative General and Administrative Expense, Total Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Beginning Balance Risk-free interest rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Right Of Use Asset Obtained In Exchange For Operating Lease Liability Right-of-use asset obtained in exchange for operating lease liability Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Retained Earnings [Member] Accumulated deficit Money Market Funds [Member] Money Market Funds The net change during the reporting period in the aggregate amount of accounts payable, accrued expenses and other current liabilities. Increase Decrease In Accounts Payable Accrued Expenses And Other Current Liabilities Accounts payable, accrued liabilities and other liabilities Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Entity Interactive Data Current Entity Interactive Data Current Lessee Operating Lease Liability Payments Due Next Twelve Months 2024 Proceeds from issuance of common stock, exercise of common stock options. Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options Proceeds from issuance of common stock and exercise of common stock options Local Phone Number Local Phone Number Fair Value Assets Measured On Recurring Basis [Text Block] Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Stock option, vesting period Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Stock Options, Exercisable at June 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Lessee Operating Lease Existence Of Option To Extend Lessee, operating lease, existence of option to extend Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Stock Options, Granted Two thousand four plan. Two Thousand Four Plan [Member] 2004 Plan Other Liabilities Noncurrent Other non-current liabilities JAPAN Tokyo, Japan Income Statement Location [Domain] Income Statement Location Shares Outstanding Balance, shares Balance, shares Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets B. Riley FBR, Inc. B Riley F B R Inc [Member] B. Riley FBR Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Quarterly Financial Information [Text Block] Interim Financial Information Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Stock Options, Ending Balance Stock Options, Beginning Balance Document Fiscal Year Focus Document Fiscal Year Focus Lessee Operating Lease Liability Payments Due Year Two 2025 Earnings Per Share Basic Basic net loss per common share Earnings Per Share, Basic, Total Assets [Abstract] Assets Expected volatility of common stock, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Development milestone. Development Milestone [Member] Development Milestone Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Number of Option Shares Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholders’ Equity Profit Loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Assets Current [Abstract] Current assets: Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV Fair Value Measurement Frequency [Domain] Measurement Frequency Increase Decrease In Operating Capital [Abstract] Changes in assets and liabilities: Cover [Abstract] Lessee Operating Lease Liability Payments Due Year Five 2027 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of vested shares Liabilities Current [Abstract] Current liabilities: Maximum [Member] Maximum Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Stock-based Compensation Expense Net Cash Provided By Used In Investing Activities Net cash provided by investing activities Stock Issued During Period Shares Stock Options Exercised Issuance of common stock for option exercises, shares Stock Options, Exercised Use Of Estimates Use of Estimates At market issuance sales agreement. At Market Issuance Sales Agreement [Member] ATM Agreement Issuance of common stock for option exercises Stock Issued During Period, Value, Stock Options Exercised Segment Reporting Policy Policy [Text Block] Segment Reporting Common Stock Shares Authorized Common stock, shares authorized Trading Symbol Trading Symbol Genzyme corporation. Genzyme Corporation [Member] Genzyme Corporation Performance Shares [Member] Performance Options Comprehensive Income Net Of Tax Comprehensive loss Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate Accounts Payable Current Accounts payable Accounts Payable, Current, Total Plan Name [Axis] Plan Name Common Stock Par Or Stated Value Per Share Common stock, par value Kissei Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co Ltd [Member] Kissei Pharmaceutical Co., Ltd Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Exercise Price, Granted Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Potentially dilutive outstanding stock options excluded from diluted net loss per common share Cash And Cash Equivalents Fair Value Disclosure Fair Value XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2023	Aug. 07, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	MNOV
Entity Registrant Name	MEDICINOVA, INC.
Entity Central Index Key	0001226616
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		49,046,246
Entity Shell Company	false
Entity File Number	001-33185
Entity Tax Identification Number	33-0927979
Entity Address, Address Line One	4275 Executive Square
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	858
Local Phone Number	373-1500
Entity Current Reporting Status	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 52,876,271	$ 18,505,493
Prepaid expenses and other current assets	645,464	499,403
Investments		39,982,213
Total current assets	53,521,735	58,987,109
Goodwill	9,600,240	9,600,240
In-process research and development	4,800,000	4,800,000
Property and equipment, net	54,562	45,269
Right-of-use asset	669,314	629,495
Other non-current assets	72,791	92,792
Total assets	68,718,642	74,154,905
Current liabilities:
Accounts payable	548,221	424,646
Accrued liabilities and other current liabilities	2,071,738	2,605,308
Operating lease liability	201,277	157,505
Total current liabilities	2,821,236	3,187,459
Deferred tax liability	201,792	201,792
Other non-current liabilities	519,685	523,619
Total liabilities	3,542,713	3,912,870
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 49,046,246 and 49,046,246 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	49,046	49,046
Additional paid-in capital	478,167,424	477,438,451
Accumulated other comprehensive loss	(121,040)	(115,285)
Accumulated deficit	(412,919,501)	(407,130,177)
Total stockholders’ equity	65,175,929	70,242,035
Total liabilities and stockholders' equity	$ 68,718,642	$ 74,154,905

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	49,046,246	49,046,246
Common stock, shares outstanding	49,046,246	49,046,246

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research, development and patents	$ 1,735,735	$ 2,564,969	$ 3,212,411	$ 4,676,965
General and administrative	1,564,295	1,524,966	3,050,862	2,822,982
Total operating expenses	3,300,030	4,089,935	6,263,273	7,499,947
Operating loss	(3,300,030)	(4,089,935)	(6,263,273)	(7,499,947)
Interest income	451,420	91,275	960,466	128,614
Other expense	(23,210)	(30,338)	(486,517)	(44,082)
Net loss applicable to common stockholders	$ (2,871,820)	$ (4,028,998)	$ (5,789,324)	$ (7,415,415)
Basic net loss per common share	$ (0.06)	$ (0.08)	$ (0.12)	$ (0.15)
Diluted net loss per common share	$ (0.06)	$ (0.08)	$ (0.12)	$ (0.15)
Shares used to compute basic net loss per common share	49,046,246	49,045,587	49,046,246	49,044,423
Shares used to compute diluted net loss per common share	49,046,246	49,045,587	49,046,246	49,044,423
Net loss applicable to common stockholders	$ (2,871,820)	$ (4,028,998)	$ (5,789,324)	$ (7,415,415)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(4,213)	(11,980)	(5,755)	(19,415)
Comprehensive loss	$ (2,876,033)	$ (4,040,978)	$ (5,795,079)	$ (7,434,830)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Balance at Dec. 31, 2021	$ 83,677,084	$ 49,043	$ 476,788,012	$ (98,877)	$ (393,061,094)
Balance, shares at Dec. 31, 2021		49,043,246
Share-based compensation	81,053		81,053
Net loss	(3,386,417)				(3,386,417)
Foreign currency translation adjustments	(7,435)			(7,435)
Balance at Mar. 31, 2022	80,364,285	$ 49,043	476,869,065	(106,312)	(396,447,511)
Balance, shares at Mar. 31, 2022		49,043,246
Balance at Dec. 31, 2021	83,677,084	$ 49,043	476,788,012	(98,877)	(393,061,094)
Balance, shares at Dec. 31, 2021		49,043,246
Net loss	(7,415,415)
Foreign currency translation adjustments	(19,415)
Balance at Jun. 30, 2022	76,605,729	$ 49,046	477,151,484	(118,292)	(400,476,509)
Balance, shares at Jun. 30, 2022		49,046,246
Balance at Mar. 31, 2022	80,364,285	$ 49,043	476,869,065	(106,312)	(396,447,511)
Balance, shares at Mar. 31, 2022		49,043,246
Share-based compensation	274,502		274,502
Issuance of common stock for option exercises	7,920	$ 3	7,917
Issuance of common stock for option exercises, shares		3,000
Net loss	(4,028,998)			(4,028,998)
Foreign currency translation adjustments	(11,980)			(11,980)
Balance at Jun. 30, 2022	76,605,729	$ 49,046	477,151,484	(118,292)	(400,476,509)
Balance, shares at Jun. 30, 2022		49,046,246
Balance at Dec. 31, 2022	70,242,035	$ 49,046	477,438,451	(115,285)	(407,130,177)
Balance, shares at Dec. 31, 2022		49,046,246
Share-based compensation	403,263		403,263
Net loss	(2,917,504)				(2,917,504)
Foreign currency translation adjustments	(1,542)			(1,542)
Balance at Mar. 31, 2023	67,726,252	$ 49,046	477,841,714	(116,827)	(410,047,681)
Balance, shares at Mar. 31, 2023		49,046,246
Balance at Dec. 31, 2022	70,242,035	$ 49,046	477,438,451	(115,285)	(407,130,177)
Balance, shares at Dec. 31, 2022		49,046,246
Net loss	(5,789,324)
Foreign currency translation adjustments	(5,755)
Balance at Jun. 30, 2023	65,175,929	$ 49,046	478,167,424	(121,040)	(412,919,501)
Balance, shares at Jun. 30, 2023		49,046,246
Balance at Mar. 31, 2023	67,726,252	$ 49,046	477,841,714	(116,827)	(410,047,681)
Balance, shares at Mar. 31, 2023		49,046,246
Share-based compensation	325,710		325,710
Net loss	(2,871,820)				(2,871,820)
Foreign currency translation adjustments	(4,213)			(4,213)
Balance at Jun. 30, 2023	$ 65,175,929	$ 49,046	$ 478,167,424	$ (121,040)	$ (412,919,501)
Balance, shares at Jun. 30, 2023		49,046,246

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net loss	$ (5,789,324)	$ (7,415,415)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation	728,973	355,555
Depreciation and amortization	9,100	8,917
Loss on disposal of investments	102,513
Change in carrying amount of right-of-use asset	98,643	101,394
Changes in assets and liabilities:
Prepaid expenses and other assets	(182,896)	(135,311)
Accounts payable, accrued liabilities and other liabilities	(428,876)	956,112
Operating lease liabilities	(98,562)	(55,620)
Net cash used in operating activities	(5,560,429)	(6,184,368)
Investing activities:
Proceeds from disposal of investments	39,929,015
Acquisitions of property and equipment	(18,577)
Net cash provided by investing activities	39,910,438
Financing activities:
Proceeds from issuance of common stock and exercise of common stock options		7,920
Net Cash Provided by (Used in) Financing Activities, Total		7,920
Effect of exchange rate changes on cash and cash equivalents	20,769	(21,238)
Net change in cash and cash equivalents	34,370,778	(6,197,686)
Cash and cash equivalents, beginning of period	18,505,493	71,430,954
Cash and cash equivalents, end of period	52,876,271	$ 65,233,268
Supplemental disclosure of non-cash investing activities:
Right-of-use asset obtained in exchange for operating lease liability	$ 139,001

XML 17 R7.htm IDEA: XBRL DOCUMENT

Interim Financial Information

6 Months Ended

Jun. 30, 2023

Quarterly Financial Information Disclosure [Abstract]

Interim Financial Information

1. Interim Financial Information

Organization and Business

Basis of Presentation

Principles of Consolidation

Segment Reporting

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and other highly liquid investments including money market accounts, with original maturities of three months or less from the date of purchase.

Investments

Research, Development and Patents

Clinical Trial Accruals and Prepaid Expenses

Leases

Use of Estimates

Recently Issued Accounting Pronouncements

XML 18 R8.htm IDEA: XBRL DOCUMENT

Revenue Recognition

6 Months Ended

Jun. 30, 2023

Revenue From Contract With Customer [Abstract]

Revenue Recognition

2. Revenue Recognition

Revenue Recognition Policy

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

XML 19 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements


Level 1:	Observable inputs such as quoted prices in active markets;

Level 2:	Inputs are quoted prices for similar items in active markets or quoted prices for identical or similar items in markets that are not active near the measurement date; and

Level 3:	Unobservable inputs due to little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amount and approximate fair value of financial instruments as of June 30, 2023 and December 31, 2022, were as follows:


	June 30, 2023				December 31, 2022
	Carrying Amount		Fair Value		Carrying Amount		Fair Value		Valuation Inputs
Cash and cash equivalents:
Money market funds	$	762,116	$	762,116	$	704,882	$	704,882	Level 1
Investments
Bank certificates of deposit		—		—	$	39,982,213	$	39,982,213	Level 2

XML 20 R10.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

4. Commitments and Contingencies

Lease Commitments

Information related to the Company’s right-of-use assets and related lease liabilities are as follows:


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Cash paid for operating lease liabilities	$	64,024	$	34,283	$	127,391	$	68,565
Operating lease costs		64,011		65,170		128,022		115,222


	June 30,			December 31,
	2023			2022
Current operating lease liabilities	$	201,277		$	157,505
Non-current operating lease liabilities		519,685			523,619
Total operating lease liabilities	$	720,962		$	681,124
Weighted-average remaining lease term (in years)		3.28			3.90
Weighted-average discount rate		9.3	%		9.8	%


Maturities of operating lease liabilities as of June 30, 2023 were as follows:
2023 (remaining six months)	$	128,491
2024		263,811
2025		228,686
2026		206,483
2027		17,269
Thereafter		—
Total minimum payments		844,740
Less imputed interest		(123,778	)
Total lease liabilities	$	720,962

Product Liability

License and Research Agreements

Legal Proceedings

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

6 Months Ended

Jun. 30, 2023

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

5. Stock-based Compensation

Stock Incentive Plans

As of June 30, 2023, 1,648,151 shares remain available for future grants under the 2023 Plan.

Stock Options

A summary of stock option activity and related information as of June 30, 2023 is as follows:


	Number of Option Shares			Weighted Average Exercise Price
Outstanding at December 31, 2022		7,985,250		$	5.55
Granted		770,350			2.39
Exercised		—			—
Cancelled		(469,184	)		3.99
Outstanding at June 30, 2023		8,286,416		$	5.34
Exercisable at June 30, 2023		7,492,898		$	5.65

Compensation Expense

Stock-based compensation expense for stock option awards are reflected in total operating expenses for each respective period.

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively:


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Research, development and patents	$	120,037	$	96,364	$	261,155	$	138,871
General and administrative		205,673		178,138		467,818		216,684
Total stock-based compensation expense	$	325,710	$	274,502	$	728,973	$	355,555


	Six months ended
	June 30, 2023	June 30, 2022
Stock Option assumptions:
Risk-free interest rate	3.59 - 4.13%	2.42 - 3.01%
Expected volatility of common stock	75.81 - 77.96%	75.13 - 78.45%
Dividend yield	0.00%	0.00%
Expected term (in years)	5.13 - 5.38	5.12 - 5.77

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

Stockholders' Equity

6. Stockholders’ Equity

At-The-Market Issuance Sales Agreements and Private Placement Transactions

No shares of common stock were sold under the ATM Agreement in the three and six months ended June 30, 2023 and 2022, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Net Loss Per Share

7. Net Loss Per Share

XML 24 R14.htm IDEA: XBRL DOCUMENT

Interim Financial Information (Policies)	6 Months Ended
Interim Financial Information (Policies)	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Amendment No. 1 to Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2022 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by GAAP for complete financial statements.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of MediciNova, Inc. and its wholly owned subsidiaries, MediciNova Japan, Inc., MediciNova (Europe) Limited, MediciNova Europe GmbH and Avigen Inc. The financial statements of the Company’s foreign subsidiaries are measured using their local currency as the functional currency. The resulting translation adjustments are recorded as a component of other comprehensive income or loss. Intercompany transaction gains or losses at each period end are included as translation adjustments and recorded within other comprehensive income or loss. All intercompany transactions and balances are eliminated in consolidation.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment – the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and other highly liquid investments including money market accounts, with original maturities of three months or less from the date of purchase.
Investments	Investments Investments purchased with an original maturity of greater than three months are classified as investments. Investments are stated at fair value and are classified as current or non-current based on the nature of the securities as well as their stated maturities.
Research Development and Patents	Research, Development and Patents Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, facilities and depreciation, research and development supplies, licenses and outside services. Such research and development costs totaled $1.6 million and $2.5 million for the three months ended June 30, 2023 and 2022, respectively, and $3.0 million and $4.5 million for the six months ended June 30, 2023 and 2022, respectively. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. The Company includes all external costs related to the filing of patents in Research, Development and Patents expenses. Such patent-related expenses totaled $0.1 million for the three months ended June 30, 2023 and 2022, respectively, and $0.2 million for the six months ended June 30, 2023 and 2022, respectively.
Clinical Trial Accruals and Prepaid Expenses	Clinical Trial Accruals and Prepaid Expenses Costs for preclinical studies, clinical studies and manufacturing activities are recognized as research and development expenses based on an evaluation of the progress by Company vendors towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to the Company by such vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. The Company’s estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.
Leases	Leases The Company determines if an arrangement is a lease at inception and if so, determines whether the lease qualifies as an operating or finance lease. The Company does not recognize right-of-use assets and lease liabilities for leases with a term of 12 months or less and does not separate non-lease components from lease components. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease expense is recognized on a straight-line basis over the lease term and is included in general and administrative expenses. As most of the Company’s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments— Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The ASU introduced a new credit loss methodology, the Current Expected Credit Losses (“CECL”) methodology, which requires earlier recognition of credit losses, while also providing additional transparency about credit risk. The CECL methodology utilizes a lifetime “expected credit loss” measurement objective for the recognition of credit losses for loans, held-to maturity debt securities, trade receivables and other receivables measured at amortized cost at the time the financial asset is originated or acquired. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard was effective for the Company on January 1, 2023. There was no impact on the consolidated financial statements upon adoption of this standard on January 1, 2023.
Revenue Recognition Policy	Revenue Recognition Policy Revenues historically have consisted mainly of research and development services performed under a contract with a customer. The Company evaluates the separate performance obligation(s) under each contract, allocates the transaction price to each performance obligation considering the estimated stand-alone selling prices of the services and recognizes revenue upon the satisfaction of such obligations at a point in time or over time dependent on the satisfaction of one of the following criteria: (1) the customer simultaneously receives and consumes the economic benefits provided by the vendor’s performance (2) the vendor creates or enhances an asset controlled by the customer (3) the vendor’s performance does not create an asset for which the vendor has an alternative use, and (4) the vendor has an enforceable right to payment for performance completed to date.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments

The carrying amount and approximate fair value of financial instruments as of June 30, 2023 and December 31, 2022, were as follows:


	June 30, 2023				December 31, 2022
	Carrying Amount		Fair Value		Carrying Amount		Fair Value		Valuation Inputs
Cash and cash equivalents:
Money market funds	$	762,116	$	762,116	$	704,882	$	704,882	Level 1
Investments
Bank certificates of deposit		—		—	$	39,982,213	$	39,982,213	Level 2

XML 26 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2023

Commitments And Contingencies Disclosure [Abstract]

Schedule of Information Related to Right-of-Use Assets and Related Lease Liabilities

Information related to the Company’s right-of-use assets and related lease liabilities are as follows:


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Cash paid for operating lease liabilities	$	64,024	$	34,283	$	127,391	$	68,565
Operating lease costs		64,011		65,170		128,022		115,222


	June 30,			December 31,
	2023			2022
Current operating lease liabilities	$	201,277		$	157,505
Non-current operating lease liabilities		519,685			523,619
Total operating lease liabilities	$	720,962		$	681,124
Weighted-average remaining lease term (in years)		3.28			3.90
Weighted-average discount rate		9.3	%		9.8	%

Schedule of Maturities of Operating Lease Liabilities


Maturities of operating lease liabilities as of June 30, 2023 were as follows:
2023 (remaining six months)	$	128,491
2024		263,811
2025		228,686
2026		206,483
2027		17,269
Thereafter		—
Total minimum payments		844,740
Less imputed interest		(123,778	)
Total lease liabilities	$	720,962

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity and Related Information

A summary of stock option activity and related information as of June 30, 2023 is as follows:


	Number of Option Shares			Weighted Average Exercise Price
Outstanding at December 31, 2022		7,985,250		$	5.55
Granted		770,350			2.39
Exercised		—			—
Cancelled		(469,184	)		3.99
Outstanding at June 30, 2023		8,286,416		$	5.34
Exercisable at June 30, 2023		7,492,898		$	5.65

Summary of Stock-based Compensation Expense

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively:


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Research, development and patents	$	120,037	$	96,364	$	261,155	$	138,871
General and administrative		205,673		178,138		467,818		216,684
Total stock-based compensation expense	$	325,710	$	274,502	$	728,973	$	355,555

Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options

The following table provides the assumptions used in the Black-Scholes valuation model used to estimate the fair value of options granted during the six months ended June 30, 2023 and 2022, and to estimate the fair value of performance-based stock options as of June 30, 2023 and 2022.


	Six months ended
	June 30, 2023	June 30, 2022
Stock Option assumptions:
Risk-free interest rate	3.59 - 4.13%	2.42 - 3.01%
Expected volatility of common stock	75.81 - 77.96%	75.13 - 78.45%
Dividend yield	0.00%	0.00%
Expected term (in years)	5.13 - 5.38	5.12 - 5.77

XML 28 R18.htm IDEA: XBRL DOCUMENT

Interim Financial Information - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Quarterly Financial Information Disclosure [Abstract]
Research and development costs	$ 1.6	$ 2.5	$ 3.0	$ 4.5
Patent-related expenses	$ 0.1	$ 0.1	$ 0.2	$ 0.2

XML 29 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount	$ 52,876,271	$ 18,505,493
Fair Value Measurements Recurring \| Money Market Funds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount	762,116	704,882
Fair Value	$ 762,116	704,882
Fair Value Measurements Recurring \| Bank Certificates of Deposit \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount		39,982,213
Fair Value		$ 39,982,213

XML 30 R20.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Loss Contingencies [Line Items]
Research and development expense	$ 1,600,000	$ 2,500,000	$ 3,000,000.0	$ 4,500,000
Licensing Agreements
Loss Contingencies [Line Items]
Research and development expense	0	$ 0	0	$ 0
Product Development
Loss Contingencies [Line Items]
Future potential milestone payments	10,000,000		10,000,000
Development Milestone
Loss Contingencies [Line Items]
Future potential milestone payments	16,500,000		16,500,000
Commercialization Milestone
Loss Contingencies [Line Items]
Future potential milestone payments	$ 16,500,000		$ 16,500,000
U.S
Loss Contingencies [Line Items]
Operating lease term	5 years		5 years
Operating lease expiration date			Jan. 31, 2027
Tokyo, Japan
Loss Contingencies [Line Items]
Operating lease expiration date, month and year			2025-05
Operating lease, auto-renewal term	2 years		2 years
Operating lease, extension term			2 years
Lessee, operating lease, existence of option to extend			true

XML 31 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Right-of-Use Assets and Related Lease Liabilities (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Cash paid for operating lease liabilities	$ 64,024	$ 34,283	$ 127,391	$ 68,565
Operating lease costs	64,011	$ 65,170	128,022	$ 115,222
Current operating lease liabilities	201,277		201,277		$ 157,505
Non-current operating lease liabilities	$ 519,685		$ 519,685		$ 523,619
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other non-current liabilities		Other non-current liabilities		Other non-current liabilities
Total operating lease liabilities	$ 720,962		$ 720,962		$ 681,124
Weighted-average remaining lease term (in years)	3 years 3 months 10 days		3 years 3 months 10 days		3 years 10 months 24 days
Weighted-average discount rate	9.30%		9.30%		9.80%

XML 32 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
2023 (remaining six months)	$ 128,491
2024	263,811
2025	228,686
2026	206,483
2027	17,269
Total minimum payments	844,740
Less imputed interest	(123,778)
Total lease liabilities	$ 720,962	$ 681,124

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value, per option	$ 1.60	$ 1.47
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized compensation cost	$ 0.7
Unamortized compensation cost, vesting period	7 months 6 days
Performance Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vested shares	730,350
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance			8,700,000
Shares available for future grant	1,648,151
2013 Plan \| Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted expiration term	10 years
2013 Plan \| Stock Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	1 year
2013 Plan \| Stock Option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	4 years
2023 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	8,700,000
Shares available for future grant	9,934,567
2023 Plan \| Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted expiration term	10 years
2023 Plan \| Stock Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	1 year
2023 Plan \| Stock Option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	4 years

XML 34 R24.htm IDEA: XBRL DOCUMENT

Summary of Stock Option Activity and Related Information (Detail)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Number of Option Shares
Stock Options, Beginning Balance \| shares	7,985,250
Stock Options, Granted \| shares	770,350
Stock Options, Cancelled \| shares	(469,184)
Stock Options, Ending Balance \| shares	8,286,416
Stock Options, Exercisable at June 30, 2023 \| shares	7,492,898
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 5.55
Weighted Average Exercise Price, Granted \| $ / shares	2.39
Weighted Average Exercise Price, Cancelled \| $ / shares	3.99
Weighted Average Exercise Price, Ending Balance \| $ / shares	5.34
Weighted Average Exercise Price, Exercisable at June 30, 2023 \| $ / shares	$ 5.65

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Stock-based Compensation Expenses (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 325,710	$ 274,502	$ 728,973	$ 355,555
Research, Development and Patents
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	120,037	96,364	261,155	138,871
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 205,673	$ 178,138	$ 467,818	$ 216,684

XML 36 R26.htm IDEA: XBRL DOCUMENT

Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options (Detail)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Weighted-average assumptions for stock options and ESPP
Dividend yield	0.00%	0.00%
Minimum
Weighted-average assumptions for stock options and ESPP
Risk-free interest rate	3.59%	2.42%
Expected volatility of common stock	75.81%	75.13%
Expected term (in years)	5 years 1 month 17 days	5 years 1 month 13 days
Maximum
Weighted-average assumptions for stock options and ESPP
Risk-free interest rate	4.13%	3.01%
Expected volatility of common stock	77.96%	78.45%
Expected term (in years)	5 years 4 months 17 days	5 years 9 months 7 days

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Aug. 23, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
ATM Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in a private transaction, net of issuance costs, shares		0	0	0	0
2019 at-the-market issuance sales agreement \| B. Riley FBR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sales commission as a percentage of gross proceeds	3.50%
2019 at-the-market issuance sales agreement \| Maximum \| B. Riley FBR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase agreement, aggregate amount of common stock agreed to be purchased	$ 75.0

XML 38 R28.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Potentially dilutive outstanding stock options excluded from diluted net loss per common share	8,286,416	8,013,920	8,286,416	8,013,920

XML 39 mnov-20230630_htm.xml IDEA: XBRL DOCUMENT 0001226616 2023-01-01 2023-03-31 0001226616 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001226616 srt:MaximumMember us-gaap:EmployeeStockOptionMember mnov:TwoThousandThirteenEquityIncentivePlanMember 2023-01-01 2023-06-30 0001226616 srt:MinimumMember 2023-01-01 2023-06-30 0001226616 2023-04-01 2023-06-30 0001226616 mnov:ResearchAndDevelopmentAndPatentsExpenseMember 2022-04-01 2022-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001226616 2023-03-31 0001226616 mnov:ResearchAndDevelopmentAndPatentsExpenseMember 2023-04-01 2023-06-30 0001226616 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001226616 mnov:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-06-30 0001226616 mnov:ProductDevelopmentMember 2023-06-30 0001226616 srt:MinimumMember us-gaap:EmployeeStockOptionMember mnov:TwoThousandThirteenEquityIncentivePlanMember 2023-01-01 2023-06-30 0001226616 us-gaap:RetainedEarningsMember 2022-06-30 0001226616 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001226616 srt:MinimumMember us-gaap:EmployeeStockOptionMember mnov:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-01-01 2023-06-30 0001226616 us-gaap:LicenseAgreementTermsMember 2022-04-01 2022-06-30 0001226616 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001226616 srt:MaximumMember 2022-01-01 2022-06-30 0001226616 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001226616 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001226616 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001226616 us-gaap:RetainedEarningsMember 2022-12-31 0001226616 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001226616 mnov:AtMarketIssuanceSalesAgreementMember 2022-01-01 2022-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001226616 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001226616 us-gaap:CommonStockMember 2022-03-31 0001226616 mnov:TwoThousandThirteenEquityIncentivePlanMember 2013-06-30 0001226616 2022-03-31 0001226616 mnov:BRileyFBRIncMember mnov:TwoThousandNineteenAtMarketIssuanceSalesAgreementMember 2019-08-23 2019-08-23 0001226616 us-gaap:LicenseAgreementTermsMember 2022-01-01 2022-06-30 0001226616 us-gaap:LicenseAgreementTermsMember 2023-04-01 2023-06-30 0001226616 srt:MinimumMember 2022-01-01 2022-06-30 0001226616 us-gaap:RetainedEarningsMember 2023-03-31 0001226616 2023-01-01 2023-06-30 0001226616 us-gaap:CommonStockMember 2023-06-30 0001226616 us-gaap:CommonStockMember 2021-12-31 0001226616 mnov:AtMarketIssuanceSalesAgreementMember 2023-01-01 2023-06-30 0001226616 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0001226616 country:JP 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001226616 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001226616 2022-01-01 2022-03-31 0001226616 us-gaap:RetainedEarningsMember 2021-12-31 0001226616 srt:MaximumMember 2023-01-01 2023-06-30 0001226616 us-gaap:EmployeeStockOptionMember mnov:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-01-01 2023-06-30 0001226616 us-gaap:CommonStockMember 2022-12-31 0001226616 2022-06-30 0001226616 mnov:AtMarketIssuanceSalesAgreementMember 2022-04-01 2022-06-30 0001226616 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001226616 2022-04-01 2022-06-30 0001226616 2023-08-07 0001226616 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001226616 srt:MaximumMember us-gaap:EmployeeStockOptionMember mnov:TwoThousandTwentyThreeEquityIncentivePlanMember 2023-01-01 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001226616 us-gaap:LicenseAgreementTermsMember 2023-01-01 2023-06-30 0001226616 mnov:CommercializationMilestoneMember 2023-06-30 0001226616 mnov:TwoThousandThirteenEquityIncentivePlanMember 2023-06-30 0001226616 us-gaap:RetainedEarningsMember 2022-03-31 0001226616 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001226616 us-gaap:EmployeeStockOptionMember 2023-06-30 0001226616 us-gaap:CommonStockMember 2022-06-30 0001226616 us-gaap:CommonStockMember 2023-03-31 0001226616 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001226616 mnov:DevelopmentMilestoneMember 2023-06-30 0001226616 2021-12-31 0001226616 mnov:ResearchAndDevelopmentAndPatentsExpenseMember 2022-01-01 2022-06-30 0001226616 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001226616 country:US 2023-01-01 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001226616 country:JP 2023-01-01 2023-06-30 0001226616 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001226616 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001226616 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001226616 us-gaap:RetainedEarningsMember 2023-06-30 0001226616 mnov:ResearchAndDevelopmentAndPatentsExpenseMember 2023-01-01 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001226616 2022-12-31 0001226616 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001226616 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001226616 2022-01-01 2022-06-30 0001226616 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001226616 us-gaap:EmployeeStockOptionMember mnov:TwoThousandThirteenEquityIncentivePlanMember 2023-01-01 2023-06-30 0001226616 mnov:BRileyFBRIncMember srt:MaximumMember mnov:TwoThousandNineteenAtMarketIssuanceSalesAgreementMember 2019-08-23 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001226616 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001226616 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001226616 country:US 2023-06-30 0001226616 mnov:AtMarketIssuanceSalesAgreementMember 2023-04-01 2023-06-30 0001226616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 pure shares iso4217:USD iso4217:USD shares --12-31 false 0001226616 Q1

http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent

P1Y

10-Q true 2023-06-30 2023 false 001-33185 MEDICINOVA, INC. DE 33-0927979 4275 Executive Square Suite 300 La Jolla CA 92037 858 373-1500 Common Stock, $0.001 par value MNOV NASDAQ Yes Yes Non-accelerated Filer true false false 49046246

52876271

18505493

645464

499403

39982213

53521735

58987109

9600240

4800000 4800000

54562

45269

669314

629495

72791

92792

68718642

74154905

548221

424646

2071738 2605308

201277

157505

2821236

3187459

201792

519685

523619

3542713

3912870

0.001

100000000

49046246

49046

478167424

477438451

-121040

-115285

-412919501

-407130177

65175929

70242035

68718642

74154905

1735735 2564969 3212411 4676965

1564295

1524966

3050862

2822982

3300030

4089935

6263273

7499947

-3300030

-4089935

-6263273

-7499947

451420

91275

960466

128614

-23210

-30338

-486517

-44082

-2871820

-4028998

-5789324

-7415415

-0.06

-0.08

-0.12

-0.15

49046246

49045587

49046246

49044423

-2871820

-4028998

-5789324

-7415415

-4213

-11980

-5755

-19415

-2876033

-4040978

-5795079

-7434830

49046246

49046

477438451

-115285

-407130177

70242035

403263

-2917504

-1542

49046246

49046

477841714

-116827

-410047681

67726252

325710

-2871820

-4213

49046246

49046

478167424

-121040

-412919501

65175929

49043246

49043

476788012

-98877

-393061094

83677084

81053

-3386417

-7435

49043246

49043

476869065

-106312

-396447511

80364285

274502

3000

7917

7920

-4028998

-11980

49046246

49046

477151484

-118292

-400476509

76605729

-5789324

-7415415

728973

355555

9100

8917

-102513

98643 101394

182896

135311

-428876 956112

-98562

-55620

-5560429

-6184368

39929015

18577

39910438

7920

20769

-21238

34370778

-6197686

18505493

71430954

52876271

65233268

139001

1. Interim Financial InformationOrganization and BusinessMediciNova, Inc. (the “Company” or “MediciNova”) was incorporated in the state of Delaware in September 2000. The Company’s common stock is listed in both the United States and Japan and trades on the Nasdaq Global Market and the Standard Market of the Tokyo Stock Exchange. The Company is a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs with a commercial focus on the United States market. The Company’s current strategy is to focus its development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.<div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Amendment No. 1 to Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2022 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by GAAP for complete financial statements.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Principles of Consolidation</div>The consolidated financial statements include the accounts of MediciNova, Inc. and its wholly owned subsidiaries, MediciNova Japan, Inc., MediciNova (Europe) Limited, MediciNova Europe GmbH and Avigen Inc. The financial statements of the Company’s foreign subsidiaries are measured using their local currency as the functional currency. The resulting translation adjustments are recorded as a component of other comprehensive income or loss. Intercompany transaction gains or losses at each period end are included as translation adjustments and recorded within other comprehensive income or loss. All intercompany transactions and balances are eliminated in consolidation. <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Segment ReportingOperating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment – the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Cash and Cash EquivalentsCash and cash equivalents consist of cash and other highly liquid investments including money market accounts, with original maturities of three months or less from the date of purchase.</div> <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Investments</div>Investments purchased with an original maturity of greater than three months are classified as investments. Investments are stated at fair value and are classified as current or non-current based on the nature of the securities as well as their stated maturities. <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Research, Development and Patents Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, facilities and depreciation, research and development supplies, licenses and outside services. Such research and development costs totaled $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.6 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.5 million for the three months ended June 30, 2023 and 2022, respectively, and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.0 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.5 million for the six months ended June 30, 2023 and 2022, respectively. Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. The Company includes all external costs related to the filing of patents in Research, Development and Patents expenses. Such patent-related expenses totaled $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.1 million for the three months ended June 30, 2023 and 2022, respectively, and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2 million for the six months ended June 30, 2023 and 2022, respectively.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Clinical Trial Accruals and Prepaid ExpensesCosts for preclinical studies, clinical studies and manufacturing activities are recognized as research and development expenses based on an evaluation of the progress by Company vendors towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to the Company by such vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. The Company’s estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">LeasesThe Company determines if an arrangement is a lease at inception and if so, determines whether the lease qualifies as an operating or finance lease. The Company does not recognize right-of-use assets and lease liabilities for leases with a term of 12 months or less and does not separate non-lease components from lease components. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease expense is recognized on a straight-line basis over the lease term and is included in general and administrative expenses. As most of the Company’s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Use of EstimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</div> <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Recently Issued Accounting PronouncementsIn June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments— Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The ASU introduced a new credit loss methodology, the Current Expected Credit Losses (“CECL”) methodology, which requires earlier recognition of credit losses, while also providing additional transparency about credit risk. The CECL methodology utilizes a lifetime “expected credit loss” measurement objective for the recognition of credit losses for loans, held-to maturity debt securities, trade receivables and other receivables measured at amortized cost at the time the financial asset is originated or acquired. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The new standard was effective for the Company on January 1, 2023. There was no impact on the consolidated financial statements upon adoption of this standard on January 1, 2023.</div>

Principles of ConsolidationThe consolidated financial statements include the accounts of MediciNova, Inc. and its wholly owned subsidiaries, MediciNova Japan, Inc., MediciNova (Europe) Limited, MediciNova Europe GmbH and Avigen Inc. The financial statements of the Company’s foreign subsidiaries are measured using their local currency as the functional currency. The resulting translation adjustments are recorded as a component of other comprehensive income or loss. Intercompany transaction gains or losses at each period end are included as translation adjustments and recorded within other comprehensive income or loss. All intercompany transactions and balances are eliminated in consolidation.

Segment ReportingOperating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company operates in a single operating segment – the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs.

1600000

2500000

3000000.0

4500000

100000 100000 200000 200000 Clinical Trial Accruals and Prepaid ExpensesCosts for preclinical studies, clinical studies and manufacturing activities are recognized as research and development expenses based on an evaluation of the progress by Company vendors towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to the Company by such vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. The Company’s estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.

Revenue Recognition PolicyRevenues historically have consisted mainly of research and development services performed under a contract with a customer. The Company evaluates the separate performance obligation(s) under each contract, allocates the transaction price to each performance obligation considering the estimated stand-alone selling prices of the services and recognizes revenue upon the satisfaction of such obligations at a point in time or over time dependent on the satisfaction of one of the following criteria: (1) the customer simultaneously receives and consumes the economic benefits provided by the vendor’s performance (2) the vendor creates or enhances an asset controlled by the customer (3) the vendor’s performance does not create an asset for which the vendor has an alternative use, and (4) the vendor has an enforceable right to payment for performance completed to date.

The carrying amount and approximate fair value of financial instruments as of June 30, 2023 and December 31, 2022, were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.156%;"></td> <td style="width:1.504%;"></td> <td style="width:1.0%;"></td> <td style="width:9.653%;"></td> <td style="width:1.0%;"></td> <td style="width:1.504%;"></td> <td style="width:1.0%;"></td> <td style="width:9.653%;"></td> <td style="width:1.0%;"></td> <td style="width:1.504%;"></td> <td style="width:1.0%;"></td> <td style="width:9.653%;"></td> <td style="width:1.0%;"></td> <td style="width:1.504%;"></td> <td style="width:1.0%;"></td> <td style="width:9.653%;"></td> <td style="width:1.0%;"></td> <td style="width:1.504%;"></td> <td style="width:11.713%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">June 30, 2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Carrying Amount</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Fair Value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Carrying Amount</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Fair Value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Valuation Inputs</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Money market funds</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">762,116</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">762,116</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">704,882</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">704,882</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Level 1</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Investments</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Bank certificates of deposit</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">39,982,213</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">39,982,213</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Level 2</td> </tr> </table>

762116

704882

39982213

4. Commitments and ContingenciesLease CommitmentsThe Company has operating leases primarily for real estate in the United States and Japan. The United States lease is for the Company’s headquarters in San Diego and has a term of five years ending January 31, 2027, with annual escalations. The Company’s lease in Tokyo, Japan has a term of two years ending May 2025 with an auto-renewal, two-year extension. The real estate operating leases are included in "Right-of-use asset” on the Company's balance sheet and represents the Company’s right to use the underlying assets for the lease term. The Company’s obligation to make lease payments are included in "Operating lease liability" and "Other non-current liabilities" on the Company's balance sheet. <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Information related to the Company’s right-of-use assets and related lease liabilities are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:30.419%;"></td> <td style="width:7.84%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> <td style="width:1.223%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> <td style="width:1.223%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> <td style="width:1.223%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">Three months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">Six months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Cash paid for operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,024</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">34,283</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">127,391</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">68,565</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Operating lease costs</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,011</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">65,170</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">128,022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">115,222</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.276%;"></td> <td style="width:1.475%;"></td> <td style="width:1.0%;"></td> <td style="width:15.676%;"></td> <td style="width:1.0%;"></td> <td style="width:1.475%;"></td> <td style="width:1.0%;"></td> <td style="width:15.098%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Current operating lease liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">201,277</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">157,505</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Non-current operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">519,685</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">523,619</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Total operating lease liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">720,962</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">681,124</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Weighted-average remaining lease term (in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.28</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.90</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Weighted-average discount rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.3</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.8</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> </table></div> <div style="font-size:10.0pt;font-family:"Times New Roman", serif;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.518%;"></td> <td style="width:1.481%;"></td> <td style="width:17.591%;"></td> <td style="width:1.481%;"></td> <td style="width:1.0%;"></td> <td style="width:14.931000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Maturities of operating lease liabilities as of June 30, 2023 were as follows:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2023 (remaining six months)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">128,491</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2024</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">263,811</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2025</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">228,686</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2026</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">206,483</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2027</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,269</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Thereafter</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Total minimum payments</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">844,740</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Less imputed interest</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">123,778</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Total lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">720,962</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> Product LiabilityThe Company’s business exposes it to liability risks from its potential drug products. A successful product liability claim or series of claims brought against the Company could result in the payment of significant amounts of money and divert management’s attention from running the business. The Company may not be able to maintain insurance on acceptable terms, or the insurance may not provide adequate protection in the case of a product liability claim. To the extent that product liability insurance, if available, does not cover potential claims, the Company would be required to self-insure the risks associated with such claims. The Company believes it carries reasonably adequate insurance for product liability.License and Research AgreementsThe Company has entered into in-licensing agreements with various pharmaceutical companies. Under the terms of these agreements, the Company has received licenses to research, know-how and technology claimed in specified patents or patent applications. Under these license agreements, the Company is generally required to make upfront payments and additional payments upon the achievement of milestones and/or royalties on future sales of products until the later of the expiration of the applicable patent or the applicable last date of market exclusivity after the first commercial sale, on a country-by-country basis.<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">No milestone payments have been made under these agreements during the three and six months ended June 30, 2023 and 2022. For products currently in development, future potential milestone payments based on product development of MN-166 (ibudilast) and MN-001 (tipelukast) are $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10 million as of June 30, 2023. For all other products, future potential milestone payments related to development milestones and commercialization milestones totaled $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16.5 million as of June 30, 2023. There are no minimum royalties required under any of the license agreements. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments are dependent upon the progress of the Company’s product development programs.Legal ProceedingsFrom time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not aware of any such proceedings or claims that it believes will have, individually or in aggregate, a material adverse effect on its business, financial condition or results of operations.

P5Y

2027-01-31

P2Y

2025-05 P2Y

true

Information related to the Company’s right-of-use assets and related lease liabilities are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:30.419%;"></td> <td style="width:7.84%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> <td style="width:1.223%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> <td style="width:1.223%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> <td style="width:1.223%;"></td> <td style="width:1.0%;"></td> <td style="width:12.519%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">Three months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">Six months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="border-top:2.25pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Cash paid for operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,024</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">34,283</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">127,391</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">68,565</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Operating lease costs</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,011</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">65,170</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">128,022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">115,222</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.276%;"></td> <td style="width:1.475%;"></td> <td style="width:1.0%;"></td> <td style="width:15.676%;"></td> <td style="width:1.0%;"></td> <td style="width:1.475%;"></td> <td style="width:1.0%;"></td> <td style="width:15.098%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Current operating lease liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">201,277</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">157,505</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Non-current operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">519,685</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">523,619</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Total operating lease liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">720,962</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">681,124</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Weighted-average remaining lease term (in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.28</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.90</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Weighted-average discount rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.3</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.8</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> </table>

64024

34283

127391

68565

64011

65170

128022

115222

201277

157505

519685

523619

720962

681124

P3Y3M10D

P3Y10M24D

0.093

0.098

<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.518%;"></td> <td style="width:1.481%;"></td> <td style="width:17.591%;"></td> <td style="width:1.481%;"></td> <td style="width:1.0%;"></td> <td style="width:14.931000000000001%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Maturities of operating lease liabilities as of June 30, 2023 were as follows:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2023 (remaining six months)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">128,491</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2024</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">263,811</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2025</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">228,686</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2026</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">206,483</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">2027</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,269</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Thereafter</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Total minimum payments</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">844,740</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Less imputed interest</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">123,778</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Total lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">720,962</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table>

128491

263811

228686

206483

17269

844740

123778

720962

10000000 16500000 16500000

5. Stock-based CompensationStock Incentive PlansIn June 2013, the Company adopted the 2013 Equity Incentive Plan, or 2013 Plan, under which the Company granted equity-based awards, including stock options, stock appreciation rights, restricted stock, and restricted stock units to individuals who were then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. A total of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,700,000 shares of common stock were reserved for issuance under the 2013 Plan. In addition, “returning shares” that may become available from time to time were added back to the plan. “Returning shares” included shares that were subject to outstanding awards granted under the Company's prior 2004 Equity Incentive Plan that expired or terminated prior to exercise or settlement, were forfeited because of the failure to vest, were repurchased, or were withheld to satisfy tax withholding or purchase price obligations in connection with such awards. Although the Company no longer grants equity awards under the 2013 Plan, all outstanding stock awards granted under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the 2013 Plan. In June 2023, the Company adopted the 2023 Equity Incentive Plan, or 2023 Plan, under which the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The 2023 Plan is the successor to the 2013 Plan. A total of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,700,000 shares of common stock are reserved for issuance under the 2023 Plan. The number of shares of common stock that may be issued under the 2023 Plan is equal to the sum of (a) shares subject to awards granted under the 2013 Plan that were outstanding upon expiration of the 2013 Plan and are subsequently forfeited, expire or lapse unexercised or unsettled and shares issued pursuant to awards granted under the 2013 Plan that were outstanding upon expiration of the 2013 Plan and are subsequently forfeited to or reacquired by the Company and (b) shares reserved under the 2013 Plan that were not issued or subject to outstanding awards under the 2013 Plan upon expiration of the 2013 Plan. While a maximum of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,934,567 shares may become available for issuance under the 2023 Plan from the 2013 Plan, since this figure assumes that all awards outstanding under the 2013 Plan upon expiration of the 2013 Plan will be forfeited, the Company expects the actual number of shares added to the 2023 Plan to be less. In general, to the extent that awards under the 2023 Plan are forfeited, cancelled or expire for any reason before being exercised or settled in full, the shares subject to such awards will again become available for issuance under the 2023 Plan. If stock appreciation rights are exercised or restricted stock units are settled, then only the number of shares (if any) actually issued to the participant will reduce the number of shares available under the 2023 Plan. If restricted shares or shares issued upon exercise of options are reacquired by the Company pursuant to a forfeiture provision, repurchase right or for any other reason, then such shares shall again become available for issuance under the 2023 Plan. Shares withheld to pay the exercise price of options or satisfy tax withholding obligations related to an award shall again become available for issuance under the 2023 Plan. Further, to the extent an award is settled in cash rather than shares, the cash settlement shall not reduce the number of shares available for issuance under the 2023 Plan.As of June 30, 2023, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,648,151 shares remain available for future grants under the 2023 Plan.Certain of the employee stock options granted contain performance conditions, the vesting of which is based on a determination made by the compensation committee followed by an approval of the board of directors as to the achievement of certain corporate objectives at the end of the performance period. The grant date of such awards is the date on which the board of directors makes its determination. For periods preceding the grant date, the expense related to these awards is measured based on their fair value at each reporting date. The estimated fair value of the performance awards granted and the resulting expense is based upon a certain level of achievement of the corporate objectives and other assumptions in determining fair value. The amount of expense ultimately recognized upon the grant date at completion of the performance period could change from the estimate as a result of various factors, including the level of achievement of the corporate objectives, changes in the assumptions used in the Black-Scholes model in determining fair value or fluctuations in the Company’s stock price during the performance period. As of June 30, 2023, there were a total of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">730,350 shares underlying performance options that were subject to vesting based on achievement of corporate objectives for 2023.Stock OptionsOptions granted under the 2023 Plan and the 2013 Plan have terms of ten years from the date of grant unless earlier terminated and generally vest over a one or four year period. The exercise price of all options granted through June 30, 2023 and 2022, was equal to the fair market value of the Company’s common stock on the date of grant. <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">A summary of stock option activity and related information as of June 30, 2023 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.228%;"></td> <td style="width:2.001%;"></td> <td style="width:1.0%;"></td> <td style="width:21.174999999999997%;"></td> <td style="width:1.0%;"></td> <td style="width:1.801%;"></td> <td style="width:1.0%;"></td> <td style="width:21.314999999999998%;"></td> <td style="width:1.0%;"></td> <td style="width:2.481%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Number of Option Shares</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted Average Exercise Price</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,985,250</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.55</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Granted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">770,350</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.39</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Exercised</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Cancelled</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">469,184</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.99</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Outstanding at June 30, 2023</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,286,416</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.34</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Exercisable at June 30, 2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,492,898</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.65</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table></div>Compensation ExpenseStock-based compensation expense for stock option awards are reflected in total operating expenses for each respective period. <div style="font-size:10.0pt;font-family:"Times New Roman", serif;">The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:32.625%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:15.266%;"></td> <td style="width:1.0%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:15.266%;"></td> <td style="width:1.0%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:13.08%;"></td> <td style="width:1.0%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:11.757%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Three months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Six months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research, development and patents</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">120,037</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">96,364</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">261,155</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">138,871</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">General and administrative</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">205,673</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">178,138</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">467,818</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">216,684</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total stock-based compensation expense</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">325,710</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">274,502</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">728,973</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">355,555</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> The Company uses the Black-Scholes valuation model for determining the estimated fair value for stock-based awards granted to employees and considers management’s current expectations of the achievement of the performance objectives for the year. The following table provides the assumptions used in the Black-Scholes valuation model used to estimate the fair value of options granted during the six months ended June 30, 2023 and 2022, and to estimate the fair value of performance-based stock options as of June 30, 2023 and 2022. <div style="font-size:11.0pt;font-family:"Calibri", sans-serif;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.44%;"></td> <td style="width:1.0%;"></td> <td style="width:24.74%;"></td> <td style="width:1.0%;"></td> <td style="width:24.82%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Six months ended</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">June 30, 2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">June 30, 2022</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Stock Option assumptions:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Risk-free interest rate</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.59 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.13%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.42 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.01%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Expected volatility of common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.81 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">77.96%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.13 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">78.45%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Dividend yield</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.00%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.00%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Expected term (in years)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">5.13 - 5.38</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">5.12 - 5.77</td> </tr> </table></div> As of June 30, 2023, there was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.7 million of unamortized compensation cost related to unvested stock option awards which is expected to be recognized over a remaining weighted-average vesting period of 0.6 years, on a straight-line basis. Such compensation cost will ultimately be adjusted based upon actual performance compared to the corporate objectives as described above. The weighted-average fair value of each stock option granted during the six months ended June 30, 2023 and 2022, estimated as of the grant date using the Black-Scholes option valuation model, was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.60 and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.47, respectively.

8700000

9934567

1648151

730350

P10Y

P4Y

A summary of stock option activity and related information as of June 30, 2023 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.228%;"></td> <td style="width:2.001%;"></td> <td style="width:1.0%;"></td> <td style="width:21.174999999999997%;"></td> <td style="width:1.0%;"></td> <td style="width:1.801%;"></td> <td style="width:1.0%;"></td> <td style="width:21.314999999999998%;"></td> <td style="width:1.0%;"></td> <td style="width:2.481%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Number of Option Shares</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted Average Exercise Price</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,985,250</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.55</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Granted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">770,350</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.39</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Exercised</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Cancelled</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">469,184</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.99</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Outstanding at June 30, 2023</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,286,416</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.34</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> Exercisable at June 30, 2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,492,898</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.65</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table>

7985250

5.55

770350

2.39

469184

3.99

8286416

5.34

7492898

5.65

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:32.625%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:15.266%;"></td> <td style="width:1.0%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:15.266%;"></td> <td style="width:1.0%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:13.08%;"></td> <td style="width:1.0%;"></td> <td style="width:1.003%;"></td> <td style="width:1.0%;"></td> <td style="width:11.757%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Three months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Six months ended</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">June 30,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research, development and patents</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">120,037</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">96,364</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">261,155</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">138,871</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">General and administrative</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">205,673</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">178,138</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">467,818</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">216,684</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total stock-based compensation expense</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">325,710</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">274,502</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">728,973</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">355,555</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table>

120037

96364

261155

138871

205673

178138

467818

216684

325710

274502

728973

355555

The following table provides the assumptions used in the Black-Scholes valuation model used to estimate the fair value of options granted during the six months ended June 30, 2023 and 2022, and to estimate the fair value of performance-based stock options as of June 30, 2023 and 2022. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.44%;"></td> <td style="width:1.0%;"></td> <td style="width:24.74%;"></td> <td style="width:1.0%;"></td> <td style="width:24.82%;"></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Six months ended</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">June 30, 2023</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">June 30, 2022</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Stock Option assumptions:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Risk-free interest rate</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.59 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.13%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.42 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.01%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Expected volatility of common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.81 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">77.96%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.13 - <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">78.45%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Dividend yield</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.00%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.00%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Expected term (in years)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">5.13 - 5.38</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">5.12 - 5.77</td> </tr> </table>

0.0359

0.0413

0.0242

0.0301

0.7581

0.7796

0.7513

0.7845

0.0000

P5Y1M17D

P5Y4M17D

P5Y1M13D

P5Y9M7D

700000

P0Y7M6D

1.60

1.47

6. Stockholders’ EquityAt-The-Market Issuance Sales Agreements and Private Placement TransactionsOn August 23, 2019, the Company entered into an at the market issuance sales agreement, which was amended on August 26, 2022 (as amended, the “ATM Agreement”) with B. Riley FBR, Inc. (B. Riley FBR) pursuant to which the Company may sell common stock through B. Riley FBR from time to time up to an aggregate offering price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75.0 million. Sales of the Company’s common stock through B. Riley FBR, if any, will be made by any method that is deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on Nasdaq, on any other existing trading market for the common stock or through a market maker. B. Riley FBR may also sell the common stock in privately negotiated transactions, subject to the Company’s prior approval. The Company agreed to pay B. Riley FBR an aggregate commission rate of up to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.5% of the gross proceeds of any common stock sold under this agreement. Proceeds from sales of common stock will depend on the number of shares of common stock sold to B. Riley FBR and the per share purchase price of each transaction. <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">No shares of common stock were sold under the ATM Agreement in the three and six months ended June 30, 2023 and 2022, respectively.

75000000.0

0.035

7. Net Loss Per ShareThe Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option agreements. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive. Potentially dilutive outstanding stock options excluded from diluted net loss per common share due to their anti-dilutive effect totaled <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,286,416 shares for both the three and six months ended June 30, 2023 and <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,013,920 shares for both the three and six months ended June 30, 2022.

8286416

8013920

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " V@@E7(N!HUWL! Z$@ $P M@ '-LP 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ) D +,) !YM0 " ! end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 93 166 1 false 26 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Interim Financial Information Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformation Interim Financial Information Notes 7 false false R8.htm 100070 - Disclosure - Revenue Recognition Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognition Revenue Recognition Notes 8 false false R9.htm 100080 - Disclosure - Fair Value Measurements Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 100090 - Disclosure - Commitments and Contingencies Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 10 false false R11.htm 100100 - Disclosure - Stock-based Compensation Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based Compensation Notes 11 false false R12.htm 100110 - Disclosure - Stockholders' Equity Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 100120 - Disclosure - Net Loss Per Share Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 13 false false R14.htm 100130 - Disclosure - Interim Financial Information (Policies) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies Interim Financial Information (Policies) Policies 14 false false R15.htm 100140 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements 15 false false R16.htm 100150 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 16 false false R17.htm 100160 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation 17 false false R18.htm 100170 - Disclosure - Interim Financial Information - Additional Information (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationAdditionalInformationDetail Interim Financial Information - Additional Information (Detail) Details 18 false false R19.htm 100190 - Disclosure - Fair Value Measurements - Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail Fair Value Measurements - Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments (Detail) Details 19 false false R20.htm 100200 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 20 false false R21.htm 100210 - Disclosure - Commitments and Contingencies - Schedule of Right-of-Use Assets and Related Lease Liabilities (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail Commitments and Contingencies - Schedule of Right-of-Use Assets and Related Lease Liabilities (Detail) Details 21 false false R22.htm 100220 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail) Details 22 false false R23.htm 100230 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 23 false false R24.htm 100250 - Disclosure - Summary of Stock Option Activity and Related Information (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail Summary of Stock Option Activity and Related Information (Detail) Details 24 false false R25.htm 100260 - Disclosure - Summary of Stock-based Compensation Expenses (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail Summary of Stock-based Compensation Expenses (Detail) Details 25 false false R26.htm 100270 - Disclosure - Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options (Detail) Details 26 false false R27.htm 100280 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 27 false false R28.htm 100290 - Disclosure - Net Loss Per Share - Additional Information (Detail) Sheet http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail Net Loss Per Share - Additional Information (Detail) Details 28 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - mnov-20230630.htm 8 mnov-20230630.htm mnov-20230630.xsd mnov-20230630_cal.xml mnov-20230630_def.xml mnov-20230630_lab.xml mnov-20230630_pre.xml mnov-ex31_1.htm mnov-ex31_2.htm mnov-ex32_1.htm mnov-ex32_2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 46 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mnov-20230630.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 319, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 93, "dts": { "calculationLink": { "local": [ "mnov-20230630_cal.xml" ] }, "definitionLink": { "local": [ "mnov-20230630_def.xml" ] }, "inline": { "local": [ "mnov-20230630.htm" ] }, "labelLink": { "local": [ "mnov-20230630_lab.xml" ] }, "presentationLink": { "local": [ "mnov-20230630_pre.xml" ] }, "schema": { "local": [ "mnov-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 282, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 6, "http://xbrl.sec.gov/dei/2022": 4, "total": 10 }, "keyCustom": 15, "keyStandard": 151, "memberCustom": 9, "memberStandard": 17, "nsprefix": "mnov", "nsuri": "http://www.medicinova.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "10", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Stock-based Compensation", "menuCat": "Notes", "order": "11", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "12", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "13", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Interim Financial Information (Policies)", "menuCat": "Policies", "order": "14", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies", "shortName": "Interim Financial Information (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "15", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "mnov:ScheduleOfInformationRelatedToRightOfUseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "16", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "mnov:ScheduleOfInformationRelatedToRightOfUseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock-based Compensation (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "p", "mnov:ResearchDevelopmentAndPatentsExpensePolicyTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Interim Financial Information - Additional Information (Detail)", "menuCat": "Details", "order": "18", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationAdditionalInformationDetail", "shortName": "Interim Financial Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "mnov:ResearchDevelopmentAndPatentsExpensePolicyTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "-5", "lang": null, "name": "mnov:PatentsExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Fair Value Measurements - Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments (Detail)", "menuCat": "Details", "order": "19", "role": "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail", "shortName": "Fair Value Measurements - Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_92b90734-01bc-4590-9a78-c00caf0a34c4", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "p", "mnov:ResearchDevelopmentAndPatentsExpensePolicyTextBlock", "div", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "menuCat": "Details", "order": "20", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_d2d6bc15-99d3-4a68-81b1-937af07c6e1e", "decimals": "INF", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "mnov:ScheduleOfInformationRelatedToRightOfUseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Commitments and Contingencies - Schedule of Right-of-Use Assets and Related Lease Liabilities (Detail)", "menuCat": "Details", "order": "21", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail", "shortName": "Commitments and Contingencies - Schedule of Right-of-Use Assets and Related Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "mnov:ScheduleOfInformationRelatedToRightOfUseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail)", "menuCat": "Details", "order": "22", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail", "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "23", "role": "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_c197575d-bfd2-4d51-8750-e47ca544a1b3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Stock Option Activity and Related Information (Detail)", "menuCat": "Details", "order": "24", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail", "shortName": "Summary of Stock Option Activity and Related Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_c197575d-bfd2-4d51-8750-e47ca544a1b3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Stock-based Compensation Expenses (Detail)", "menuCat": "Details", "order": "25", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail", "shortName": "Summary of Stock-based Compensation Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options (Detail)", "menuCat": "Details", "order": "26", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "shortName": "Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_e2c7cca8-031a-46b6-86b9-7c7fa431947f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "menuCat": "Details", "order": "27", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_e2c7cca8-031a-46b6-86b9-7c7fa431947f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Net Loss Per Share - Additional Information (Detail)", "menuCat": "Details", "order": "28", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail", "shortName": "Net Loss Per Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_cf9e30ec-d322-4384-845c-9e6a1d6f6d1a", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "0", "first": true, "lang": null, "name": "mnov:ResearchDevelopmentAndPatentsExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_0e7f1bff-fc5f-41b6-85bb-4508e0fe7ace", "decimals": "0", "first": true, "lang": null, "name": "mnov:ResearchDevelopmentAndPatentsExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_b9c6c9a9-fe2d-44e2-95a5-53b5ec0f6e7d", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_c6f64e89-c598-4836-90f9-bfab95708433", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Interim Financial Information", "menuCat": "Notes", "order": "7", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformation", "shortName": "Interim Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "8", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "9", "role": "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mnov-20230630.htm", "contextRef": "C_f726b5e8-b30a-411d-83c0-4b7ae7f37452", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 26, "tag": { "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Tokyo, Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "mnov_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued liabilities and other liabilities current.", "label": "Accrued Liabilities And Other Liabilities Current", "terseLabel": "Accrued liabilities and other current liabilities", "totalLabel": "Total accrued liabilities and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mnov_AnnualIncreaseInSharesReservedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual increase in shares reserved for issuance.", "label": "Annual Increase In Shares Reserved For Issuance", "terseLabel": "Increase in shares reserved for issuance" } } }, "localname": "AnnualIncreaseInSharesReservedForIssuance", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "mnov_AnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual increase in shares reserved for issuance as percentage of outstanding shares of common stock.", "label": "Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Shares Of Common Stock", "terseLabel": "Increase in shares reserved for issuance as percentage of outstanding shares" } } }, "localname": "AnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingSharesOfCommonStock", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mnov_AtMarketIssuanceSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At market issuance sales agreement.", "label": "At Market Issuance Sales Agreement [Member]", "terseLabel": "ATM Agreement" } } }, "localname": "AtMarketIssuanceSalesAgreementMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_BRileyFBRIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "B. Riley FBR, Inc.", "label": "B Riley F B R Inc [Member]", "terseLabel": "B. Riley FBR" } } }, "localname": "BRileyFBRIncMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_ChangeInCarryingAmountOfRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in carrying amount of right of use asset.", "label": "Change In Carrying Amount Of Right Of Use Asset", "terseLabel": "Change in carrying amount of right-of-use asset" } } }, "localname": "ChangeInCarryingAmountOfRightOfUseAsset", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mnov_ClinicalTrialAccrualsAndPrepaidExpensesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical trial accruals and prepaid expenses policy.", "label": "Clinical Trial Accruals And Prepaid Expenses Policy Policy [Text Block]", "terseLabel": "Clinical Trial Accruals and Prepaid Expenses" } } }, "localname": "ClinicalTrialAccrualsAndPrepaidExpensesPolicyPolicyTextBlock", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "mnov_CommercializationMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercialization milestone.", "label": "Commercialization Milestone [Member]", "terseLabel": "Commercialization Milestone" } } }, "localname": "CommercializationMilestoneMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_DevelopmentMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development milestone.", "label": "Development Milestone [Member]", "terseLabel": "Development Milestone" } } }, "localname": "DevelopmentMilestoneMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_EmployeeStockPurchasePlanOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan offering period.", "label": "Employee Stock Purchase Plan Offering Period", "terseLabel": "Employee stock purchase plan offering period" } } }, "localname": "EmployeeStockPurchasePlanOfferingPeriod", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "mnov_GenzymeCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genzyme corporation.", "label": "Genzyme Corporation [Member]", "terseLabel": "Genzyme Corporation" } } }, "localname": "GenzymeCorporationMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_ImpactOfCOVIDNineteenPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact of the onging COVID-19 pandemic policy.", "label": "Impact of COVID Nineteen Policy [Policy Text Block]", "terseLabel": "Impact of COVID-19 on the Company\u2019s Business" } } }, "localname": "ImpactOfCOVIDNineteenPolicyPolicyTextBlock", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "mnov_InProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date, which is the fair value of the acquired in-process technology, adjusted for any amortization recognized after market feasibility has been achieved and for any impairment charges.", "label": "In Process Research And Development", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopment", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mnov_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net change during the reporting period in the aggregate amount of accounts payable, accrued expenses and other current liabilities.", "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Current Liabilities", "terseLabel": "Accounts payable, accrued liabilities and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mnov_KisseiPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kissei Pharmaceutical Co., Ltd.", "label": "Kissei Pharmaceutical Co Ltd [Member]", "terseLabel": "Kissei Pharmaceutical Co., Ltd" } } }, "localname": "KisseiPharmaceuticalCoLtdMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_LesseeOperatingLeaseExtendedTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease extended term of contract.", "label": "Lessee Operating Lease Extended Term Of Contract", "terseLabel": "Operating lease, extension term" } } }, "localname": "LesseeOperatingLeaseExtendedTermOfContract", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "mnov_OperatingLeaseExpirationDateMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease expiration date, month and year.", "label": "Operating Lease Expiration Date Month And Year", "terseLabel": "Operating lease expiration date, month and year" } } }, "localname": "OperatingLeaseExpirationDateMonthAndYear", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "mnov_PatentsExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Patents expense.", "label": "Patents Expense", "terseLabel": "Patent-related expenses" } } }, "localname": "PatentsExpense", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "mnov_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of commission on gross proceeds from sale of common stock, maximum.", "label": "Percentage Of Commission On Gross Proceeds From Sale Of Common Stock Maximum", "terseLabel": "Sales commission as a percentage of gross proceeds" } } }, "localname": "PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStockMaximum", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mnov_PotentialFutureMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential future milestone payments.", "label": "Potential Future Milestone Payments", "terseLabel": "Future potential milestone payments" } } }, "localname": "PotentialFutureMilestonePayments", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "mnov_ProceedsFromDisposalOfInvestments": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from disposal of investments.", "label": "Proceeds From Disposal Of Investments", "terseLabel": "Proceeds from disposal of investments" } } }, "localname": "ProceedsFromDisposalOfInvestments", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mnov_ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptions": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock, exercise of common stock options.", "label": "Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options", "terseLabel": "Proceeds from issuance of common stock and exercise of common stock options" } } }, "localname": "ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptions", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mnov_ProductDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product development.", "label": "Product Development [Member]", "terseLabel": "Product Development" } } }, "localname": "ProductDevelopmentMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_ResearchAndDevelopmentAndPatentsExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development and patents expense.", "label": "Research And Development And Patents Expense [Member]", "terseLabel": "Research, Development and Patents" } } }, "localname": "ResearchAndDevelopmentAndPatentsExpenseMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "domainItemType" }, "mnov_ResearchDevelopmentAndPatentsExpense": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research, development and patents expense.", "label": "Research Development And Patents Expense", "terseLabel": "Research, development and patents" } } }, "localname": "ResearchDevelopmentAndPatentsExpense", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "mnov_ResearchDevelopmentAndPatentsExpensePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research development and patents expense.", "label": "Research Development And Patents Expense Policy [Text Block]", "terseLabel": "Research Development and Patents" } } }, "localname": "ResearchDevelopmentAndPatentsExpensePolicyTextBlock", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "mnov_ScheduleOfInformationRelatedToRightOfUseAssetsAndRelatedLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information related to right-of-use assets and related lease liabilities.", "label": "Schedule Of Information Related To Right Of Use Assets And Related Lease Liabilities Table [Text Block]", "terseLabel": "Schedule of Information Related to Right-of-Use Assets and Related Lease Liabilities" } } }, "localname": "ScheduleOfInformationRelatedToRightOfUseAssetsAndRelatedLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "mnov_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, number of additional shares issued.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Issued", "terseLabel": "Further shares issued under ESPP", "verboseLabel": "Shares issued under ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesIssued", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "mnov_StockIssuanceLimitUnderEmployeeStockPurchasePlanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issuance limit under employee stock purchase plan description.", "label": "Stock Issuance Limit Under Employee Stock Purchase Plan Description", "terseLabel": "Shares reserved, description" } } }, "localname": "StockIssuanceLimitUnderEmployeeStockPurchasePlanDescription", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "mnov_TwoThousandFourPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand four plan.", "label": "Two Thousand Four Plan [Member]", "terseLabel": "2004 Plan" } } }, "localname": "TwoThousandFourPlanMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_TwoThousandNineteenAtMarketIssuanceSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 at market issuance sales agreement", "label": "Two Thousand Nineteen At Market Issuance Sales Agreement [Member]", "terseLabel": "2019 at-the-market issuance sales agreement" } } }, "localname": "TwoThousandNineteenAtMarketIssuanceSalesAgreementMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_TwoThousandThirteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand thirteen equity incentive plan.", "label": "Two Thousand Thirteen Equity Incentive Plan [Member]", "terseLabel": "2013 Plan" } } }, "localname": "TwoThousandThirteenEquityIncentivePlanMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "mnov_TwoThousandTwentyThreeEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty three equity incentive plan.", "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]", "terseLabel": "2023 Plan" } } }, "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember", "nsuri": "http://www.medicinova.com/20230630", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r103", "r104", "r180", "r183", "r346", "r348" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r167", "r168", "r169", "r170", "r216", "r303", "r325", "r343", "r344", "r358", "r363", "r372", "r398", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r167", "r168", "r169", "r170", "r216", "r303", "r325", "r343", "r344", "r358", "r363", "r372", "r398", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r167", "r168", "r169", "r170", "r208", "r216", "r243", "r244", "r245", "r302", "r303", "r325", "r343", "r344", "r358", "r363", "r372", "r392", "r398", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r167", "r168", "r169", "r170", "r208", "r216", "r243", "r244", "r245", "r302", "r303", "r325", "r343", "r344", "r358", "r363", "r372", "r392", "r398", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r103", "r104", "r180", "r183", "r347", "r348" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r155", "r156", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r359", "r371", "r399" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r155", "r156", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r359", "r371", "r399" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r7", "r370" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r16", "r17", "r18", "r88", "r322", "r330", "r331" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r15", "r18", "r60", "r296", "r326", "r327", "r381", "r382", "r383", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r252", "r253", "r254", "r386", "r387", "r388", "r427" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r54", "r55", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Share-based compensation", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potentially dilutive outstanding stock options excluded from diluted net loss per common share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r65", "r73", "r87", "r102", "r139", "r148", "r152", "r159", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r261", "r265", "r278", "r370", "r396", "r397", "r434" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r82", "r89", "r102", "r159", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r261", "r265", "r278", "r370", "r396", "r397", "r434" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r32", "r84", "r345" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Carrying Amount", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r27", "r32", "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r27", "r64" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Bank Certificates of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r11", "r69", "r77" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r41", "r164", "r165", "r333", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r386", "r387", "r427" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r1", "r45" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r1", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock Shares Subscriptions", "terseLabel": "Stock purchase agreement, aggregate amount of common stock agreed to be purchased" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r1", "r370" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 49,046,246 and 49,046,246 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r19", "r91", "r93", "r97", "r318", "r323" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r59", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r256", "r257" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r30", "r138" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r220", "r248", "r249", "r251", "r255", "r364" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r98", "r110", "r111", "r112", "r113", "r114", "r118", "r120", "r122", "r123", "r124", "r128", "r269", "r270", "r319", "r324", "r352" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic net loss per common share", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r98", "r110", "r111", "r112", "r113", "r114", "r120", "r122", "r123", "r124", "r128", "r269", "r270", "r319", "r324", "r352" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted net loss per common share", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r125", "r126", "r127", "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r429" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unamortized compensation cost", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unamortized compensation cost, vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "verboseLabel": "2007 Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r45", "r80", "r94", "r95", "r96", "r105", "r106", "r107", "r109", "r115", "r117", "r131", "r160", "r195", "r252", "r253", "r254", "r258", "r259", "r268", "r279", "r280", "r281", "r282", "r283", "r284", "r296", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r271", "r272", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Schedule of Carrying Amount and Approximate Fair Value of Financial Instruments" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r181", "r209", "r210", "r211", "r212", "r213", "r214", "r272", "r299", "r300", "r301", "r356", "r357", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r271", "r272", "r273", "r274", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r181", "r209", "r214", "r272", "r299", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r181", "r209", "r214", "r272", "r300", "r356", "r357", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement Inputs Disclosure [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r181", "r209", "r210", "r211", "r212", "r213", "r214", "r299", "r300", "r301", "r356", "r357", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r275", "r277" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r30" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedLabel": "Loss on disposal of investments", "totalLabel": "Gain (Loss) on Sale of Investments, Total" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r85", "r161", "r317", "r355", "r370", "r390", "r391" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r384", "r431" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r29" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r158", "r443" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment Policy [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Operating lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee Operating Lease Discount Rate", "terseLabel": "Weighted-average discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total minimum payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r432" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2023 (remaining six months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r295" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Operating lease, auto-renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r8", "r102", "r159", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r262", "r265", "r266", "r278", "r353", "r396", "r434", "r435" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r6", "r66", "r75", "r370", "r385", "r389", "r428" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r83", "r102", "r159", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r262", "r265", "r266", "r278", "r370", "r396", "r434", "r435" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r42", "r43", "r166", "r167", "r168", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "terseLabel": "Net cash provided by financing activities", "totalLabel": "Net Cash Provided by (Used in) Financing Activities, Total" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r27", "r28", "r31" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r31", "r70", "r78", "r81", "r90", "r92", "r96", "r102", "r108", "r110", "r111", "r112", "r113", "r116", "r117", "r121", "r139", "r147", "r151", "r153", "r159", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r270", "r278", "r354", "r396" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss applicable to common stockholders", "totalLabel": "Net loss applicable to common stockholders", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r139", "r147", "r151", "r153", "r354" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r291", "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r286" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r286" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Current operating lease liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r286" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r288", "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r285" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r294", "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfRightOfUseAssetsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r86" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r14" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax", "terseLabel": "Foreign currency translation adjustments", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive loss, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r23" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other expense", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Common stock issuance costs", "terseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r24" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r380" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r81", "r90", "r92", "r99", "r102", "r108", "r116", "r117", "r139", "r147", "r151", "r153", "r159", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r260", "r263", "r264", "r270", "r278", "r320", "r354", "r366", "r367", "r383", "r396" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r40", "r76", "r321", "r370" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r35", "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Interim Financial Information" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r215", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r215", "r297", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r56", "r79", "r442" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development costs", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCarryingAmountAndApproximateFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r3", "r46", "r74", "r329", "r331", "r370" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r80", "r105", "r106", "r107", "r109", "r115", "r117", "r160", "r252", "r253", "r254", "r258", "r259", "r268", "r326", "r328" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r136", "r137", "r146", "r149", "r150", "r154", "r155", "r157", "r204", "r205", "r304" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMilestoneMethodLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition Milestone Method [Line Items]", "terseLabel": "Revenue Recognition Milestone Method [Line Items]" } } }, "localname": "RevenueRecognitionMilestoneMethodLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMilestoneMethodTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the characteristics of milestone payments recognized under the milestone method by arrangement. For each arrangement that includes a milestone payment, this includes: (1) a description of the overall arrangement; (2) a description of each milestone and related contingent consideration; (3) a determination of whether each milestone is considered substantive; (4) the factors the entity considered in determining whether each milestone or milestones are substantive; and (5) the amount of contingent consideration recognized during the period for each milestone.", "label": "Revenue Recognition Milestone Method [Table]", "terseLabel": "Revenue Recognition Milestone Method [Table]" } } }, "localname": "RevenueRecognitionMilestoneMethodTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureRevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition Policy" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r293", "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "terseLabel": "Share price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r217", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r48", "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity and Related Information" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Assumptions Used in Estimating Fair Value of Options Granted and Performance-Based Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r143", "r144", "r145", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r29" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Non-cash stock-based compensation", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Stock option, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Number of vested shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]", "terseLabel": "Weighted-average assumptions for stock options and ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility of common stock, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility of common stock, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockBasedCompensationExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate", "terseLabel": "Percentage of employee compensation for purchase of common stock under ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Shares available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Stock Options, Exercisable at June 30, 2023" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable at June 30, 2023" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period", "negatedLabel": "Stock Options, Cancelled", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Stock Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average fair value, per option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Stock Options, Ending Balance", "periodStartLabel": "Stock Options, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of Option Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Options granted expiration term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureScheduleOfAssumptionsUsedInEstimatingFairValueOfOptionsGrantedAndPerformanceBasedStockOptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Common stock fair market value, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r67", "r68", "r72", "r379" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Investments", "totalLabel": "Short-Term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r13", "r45", "r80", "r94", "r95", "r96", "r105", "r106", "r107", "r109", "r115", "r117", "r131", "r160", "r195", "r252", "r253", "r254", "r258", "r259", "r268", "r279", "r280", "r281", "r282", "r283", "r284", "r296", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r131", "r304" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r0", "r1", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of shares under an employee stock purchase plan (ESPP), shares", "verboseLabel": "Aggregate shares issued under ESPP" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r0", "r1", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock in a private transaction, net of issuance costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r0", "r1", "r45", "r46", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Stock Options, Exercised", "verboseLabel": "Issuance of common stock for option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureSummaryOfStockOptionActivityAndRelatedInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r13", "r45", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock for option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r1", "r4", "r5", "r39", "r370", "r385", "r389", "r428" ], "calculation": { "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r47", "r101", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r36", "r37", "r38", "r132", "r133", "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_DisclosureInterimFinancialInformationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r119", "r124" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Shares used to compute diluted net loss per common share", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r118", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Shares used to compute basic net loss per common share", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.medicinova.com/20230630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "https://asc.fasb.org/topic&trid=2126967", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r373": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r374": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r375": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r376": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r377": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r378": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 47 0000950170-23-040621-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-040621-xbrl.zip M4$L#!!0 ( #:""59MG@ =Q[S?GB1U>3 MNXLJIK+*-OO7GU!6%1<#AH8L4!7J&=MUR-T*AT$__Z^M)O_CL1TT] M'/R\1M;Q6N$'=NCJP:>?US8/MW9WU_[7+S_]#X2*[3>[>\6>_U)LVG']V6_7 MC>T/F\G(%S\#P^W7CUZLN7+^LN MU(-FV)^,X5+-NAV>O"H0FIY[:^1U_+C8UF-?;%!,2X0E_/^(B TF-JA:+PFK M_E^,-S"^^-7P]&Q4?SH>%S_8'XOX([CR8.#[_;/B33W0 UOK?G$XOV0/[M&N M%YO]?G$0?]44![[QH\_>K<=3_L=/QV.0!IK M/&9M>M#&5S/JN_K\V/BV/9)B7+V:?GGET/&-A_+IH>/+A]97;N#RT>4K$.(8 M'LW/CP>Q__&=P^/71C?GAW^]=OR5YXO?S@^MO]YV7A)O(^H[JGM^^& XV .U MCVI[\\_<>/1J?';J7\&!:# ]\ORNFOJF>X(G(*_^^]W;0WOL3S3Z]M&=_T;Z MC;?KGX:?7\$7\%M*YP=.&O1)Z]/S@X-N3'N!V1=7#JZ;(:-$?$\%TR/F/_#P M,/0FW5+\RG\=^T%3F[Y'OGWF=IPWB$9+FSW%>(2B7)H[Q!;/AS!!E,Q_>3(8 M?K[RHQ/O:EO#I[JUKV@2N"K/KV2'D\%X=':SS&9?7A7%US&"[Z]<8W[\Q0!X M-1[I01.&HY/VX>+XX-%\2W+I/#<_W%TGH8A6\Y,TH_%U!<*'5S4]'MVJ./4* MOEW[Y3^*GXZ]=O!O\=.X'O?]+P2C?_[T:OHZ?GKBQ[KU7,C_>U*#B+>& U#C M&!V!'M8*.WWW\]H8M/MJZA%>Q=.^FIWW)S-T9T4S/NO[G]=.].A3/=@H]&0\ M_!_UR>EP!&-X_/I4N^AD-PIY^O7U6GM95W^>_\C5S6E?GT6;\O#M3_77C7AN M/YJ^K)WS@_;EA=$5M?MY[\^OXP <0P,<@:&6XE\B46"-&B$.R MM!@Q([07H12,T[5?$"(4]/[3JRNW=O.=FM)A7EF#6%#Q3AE#4AGXRQ&F*T9D M$/[RG6X"I+@(*V_Z^M/#;B_H?N/O=7-625(:K9'WPL)9)(C1&(-H<-PK;ZR0 M[/+-[0Q@^)QMP=V-=']WX/S7__)G#[M)#$Z/TJHBU;WN%,Y@JTI:I+2'DU(G MD59PX\PH7W(AI2WMY3N=@_-4X^_A3$/W!CYK'G:W_[Q-V6]&VK:8/KU-P4VP M)>8P0$"63 E0=- .BAQOMMD'TC(-0?*6)JT+EB%XK)H-Z^H,/'S\<;H//:.J-0=T' M2QY-/)C9JZNW?LNC>*<\8\$@PPA#,%8Q7$LQ1%SI)+4X4,4>\RA$"2ZX0R8X M>!3'"9*"8^29L)HSIHDI'_PH5\<.G$EX*N J &=1*1Q,4!L$5,!)S$HNK?[V M2?9/6Q ;?'KK@5:\K;6I^S#T]X8#.W4EAV-P'_%)]\,Y"WL_;.IX&SOG:_/XD>;7_3(M7_][ILHS*EC(M]*A$C#G'$, MT=;VA.1(^U(@SXD3V)725V:MF-*(G]=F_&7#349?AB/7^,':+_L0I42-+C2GP (%*4<+]<$:1*K4"HH0] M#4R !^)W/_[938__ZBJQ&/G@8918W_SR4PP*-IJ6@\-]%&V0L!$YZ<]K#3": M?B3D[6?'HWB;D9:B.?=<_]JXZ(ZNGF-ZN*P AH 2\C,R*>P$>'?R9-))156G'%%FTI&8/[#_%X3U] MZ^!B7T_[$*&,W_D3 Y=P]4GT?C'U<&X]Y ]0;&!68$'#@")M?ZV;ME_EA MF\">HUF!)]6UVQULZ=-ZK/O3\_[TZL;+G0OO_*[NH'XZ']8_\TCKON!]HC_$:%2MR%WPC.@4>M'"IEY%\! M.+J6@'NZXH8$&C I=6JC\J9!40_N,2B64T48(B]B0D#!!>*ZQL:D-YKG# ;/&_GC M>+;/?CHZ%J_:^[HWVAUS%171CNN (,X!CA^ M (B 2^BI35E!0$XXPFXM\60 M0J.9-E08)&*4PW2@2(T I3F:I2[XCAOL#9SHZ.1][_^3#NT3'V9?T\ MQIUR1\"%*L"2-G?',+RB8'1 _FQ9!<-+YUD6#=XKV9NH!I/*DMPK(+[WH[WP+(G' MPDKB,=(:(@]6V1+)2D!@:;'1P%*Y4)[WM,8"6FH<5[ MU 72L>S5[\LUN-;>Q\ ,B#SSIH*!Z0-0#RJ5\-PRL^IL<7ZZM[6-0=OF)QAP M\=='?G2R A((9-XKX*3Q-)-78&EK[ 206LD/>&Q DA!I%09Y)@#+VP"%FSI MP?(YTJB+ 4X+NJ^,4ZB4, *8L@Y)QSFBRGM=>>MD>MF&!T_8+F="J!2^"A3" M5>Y<0"R 1],JV#BSSZC2E?4BEUTL3]*6EJK$)1!4B.MXK$^V2!).456ZTAI: M"6.S.O^\3R3S$O''^\02J!JSX 0-5\#9B"P1A!8*>4^HD4Y5):F67$.+C\03 MJ%?C@5OAJ@II3R1B(I3(: +>TTA/+:FD(,D%A M,58&I")#YLP$0ZUFE4V.=J3J!!.P-(E%P"8XY(F889K"'ERR#DX1T"@Q"R\? M>K Z)Z:I7:U'9X>Z[_=#FY&XE#'9'+_3HS_\>+=I)G&58#RJ.0]B5Y-QEAH8 MB<>($ZD0LY5")I;\<@=V"^&"H"J'<,MIJ:6CLM0*.*>O@-N(RH-J*XY4Z;3! MNF2+09T:QT56T@'/*:N@?:4KG&QZ\9[JC$O< MAH/6*R]+4J4,BLNRM"B )T6LPAZT @%\X-AB81@1+V^"^5'*(1WF)ZG0TE6@ M:ZM4+/.4$DFM#?*J4I+1T@-E22LYV^'(U(Y1IZA"U%@2IR,$,MYH9%BEN0H, M!FARUO!W7?G[WY]0!&8U>35G=QPDL6L0?A5[2( MYZ2)1,6^"+2\!_A\>^BCJFJY%#HN9M=88QA,)*ZT=]'KB9(H10E;_#3'0]W< M:LQM/4-LX*BKP'?PB&AE7*4.[I,8 @12Z("%K3Q)-M1; :4_3\Y:!:^UYA4* M!F)!QG2!N0-Q!9L^ %TD(9H,I6 M&L-)A:LD4RKGGO$W/_PTTJ?'M=7]J0)G/1LW_O$^?7 "G\H=-A&78F@B HB_ MQ!A9$CL:@,243RXT68:YJL6LI" !Q\I8S8$/5XIXQSW3R7JY MU*:?%F-/M@H5\U(ARQ6X,U ,\+R@()C41O&X4KY<.*U8CKFW*N 2QXD$J4H? M.X&4R)@2'#^!:+LB')=LV0OYGC3B[I ;6Z(-L&(=UW7:V1IJJRKDJY)C94P( M+CEN_&Q5S<^TW-%@5X9*H!!"B9A2'FDN#**\U#&F#((D:SUY7=7S#Q]M',:! MHLK&$B4OXC1$@!OQTC/O',=RX;.X"W:^3U?XT)G?U>!>#>$<5;+MLR,!'$N/ M$2&R@FA6$T\77CG];-S68Z4QE015.CCP:"5!4DJ!I*F8X\QSKM+EMBDG9)YG M$1]PW.^QCOSAB8P-[ Y&$U.#4R[)D3%.K9E&2< #$\\1ESX@IIV% M\($$Q#'U'@M)[.*9QI-%>#DP61Z$$< /(#0!VA=+HUA%XPXJA".#,?.8!TE# MLG'MDN2CNVR87E%02ZF0-X!M3'.@ D3!!8(TC#(+;Y)S(ZM5S?8,)EJY0,O2 M8"0@- ,391AI; 2)B>5P2Q,LR;D%A M*/A6T!5C7-*26ENE6]&0XOQ(A\M E 788W'9'XD5B1IXM,)&(0&N+]8M &M) MMEAT"7(;SQ.Q8ZPK%2M,!<;@#)V#8)U3AU2@.L0B;:Z3[0;]G$'#8KR?H][* M=I<3K QB5GED!."3IDQ9:SP18=G74#_ARLS.2EFU*+UV&CD6,&*Q[X[6'"-L M2N5+BDN5U\L^?11F1:E,,+'FA(/G"I8CK6*354:H%I0++Y.MX7JCZ]'ONC_Q MOYZ=O_P[G#&2]+.WD:)?5<_Y0;N#T\FX:8^@7>5>MG03(X/X3QPDGW7_AO'A M1_&9 35]LQ^V_6G<,K*K&[@DC7=>QVW. L$.1A;(&C+SV2,& 1(9Y[9C$.9;(NI"!,#'F*5)N4IKJQCV96[VLCP! MGF*E$QZ01E#CXB[2$$V4%43MBGB(^R3W/KF0XIXK#3XS[75$9 M8F\$BXP/)1+.B4IS2LIT<\Q+,@W4(00J<)).:XQ"&3>LUX;%S)A%NL)Q*_N@ M TVN4^2SK.%)P+*"(L!8@H%@4<<%/[&$1V+XBX%T+>A*FF2G[)8@=_D\#28, M-\1;YI&E%)1JI$*@8H.\PP17F)5!)*O49.8*$M!CL#YN.D@AEI &C!-HI_%Q MK[22E:6W)7,B.4>Z9+#791&5IUK%YFH*_D.,"H5B4("$5[+2R@J;7C>PE+*A M"<0$PO#28%4"&OJXVX85R%#)D>*$!&FUINFV8TK&<2XFJ21MI:6%(,U*'L,U M!M%W3'+'>08?5.FKG%=93@I:"2V)EN;=)])]7!5*3Z5(KLCV"7NM+WXUW!)T<;^TQ<$WC=D?Y;6"D=J' *01 W.4%4=2P04< M"Y1CK("N+'OE_?/OW_,\^3Y=*6:<\LAK5<7V7"72<0&,K$KK2OC+LV2KS9+) M]R70/"QPH04%8E&5TL:*,X^,EP9&B0=&3 28:K)Q>2;$2T:(.\PG$8KC%N8" M&2:!RI@XM^>\1=A7SK7[/[@D2/"+2N" M9B51+#U.N10]AIYI+VB ;&H-Q)-6 0J$=HDD<8A C&F"\I289#<*6QJB]E2J MG0SJJ5X_?#P%_WZNMY.IO_]E=@YX.3_!_)OY^WB&&\[6M,VS;SG?],L_><8/ MA]O73EX_6?/!B^]:\=#LQ\V3T!*5F\/^WT]:MK&W^?7#AZX.U<^WW\<-L/AB?UX*;3WE=H5T[QZNK=7Y'&J_KK!IQK.!E9 MWTS?'GN Q/@S^,$O_U$4/YT6S?BL#Q8:APNJ!]'Z-O Z_NOK $,(-?7_]1L$ MWI^.7Y_HT:=Z@,;#TXWI!^T109_4_;.-([#"IMCS7XJ#X8D>S \VP_%X>#([ MOKV$[M>?!AM]'\:O0?;-J1[,[^#+,>@*P2?6;X =HB^ A=?OXO)%__;OR7#\ M^IM+3S_L%0WH.KP&0:$OM1L?;X1ZC%JS&,0K_^TOI,*O?WH5;P#$<7J',$ZU M[M'.=G%XM'FT<]B)9!]MHRLBV<.=K0\'NT>[.X?%YMYVL?/? M6W_?W/MMI]C:?_=N]_!P=W_OI8N;=BGN_[UY^/?=O=^.]O=ZQ?9603%GZC8! MSR02W=D&:R69'CUK)7;K)[RDM^^*E]AAO]@_>%7.)7GZ2 MQUX0! ,<;# F-["+$./%Z<\UIV_1",_GD^X*\(])?L:5Z&I[F) 3_% M..XT!ODA)I6*_8'_\1NACC40_IN&KIZ,A_,1%.\:QNL&?MT>COKZ;#@9PR6^ M>O=Z>CF"6TW,?F!CV'O:^(W&GVH(3/W5$=>>>RU>'VY@-+_ZY[JI3=VOQV<; M\]_/#H*CW/DP;"_'X\5 *:_&[I8CU+>'P(O1MY<\GHI^)NOK%[M#SW,[GIDH MJ0>OOX D!EY_<=&^S>*']RL_,^Q!875_=DX@Y.'9"0SK\R&J!PWZ+CQYPCGU-"#)9!5;I'%X132BSG/! MO&/2Z:[@Z9\3/0(WUS\[\*?#T7BM:'=I&_^\5L/C-]Z"00[[1O?[P[$9?DW( M =PMW=O=JA*L>GTWH-UH5]D85@ (_OEA\^!HY^#MOXJ#G??[!T?%^P\'AQ\V M]XZ*H_T"XMX]H2J#T9H13Y$4V""FK48RJ+;;/RV](97#JBM5OJD;\/#_ DV] M@4^:)5=6G"B["TF_&S%FZKW"U'LA8>U7#M#)*(&J[@3G0+S-AI5F#B+ ML52.FXVS+L3+Z7#>[GY/N2$F?L M^\W!_KOBQO^.]F\B3JU_-A_HVYBY5@1:B!]@TDLZMJX M:^;G0?=P"[[S0'C )4=6\!(06GMD>! (.+Y2FE-=ZD?C^TY;C/8&GG"O?G-]:'B>VV ?-N9WMW:W=O__?-7K&[M[7^)VWVI53@ M=#NMN/-5VW$[L(IA*$;G ZK03=&<>ANKJUU1#XIZW!3VN)UQ^78*,KO---WF M+EX62YIU8^K.M!N]\XAK)UE 8NYQ>8<;1L]S3??=!?J=LO/22FZ)P,C[ MN&MZY3Q20L);:2S#I;+>5]V ?EQL,CH=CMI.9NUJA:WIRJ^MH?/7$W%-/.)T M-/P519[R3QJ@KLT76B4W]TI+_NSM;A3;LKKD;JH"P15E0HH?Z$ MJ_D.',ME0F.Y.O&2[#1<:O&V&(Z*=A%H\8_)J&Y<;>.PA_CI\I#(]\=E!?FGTO8=&-^III88XK/QW>+D=MSI)/:N;Y_1N-Y0+)IE3Q9QI;4-)(MXE;YY[1C(F&^ M$D(H&S!RP9. M;@M>[H^.AE^6?LKDK2[^$6N,NIUWE.>S;(8Y'C M^Q& :'VJ^Y=BO_T0:NN;/+64TW_9#!=HA@ O1<27[TY\/'[)VVI6OKZT4O=. MU\C]\'0M&;Q5C %#0PPB1<0T54@;(&2.*DP8TS[N O](ZA;3$YO@T)Z'K'6J M&#9E@AVJIY2E(CP^^19LP=^K >^6*[VM[]\C5N%O6Z*(]_WIW$T%=/AU"MV M![8_B6N$BNC?KK&%Y-1P!RWHM)MI2K3@J3HZ#.*"AO[B9EKBUD7UN(9?3E>_ M^9%WQ>ED%'=O&1?C80%'M/4ZA/Y@?HP!Y/C8%YMVO)&&'A(=E4NZ3(NJ=77W M,JWJCD-*D*^\XQBR3N\Z"UX7U7V7>SUYFFJ6L;BZTI+,UUD65ZU\B;*X#PIX M;R%DQF K&9>(NM)") "L3)*J1-)K52H@OHX]NCG;S(&=$6J.ZG'_&:*!3E,$ ML=,&.-MV5ZU>\9^@/DP*L/7B<]QT+M&)H^\: >6\-_\#CP,"OO?H)RDD-@A9 M*%BDI["7[K5HJ9TD!$-@1!5BL:^DT15&W @5M&9*/7Z/@:.1CAQ_VH5MR5W6 MN[W]W[-CRHXI.Z8%.R9>!AFWFT?<"8=8R0C26#!45I5FTE65D(].K,[IU,Y7 M>QRW=6\[ZUQ;5>_AV^=:4-^I[SJ"6'9/-T[_>TJYBNGFI<7;MUO=3)_G>O G M2]XM.%/R0QM>Q 2(U_:XL'W=/..$>=1RAJNEG!W/1O8](YL2XZ)IF?$/S8_9 MQ+*)91/KTL3V9MWN6ACS,YY7# <%W!E\K5'('O*>3^W+LVSXF<4;KHO?C1O$#^;$XUDW;Z]@5NM^' M;V.?_SA']N])'6?(QL/"^-D!<-+S2;(RMNN8-C^?395=FF&;!U5Q^BQ^'9N? M%PZ^!<"+AX)DK&_AC]"BW1FF*7Z \T'X5303L,WF>!@[4!;3+>SA-WK\S>(![?'@H_BGAPNS1!1[3 MHO"MR6@$3SW=WB$FZL9Z_"0[OBS6#O[EFV>N-5KL\]T\&)_U.3K;[2Z9)WIP MC_Z]X>KIAW6%U$NSQ4A"2-T"&˓T> ]KY/F#8:#B(043_K/ 04)P5NY'/ M:=LN<]C68UW$]O[?XOC%.2Y7OAQ,X$B&>83J _]ITI\VKCE$1\4/D:6)U[2D MZ[,#QL=UVR'Z-':(7C2H3^_W'*M]\^,3(S&N*J&8)<@R&Q#S'((\+CC"NM*L MY%X)3+KJ]WJNOZB^&3 O_3C/2+QLGCXC<=KZR4C\G$@,X*>+/LC%%]I:0.)8 MG>A:^C&+QIX,'@YBUDC>-KA"8CS+(;7<#:(2:,*/A4@TR_C MX_FWZQ!M^_;6G _UH-VBKUWT.*VXMJ^O76SZA0-IS ^YY2&N'WCK//L M^=&WW/'YL?5@RC<(-8C.

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�#7>SG":S(=AQ+)(<'4FVBA&K!:[4L!C#O-91Z*7;9")$MSED MYR&@BM]N]L1I.6@;;=5>UME:5PB)T*55]24!045D#O4]F+/!H7YW$9[S[.7' MUY]^Z>$AN]A Z])YMS)U2N8PXJ]8/[@J6R-1)4@KIO-@69E#P/O-.-T.G+QV M_M"G!?B79Y&O.O X, 6@ GBPC2EJ*V M@G8Y0]VT*5W?JN\U'@.6E7K:X(K" MOT,V@=>Z!DM!;[]CQ<7_X)Z63Q)NUH>AH$[<'#QU8':X><0<:E+UE?_Z$@W MKWY[^>YWY]E'L![.S?$R>KX;<^2W'+42?O_IXFP-,E0[+P7NTP%2O8/E=])5 M[4_!GNGX5']+S0#]C.CK/0RV8YQW_;.QCTG>=$M_ MH^)!5[7;=:9_*NLZQV*T2X;X]=N[%H/]R L=1T(#!*Q[5FJ="3H.EW9GA.[Y-8MM9OS4")I[5R)I!7=!NM':%!X@9VXK3 >R"K3>0L- M(-U(-G/H)6$P?",Z6A#AQK(2.DVZ:2NPW<^.QH&62HRA%X65F&-W,UEM%I$V M-[J=Q^#/E;6Q_+H5B1O)S08E;8WJ@,56?P^XQ?]1N;!FA52,32C%[IH;KA?> ,#?0AIX(CT&1T3ESI,@['D M+68:+_[8;618P/K8=1#_8(UFT9MO:]RV8*/"Q]]P4&V(OY?&ZX@O.^+KIC#@ M V-(Z,ST( 'GI-]1HN1N=&N0W]Y-5H+2J/HF*OWU$AR?\D)B1'0E88S81Z"L M=6.)NN1FJ\*F.A:WY??>D ;9*RH1AR.XHE?!P7>@]MB^8!,ZV^99*WF">XLP M)M#39M$E/B792WIB;XX6FQ"8GO2'-U>:[=JU4;.5KL74^Q1E'\6NM"+>/DIV MG3W.UKCBZNZ 5QV'V ^P[K3+.6/_ -UJ*I)TL;%Y4=UW6)!]?Z"5'+0'NBOA MMZQ?.A]OO]3ZRBB]JM8L-]@%ZP\4O*EQU4U-T*39;(,JJQ.VZH@^O&! M*H> M^/M7DWK8L 2^5%*W]\$=MK);N(=73@'VUN9QV"FCF]9VBD/'?1L@PTJ!HI"F M,PN\$#C17"QUT*,R8>W!)Y!UZW\S>[LY*]N,0*$Z;K8!=2'!G1YY)36C),WL=D MW9ZAL?(_LM[9-'L+#.H!L^NX_8_]8V, M$,*^&(N*8=,7CGGYZUZX&"I+LZ=]V)9/;AKI?-" \/'/[&S]XG4_ZTUGG4U% MVS-]6]G60*/ZE\M[,ZW\#HC1+;C]DDW6-N6+3/?"T ,$CC]W7^C+2<$NRK:! MQW^3XH5YE>=J"G8W@* 5;%W+YW67@NF)4VF1TL_^"=\/ ]CH74S9F_C,\_[^ M[B*X2FQ(9JJ%XR5U*98(_]N_-N**B[QE2(,;KW%ON")=1F[XPT^Q8QG;6.!# M=7D)GAJ5;XK>]M?>87CQPW#1_X> B)@S(?GQHC +P[#S+FL=-%LIR&,YCBD M,ZY26;URT-HB.;K*.FSMW:"T]BL,CWJX^B$&/PQ?'H\/=X".A^0"T!Q_^?>? MHI^LI#QPG/.H?/ZLCX@8'@TQ#LD;.Y]')(N6+^/DB]61,]&1GRX=GF,E<3J2 M:$W^2;//FORCX<*CP5D78-J0+5PW7=_,78P8NT1-#?;Z!I;CD,L;5L'P=<"/ M"2R'$8FV!;YQ\L6J7*MRK3'W?+[Q4E1?Y-)45'YLG= ML?$>N'00',?$)LL:RQJKR:PFL^)B66-9\_188Y7;)-AD66-98UECE=LLV619 M,T;6'#&TNALB']+8"_63CNJ^#CO-=<\?@4<[P0"L.19W')DQ&Y\80WIJ9%RX M@TP]H/C\:1R2,W[ FZ!J'$6R>&32. OU9V%H''R8TL*W,&1AZ'%@*$A3*X\6 MB!Z?Y!:(QL %"T06B![IR!OK$%D<&@')+0Z-@0L6ARP./0X.4?>A\A53DL=) M)P]W\[\V>3@12?S]/?&B:!PY_Y&)XW2,E._E@U6*MMAE]C9&$M_5V;7B-&UQ M&AG)+8Z,@0NS(+C%D4>(F2["(+$"]20%:F0DMT@R!B[,@N 621X#2:*46H%Z MD@(U,I);)!D#%V9!<(LDCU!0N/#"T K4" 3*;K^S&33B/E@ZVUH9MLQG_$K1 M5NG,PLIXN%W%5IS&)4XC([G%D3%P818$MSCR"-[J75U5*TW3EJ:1D=S"R!BX M, N"6QAY!'>,_O0G,IJ M',4)(Y/&Z1@81ZTCR.!J66TI%:X;IRZ+7#B["W=DW)H%8VX0D-NRQAHL][(0 MOOFN1Z<@H\.7 0VLL%HTLVAFT6QD F+1[#%3@:/8B6UQ;/QB.C*26QRS.#8N M ;$X9KTRBV83$=:1D=RBF46S<0F(13/KE5D<&\O6P[GAW01E\G/9L,*!:3-X.B:%;5L\)D<<3BR.-S818$MSCR M&(=)W+6!O16G:8O3R$AN<60,7)@%P2V./#R.I/Y=R_>L.$U;G$9&3A<21*K3\R!G&R6\SFGRA3C.=%WEPX;"4<(6$H/&=-7J[L3K-9&!BV M=&#D!+<&QB-4==IM9D]3FD9&<@LC8^#"+ AN861"K5.L-$U;FD9&<@LC8^#" M+ AN8>01CB6RWLC3E*:1D=S"R!BX, N"6QBQ,/)$I3\>F.&J)@#V)=;2% M.?8DUD?4GW$X >FT)[&.0$Q'1G*+8Q;'QB4@%L<>$<>>C6);W-1Q[ Z,?T > M6X?. J$%PA$PQ@+A>($P328@G:,'PJ<@IB,CN<4QBV/C$A"+8X_:YV041Z!: M(+-[$. MJ%M$M(AH$7&,LF(1T2*B1<0[GD"_B.)1-)ZSB'CW+#/\RX!.^N-5%/GY6H)X MR4@4X(WRD)6%^&%I,/?C()_G#8R?7TG\O\B5K%BA$[LO!5R5UTW%FOQ\F-B] MDNYT&0;!]92/ID+X^][#W%;.R8#8;(?8#B_KIG;650[4@#?!WZL:?G5*Y=2L M@.]D#6]H2OZ%9*R6 BXXP_R[/E%SX63P9'A?K1^-][9%DZ].3+Z^*I6L:[@. M7JTD#+V2!6O@&4WIE#"LW:$L')6OV(K#A],6IH>5 ' 5QP%D;9VOX%G#FH"% M4\@35BREU6C:/:%<L, M"9;.7VXB$JMD7WP 5]3P!-Y6E13+(ZU8S[=+]C9+MF]6[9RQ"V0"@&(MX0,P MNVF!1VMX>"F /\KY*C77*OG/-J_,PH.[\9FX_F#A5 P>VW)]GUG?L(B:4PD+ MB'-<<" '>"FL90&7[=2DP'[1;QJRK7UICSDG,8MM:*?Y3 @EX!O:D;4+K-3M-U M"WA'*",[S6M!:+\X&:7+@#MPG].+7UP'D ("9RT"-:$P! M15)O=0/>C?<8%$#$PWI-+7';A]8-?(&""; #Y."GJ(A.&>@N( A(I=3Z@L'" MJ(2&("WC?UWE^)A/>'/=*T" 9+A.KO$7MEU) -CPJG4A ;@^G_;/-1@(@___ MV[O6IK:1I?TY[Z^8RNZ>(J>,\ 4[7,Z>*L>8C3<$B UGSWZBQM(8:R-+7ET MGU__=O>,+L8&3+!!LB=5NR%&'LWT]9F>[AXP)8%XSCQC$QFP*$#3,>+?P=#& M$EIB?T76M7R0R!D$T6@LB1,..=B?P0"L%1E.F A8/)SM""=+M(3GA?JJ8_-^ MU@WC5Y!9CA>@#8:'D9.P1#)K#WQ/O@E7HQ;[ .W!2=\*Q\&_'YI:XDRL" UE MYCDBLW0E!OM#N@=B?T(6E <0MM#S2=%Q*,!+R$_R,"Z[ ?SD 4')M", @4_!EG)=I^V8T@@7"*Q(JP%P$_9!."P<8<0N ME%Q-(M-2%A$MT6]@12#:\$]D-RXWP^4^. SYD.=]AX4XD7B,E5(*X+VN%^+D M+<22?(RR#GP<^-Y($4%!.@/,8AC)=$^:'?IRRP8Q\N734H+3-4DJR">4:"0$ M]/Q4C26O)-^0*S -@;,G69EB'BXA73#HHX/6B21PR$'^Z+,IDA.&5(M/F:WA MWPK@GQE[SZS-2[RGCQ+O@7S,M8CS3*"J/\7@J\;\:"X M2/V WX3"ST@_[#:$'W);>1WXQ+&_"Y@(#$WVG^-W8/6P,GL$% YCG_(LCS1C MV8*Q,.V!;<+H@!L1V:9^![00)T#TRKJ-8U ;#B@R %J/8\?A/4'[$H,OHR$, MA+0Z@4*I0!4[=("V__CIKEJNF(=?P>=>DR&6G^P?!NQHVBLW,U[Y.%E_:VK] MW73]9ZE'ED/N'K(G4=9E0#XB 5ORF]8AN1E@E)0-7';3==$@=85$["X2:,0J MY>TO1&X.2[&$52)[B2N?" [F!#]C1\(4HS[0O58IL6JY6B6G["N?CR:Q+P2N M9Y*R/S8R(!EDVQ\3>(5F!+E+7\"$,]XJL._8"!8S#-1L?H].9[9\L"<^W:0X&_XSP<;^;!FDGE" M8[%9?%F2&5F<,]VDH.CH7D&1O/PL8.W9V\]> N36\(SZ07(TC$;CXQN0(\>2 M^;0X!$OIYN5ZL5>@W\6&DTD@@D4";" M#9.$*O'B2A26M F>>X,!["99?Y*);\(@Y7(E&23^VG)BDYNDFJ^ E=)T@8+K M9F7O'D6'277Q&'8Q\OA]FP]@M0?63X/ ]V]&"N!Q!W#0/L8Q3\F>!%BV. M&K+\"%$?.1*?P2J-::Q2,>K+Q2K)0:_$*I5D]/D8Q9TZ&88],.4(N*90:0R4 MTL \&?A2B]FP6,ESMXR-@DOYXF:W@[!&!"'KN*8W6B@C25N5A:4WH:Y-U"4% M!HVN3QN0K(JOPH#L/F1 ?/B.BWN2(1"#8NEJNGY\YF?R8$BOZG/W.\.(/\;> MY6\'L#FB? J#W5^G2JVBAY)!84OH9DZ6XY'I!SR9N.%.^]\DSO9X6]*D;YZ;#7\LS'O@YZ:4.55\59W%#)>WG;,XV@M9E:0O8]T3:[ M_9P7FR^OT$C5GS12,#?N4-T)HACNXR^IC!$@&XSQJ(7:+!NR2?N;]=ENKS0W M_,0&#VO9X81TLJ6*E;MQL;VN1ETJM4]%*'%-%*A2$YF/CST2TJ+MA3+!:$]MH6*@M/"YIQ"QV_ MH"&KE]E6MMX9AXV+NIL77UDS'BPNI?X@VY=\,EC7=@1(\:=N"4/(!MO*?O:! MC2,?IT5V,RE/Q\8/ 9:R Z(880/+O:*Q./?@US.I: M^I8!M3Q"$&O*D,+'>HI/#-8CDL2U[D^]M(1MI+@[*27V'SMK(*2B:FX!4-:2 M?@.[SB!A"!+UL0=(0C8>;@,5MR5SD@IT(94^F3#' 09Q27HW D>\6ZFCXQA% MSC7!\+072$^8D2]A7-.DKA65_5IMNE+==DTGLG!H*08T<\OVA1GBT;_+3GE@ M\;]+S).UZ9X*_=@2*88^IR\KF8H#/5,DH\\DU7C\(/90\(UIUB&7N1-XDM4S MP^!9E0\@(\1>":ZX]D);;CO +P<\[N"F^C+$[>/@&]C"8(Q^G#O4]X,$7?6^ MFDS/8$I(\.6V;$3@*T B1:EFU'^)H0H8B@#W0IX)8\KF)^YD>MX!;-03IM@9 M13/8>?P]DMH@%KJIKY-( =05;M)WS(VHD0"VWQMR?\YWZ)4PTWN+DYUTQMAA M!;^'N@:[,MGR0:J!X*!P&8*N%_K0+N49.T3O(>&B,^TIH19LRN;'C51D)C:* MW8)QW^)(FPZ\ZDK3%5::[NM*TY4)XG:E8NSN5GXY'',+H7G0NFA>= M_[19\_2(P07%^QKL_NE?<&ZG=X7 M':-<.CP)J6F9;6(PLCC 8;46:EEM=5,3M7N%D_<])[BB38X5 21<"Z.T:[QK MG9U>=,].>FPMC!!:U?/N6:M]A#9H>2=FVN#@_/_ H(Y-[0"SO6AC[8B;V2L- M2;L]6B( *JAX@SI,R#1NG3U7F&I5GVU*WD^:X*;]" >V P8BF!_S:=^IT]HT M^+,['?Q1T9KL@R6,46U5/L"KL?,P/D7+PLZ"&%T9X:'O_[ _+C6>5,UR,;@7 M[_KL4=I>7?6J'["W832*Y(FRO#!@-(I< M.O6S9/?-N&=D-GB%Q&@-;3& Q0 %* O[#,]@@"R4PD"_2QM(JM])H=B9W$^/AN91R$5N0 M$JV&]P//B5!^YQ@4+^Y4FQRP3D]%]H(6H<$^"9-'0=(PVW:'LI&R8X]H8T*- MSEU:X?00 2U'-5'.MHF-29==03S9^W/-#HN'$R*YA$-ULX9!B;!IO)V.@:EO MJN3%@A=M/!V,V*S["9YQ"#G%XJ/4$;:RCO \42:-0I:=FI$XGOY$GO]4:GR[ M4M_J?XC5=MJ=4RZ#[Z,/QG;4L/Q434L9X!!$8&YN[*3Q,IW7T7D!%H*:]GA* ML7_,+*>_GV.:U>P%71. 6;SJ:A694X8H*F,5,U-9 (WQ9""5[Z'.03#IR/1N MA")G)M\$;&'VIA< ^+:4Y>D_/ :R;X#J825^IT%9D\!]X0L\2GN7!#I8#*) M-H$K-8&M-)&Q$_MV9?T8RE*&[]WXD@AM!I=J!N/&Z8'T_0 ]XKQ4=RYTDWQ) MV^>GEW>H3$0R:1Z6,@D\18!' ^RS_G<$MH_L(R@=OB[NS([7!I!"JET4V0VE MCY-,/_^9YTO/F]]Z!;;T&=#B!*V6]1E0@:M 8CFD2"HBJ"O;OO+\JTQPIRB> M\2%RGS>[%ZS3,=C9Q>=V=RU"J*QS>GS6_=J\Z)R=KCA2OZ083QJIKUS159=7 M*A<)PX)%ES"*TU>,=R?MWYHGZR%@%*!O'W5.?],1^N5'Z./+Q6SWQG-NU UZ MV0MU2$581D74UG#Z.ASVATPY[0LJ3\^.%M_6AG4I47SET^RH,G,5N\R).!O* MP[@Q]S$Y,/)EC"VYIC-[LR>\?6C#ILZF;%&J0?""P,9]'L:F33/R90HDT-BR MS200Z0-=Y'5+L,VG>2=W_*DKJ$J4WV@!U SB&]]B F'=U;7<5:N8)*[?PY>I MM<"L'0LPL#\B!!M/?2$ASM.!9H5? 5>^7ZF+]M;#1#:-=]W.6AC(WA=VW&Q= MG'6U>5QZ:Q&&VD;+A.>+K^:>!$+AF0$3#"S@\B)+P*/ M XCQU97I160PQCE 7]8I)5GN'3QO 'EE75!"=BR_DF2[K^"6M5)BBZF'@.?# MF'24J"Y)Z^-A"MT7J:[DS)J[F>W[E.TKS;V0#^:D[IA6U_+)*EHT.H&Z2:__ M_ OE8L]&;*,3(!H/[RN/XZY8;.E.#-947,8X CV$JTHN':2381R)[B5W,-I@]@R8(Z@;9'B2^E5'UT$UDJ2>_R''K![';0_R4UP0G9 MP M;GKH93Q;^Q4=:\:UY#]^8%]\/2B1(1!//[M!]RUX0TT?I2[W:KVA>L7H5 MN;ZXM@,J&+JB2H0K67MR%5"4.UP+3UDUWEV>=MN_=7H7[6[[B/6:)^T>.SMF M[6^7G?7(1?P3\RPNNYV+#B8BGAZQRUX;5ZAV'MJO+CT3T5VHO5">U+UV98D! M1RM[%8T]%U3,=T?MX^;ER46/79ZG$9U"KPRT^[1SULTH MN59HK="[5[C[![\]$."QTS/E]5#D7>/=U\YI&[SU<7LME/CBSVRY@%;@5=8& M%$V5ZVMV3$0:7#?>K>81]+D7R:(.C80?F0 M'M]V^,2+0AC^3EB'\E65,E%0?0%DP>'C0!P$8LPQ[A\3QR>NT]CO\?TP ?]! M^?II0']F!0;3I:EIY>0@?I,:#L:S$N+2Q/:,_<8O2/>=T'K@D0K._-$G]F%Q MNU//P _^_04,Y12E?9F=SQ/Z4(!8WDK^]E>5GO;IEF37Z+]"DMC3W&572]'P1^J3&2EER MSE/%E>D/<.)AY6'TEFJ]7HK_ R8 P?*N4T^XEJ7R;\:SO"[_M/U[97T]HN-T MNJAH'M.SOO'UI&!D6Y8C%N9M(P\ ;S;\4%PM1"NJB?]&Q-?"_R#]'T'J:G_U MBE#]F7PJ\#T9*PZNU8Q*(2S=*W$PCRQB1;&&*^019T-?#,#@A.$X.-C9N;V] M-0)A&M?>S4[3-X?8'6)'6-?I$.XS[F&2)"*[.P,PV=C1U0^;ICNV)EPM,504CY MHJWT]@G,K.\DN:1V>I%\EU+H?(Y5\9GNV5M3B:=3&:>AQ]0FGN$MH3/CI US MOLE:5&G9O4\]P:MLZQ@+"TX]@P%7MVNURE[]PX-G+NKUX$5R[%U2T4?;V?J\H>Z-7NT BV'0QJYKR=RKVIK63A=W# = M6P)NWX/C=J&X/:FPMY8_)1@^$\3A]\&LRA[.0B])0NF[N/S MO>TO#\'SL6\[K%J75_:\ )[G5C,V*;ZWH8YC@XBOA5\'MS<+(E?2Z/8+EX)D MW=XU&GO[V3]UF.N/H,R/SU\CW16+V(.N*P;<]."JMRH?M'W/F7W9,+L1P_Z1 MZ]UL(V"_V@#(GD;854C]W =8;H^Y,Z?5:O:>R)Z@R^I8K5R-\7F/^WWNBF#[ M[ [OOU,=\*OE\D*7C#V35"L[N&(:_&O[I)U#+HBOA;\8X#^'21'%1/Y5C?SS M:MPWHBIH(\D_"_RK&PW\9^]0>#GPUV ZYW@B=PJOB:^%7X/I?("2(H+IZH:& MT?]9".NNT?2ZDO\^FJ[J,/HC8?3*'KLT>D;+2'!UI58OLZWX7_OEQM,H6R>L M% 9IY,X2:.)KX=S-CUAIF:YB=+YBM@]8/!ZTUS-XLI)$[2Z") MKX5?P^Q\H)4"PNQ*N6)T3GL;B;0+8=\UT-X$\A?0$'"]Y]07#&]HL2U5A)F.D$XK?9SSEQC2NR &NR)W6:^)KX=>@ M6KO&%X#J7NNS!M5YM>\:5&\"^0MH.;*@^H+?>:XWFK#V'?PVP&ARSQR*$4]0 MMD:W17#PN5,_37PM_!K=:A_U G3;:IYH=)M7^Z[1[2:0OX"6XPETV^*.&3DR M!>/$=K_W>2 TUBV4N\^=,FKB:^'76%=[K!=@W:/VL<:Z>;7O&NMN OD+:#F> MP+I'8F"[MH:ZQ?7VN=-%37PM_!KJ:H?U JA[TORDH6Y>[;N&NIM _@):CB>@ M[@GO"T>CW&(Z^MRIH2:^%GZ-@'*/>^V-'V/=+[I1G?Z6Z@[2P[)L%J%&>)<1?41#:@TD\_L' $7?;0TEDGB*@(>6'8P=/CF074.VD3Z/OO:^-#U"X/3UNT:] M5OMEVBEE6#H]AZ+3]_V_T3I8[+/P!;9E24095JS^GS/U+AZ%_SD/S^5PGBS^ M<\^>:>:_@*C843298_J=W>GOW X%?,=G(VYAURG -P+'X8-0O=B"F2R[SG6RDC[D%Z_M(/1QJ"&X/RL"%T8=%BWIV'SISJ3/1O6"7X"; MPO:+?3'DS@!]-PY$'ED]@(Y31.C&:3P>A4//!R)8RW%>:VI *=P13T>M &=Z M /3S#ON>#P2F"0(*@-TJ/;X->T4O@JVF?2>L0_FJ2IDHJ+X TNOP<2 . C'F MB+9BXO@DIS3V^_M!_AL[ -SHV.'D(/[^G%"_?%V];NQ5<4,[-["GIF34GWJD MAG-^_(E]H]&8>N:1\XDR190W^WABK>.\8VY9H A20\I&Q78U1Y[%$: __N;7 M]]7WFZ@3!]Y:X/XS'-U!>W>6@-G 6:!;*+F M@.: YH#FP!+R>S1^+F1 >,-:/K* C9?HE5R]6:!N6% >5:RXJ@99\F M!V_*017:2:A<'X[EH2O-#\V.]^#&'^#^*?Y;/ MC->#/_>BSDMEZ9^1;0YMUKGEW^T2^VH<&25V/H2_M*?2FJ@MH^:'YLWD6*4;MP:VF+ VG?"C"CM]FPPL$WA:\>E%5,;2LT/S0_MN/+B MN+8\-\ZF5;F[F;1<\&7:9VF=U#92\T/S0_NLO/@L'MQS5/_XZ:Y:KNP?!NS< MMUW3'G-G=O?U:,>'/+@RG2_VUOKZK!0537Y-_K4BO[8_.E]5)S+JU-("<"3_ MY"]@2IM.+.)TY%M&L[:EL95.]RD#D9"$"0FP &A;_?5[ %Y$BA0OLFS+ ML^QT:HDX5WP'!P<@A'[Y_=%ST3T1DG)VTCD\Z'40839W*)N?=+[?68.[L^&P M\_O77[[\P[+0^>7P!MV0!S2P%;TGYU3:+I>!(.C=W?6OZ,_3VRMT9R^(A]$Y MMP./,(4LM%#*/^YV'QX>#IP999*[@0)U\L#F7A=95B3\3!"LGZ-SK @Z[O?Z M1U;O$_P[.?QX_/[C[T4&_>7@LX7"KVS?T6:"W0S1EQW MB2XIP\RFV$5WL=)_HR&S#]# ==&MYI+HED@B[HES$,I\E,ZQ#'U06,R)NL$> MD3ZVR4DGY8E''&I3QN^Q<4/K[?UV!-V'E1)T&BARR85W3F8X<-5))V!_!=BE M,TH,"66B=+'J7 /)+$/YOR^&S5JM?V8P5'"4DN? MR(R=AHV+>1>:N[I9\_2LWJ'5/XPY"0N\?E:1YM"$7?*H")-TZA)+DQ%A,))6 M7X=*R"Z%2IAG6$X-,SS,6 ?=FK'KX2C2T3OL_GE]%49-3.Q2]K/8"Z _ZNKF M*98D)@^D-SX5"80Q?<=L 5J),?[-BC99^ M9!WVK:/# Q#60:PP^C>8VWV:$3&N6QF1!,6V1L0@:>T?-NDM1+661IE763Z\ M:IA0,3YKVU4X#O0'2W\H-20W>IHI+1RJ7>(J&3\I-:%XI&_G=SJGQE_J^Y_) MR-L%1$&&-M]EK4%0E-^WQ"+.W2$.\*T>!DG*7ZG%C'%E=.E'\4/?IVS&PR?P M3(_4I[VN+[A/A*)$IJ<%(V AR.RDH].X%>?J'RZ> M'D!.C4ER"K(Y13=W@86X5ROS8EY%E6:^TLT2F1PY&Z>C%_?0% M:>HGL$BH2@Q:F]T=IZCVS6F'S)HZ#2R4T7*7SQ.:?7/8QFY3AX'%#MP*D,]6 M1+5=UM(GT([TA^^WPSJE4U?A1\ZXMPQMNX7__(@7#O'? 7,N&-BU'$+.$)XQ MJH,H5)/UR6-+8UM7J'\][.E_8)626K D'S%S4"@-I<1]Z:X+61,?2.*,V%?S M>7U41QX<[\!GL\PYX\R!$H4X\ '6?M2!Y\XI M=G7%>+<@1,D4G$VX*E ]U*@F\I!>*48B45HFBH2B4&H+[H[!'6,!= NB*#B] M'=)9$16P][>"';W+*/FU#8.GAT'2*D>SD1^O3"!!GW$/NFRAURWWY(K+^@F@ M@*N"( /6P6 %H^,_!;V6M5^ M\@IAR!01U$NV[#>4^[7H*Z#]S=3[JY<7%HJ$I5X8M/7^UDC>DGO" OAC\WEH M62& !605N'W,X1;)0"DA+5K-T+K$5/R!W8!<$ZR_FU16"%@Q905FGW*8:3'( MR$%I02UNS7"#VM.CRG2=J7^9HFQ.('F18O3*Z"LP_)S#,"4L*H13XEHDFR%I MBL93;(H6SX<28_.DMX&T'+_#7@X_(\?2FW_A(B:6U$*W!72;EB>E9!60'19# MUBXMG@37#5%ZD3XFXFZ!!2G$:IVF JA^#B@08+8"$(A 1D8+T\Z6 F-8=VV< MXNKP5 6T9? >K[NC4H>A<*;,'<73%: FDU M5P6P'YH5IBV\.ZU02Y M9:@ -;\[LZE:;?'<_00[4%]%A.7W MN#;5B!:*S0I?^(2&H= R4W2D;$M+ >IT]DH,;,-S]U5GTVRUI:CRH.KG-][* MZ],V@;U4I?J0YG;!= 3-%7$ M5WZ7L"J^TJG+6&/QF07VH- @PQ.9A(Q-*&54&X;/&8;76 7"]'-RMHG-=QV! M3914!%]^Y[-)\*T,29VK@FFT#;H=%&]FP3Q=7WY7SHE/$5 1+/E]U7!1?YI? MU+>3X)YGG_Z+I)]^54CE=W6?-_^@?AMX#;<- \_#8AD=OQSY)H?H7XY3M5R5 M/O4*]&UE5011?@:(T=EY ;T7$Y3>[TQ-5RBRD[4(4HBVQ;&U_*=*+(O-, MKDH9&)5;Z;S61NSNSOXTW71J)J$BBO);Y$4GAMKJ^IG/%#6-@0;L%0&0W\'. MGT3Z?X7_2W?MXH'H0>9Z G,Y070WCX%*_]CZQQ@*/5A01!-\> '"26?]:?C+ M:'.OR[''&?2E6 X5\;0)'22#*61L96X@^B9XX,>D%$@Z*/P,2Q#*G8D1Y 0B M.@3*J.OJE]PG'24"$(5!DL"V.NG,L&M^'6Z8I^&O&8&33&GZ1I*INR9?3+?2UR"X6SK83?7+\;TFE?JZ[M&V@#()(+; MA#CR4G#O#KL1"6=F-KC&C]0+O"2*GRYHO8/\4.1KHSYYX),%#R040)<\$&,8 M'5G02PCV$O/36PC-Y>7I[9#964^*6O;2A71 P3SEB=#@/836G R>33"\>(6E2F7T8+<^*QL060M[.>-'6:T^P2_\V M.C;,VM5T>SDJ($D+74B=D_#OD UL8'..E%@E?0803;RA!W(_4@HBS0.C[ M*5(;TW%'[%+B&PH3J/+U31T3 1%@/ 0Y.DD(XF.:.!MFB0UIYFDR]C;?#!@+ M]/HQ#@>S\I/Q-:>77,3Y8R#3!> H4/H:1WWU:\B1R21QGSV3\#TM(^M,1$TF MK;:,*1[H?8B==&>[47G-H9B5[U3'C] MPSOF5'HNVSR7]+W-0Q>>[_(E";OEYO:]="<% M2CP$!^H:BY]$Q;E);PW+P1RP,AOHFS!MQKZ7G?$?"O,0''K_\#4$L#!!0 M ( #:""5?G#">NZ@D /%Z 5 ;6YO=BTR,#(S,#8S,%]C86PN>&UL M[5WK<^(X$O^^?X6/^[);=P1"=N>1VLP6$Y(IJC(A!A,L).'LJG9^UJQYF/D\ M(.SEJO8TJ+<'U]UN[9=/W_W\MWK=Z]QV[[U[//7:?D0FN$.D3[F,!?:^'WS] MP?OU<__.NR/L]V MO;X<_EI@I*Y['11A[[+5;%W4FQ_@W^/Y^\L?WU^V/IR]?W?>_$>S>=ELKK'Q M\5R0EU'D?>__X"DNN#=CF-*Y=TL88CY!U!NL;OI/K\O\,Z]-J==77-+K8XG% M! =GBS$I(+BD*Q@S22ZE/\(ANN.^%N^JMH9G]BSH&1=%(N'(IU*?Z MBJRN+M7/6_6+\[.9#&H>6(-)?>\2-UF1SS+TTPM-??[QX\>&_C8AE<1$",.> M-W[]>C?0..M@H0BTAFN?OO.\A3H$I[B/AY[Z_=3OI@8)<4!\PO@$:7LJ S3? M730;$9IQQL-Y0S$U^O#CMT$$EE63XIJS #.) _@#I@,)X'KP&5%UV\$(XTB" MR/K.(X&'5[40AJ^O1E:Z^ON^XT7S,;ZJ21*.*:XU3HPP^5;VAKTQ%GH^R38# MHG L\ @8P*_NN#P&_-UOYHQNKI$+7" DZ#TFDQ= 68!&$ M6 BU!$OE=4%,<6^HXU%O^"1Q6TJL*?N8*A!W&!S^CJ!G0DD$/!T<(4)+:>=$ M,KBER:\HBH66,IG[[.5T2MSC]I757\NR EM%&O01]6.JHY\J3E+4>!9AB!G! M:@REL%,D-R6=0;ZV\%/B(>&O)(,_,\*EZX(E14/&8:A'JQ.09\4_%#R\JL6R M_H+0^+/-'3*)YHE-NY*EY7 #Q50WJQ2E6$4,7C_ I MEB B'ZO;([JP@B,XKV,AP#@F9&W?YS',QP%UTC(>;@6/]"-,:5@9N:AUNG:34-:9RA:1-7!$^YN*(2 F>:MK(3 ML700W9+]$MSGU<%M"#JJ % 15<10,J8TU(M&6&QQ3]=Q%\;9!X''B 0WL[%* M_RO$9M]U'6Q!E.W@(09 09=!680?T6R-_AY7!V9^R/W">3 EE%8&2KD U X" MLI#X :9JEUVC,8D070O"E0&\3_PU42WAMJH#=TL,,J^6YIOAQW6PA;%V,.(B M>L0B[+()EHN,:D3G'+2"R+J9)>\Y\RMIO$Q1T&4/@OM82M5PA_'4FJ2#)YCR M<5@E>"4#K>_'8:P[9]JDJ:[K(FVJWBLDR]X0\F=ET.=G3+ N!)]H_D 1B\"V M2C?:LNL%P87C\,H9MZ]:3PP'-T@PB+5RS=A0&1&?5 =POCW3J62C,9S@^[&Z M^%ZK);"J,YBJX%I)%=75!.U MI1NHN]8[%#UCND.99!=*L=26!=PH0O+E7!%:$#>O@VD4.8?8AMBF*F]3VA2- M!2%+=D^-PI?CM:;YK2JW(5;IH.9&&,NV+LVS8)/,DJBYC<=0W1?< MHU&8DG-W?@MJ+]42-*J_#*<%0(6-/R.8(BX+0%[[>T:)DZ]M!.<2/3ISX"YF MM "GJ"5EA%+ 9",W&3M.YNQD(K6A^2V])+/6\QF.%O(+VT#9*%_$8J?BWJV] MDU>*[S2*E0RVK:N3D[JVL%B 4*9;8P12@M%Z/,WT94J$TTT>6Z$IVWS)CTH9 MVL41K\9F8^D./KMV^&N'H[BVVV7)1'F-/N8&Z 2S&-\"KUH9".1'_R;1Z#J6 M$7")FYE/8_44@;(:_ O6.]RNG^M(5+"LO;,[&:LTM):#P)@/8&0P\9*K,G A M*&^WM7%*5 2<(:%NIN1UJ!NZJ C(DCYKF-?9G?ZZVPA-+IDLV3 #*@J>V Y" MPHB,%,\$;SJDZ^<:"AVRRR(L8%VQH-+9L3+@=G3(;57Q+1> E"V6A/[\42 F M(0\I-"S0GY;8@O_&BT589K/5=6T5QV:E'RB*>#H$;$[Y73:53US$9O'EE:YK ME%86$7M4/#FKBMU'LFFAS9B;9Y^$[FBM@G)U5K9?4(K/@DJ-[KRASC2-G9V" MH@B=W2G(Y;#1V2VJ \P-WP(N"T",>=XHO(G2UJ+^#;)U?E?@^#>SI;8M23P? M?CY31;LCKT_H.E!Z*6$>!)\04,/G^9-4^U?+-PI =E;O0,BK<2!5 MAN]*&:L'_P#:ZR[,S0P+G\CTQ9ZNQLRK3N<*4Z6:C5,-D'0C07PPZ/+40_K" M&N4#%H2KO4"AFI$=O/@-GQ=U#Q1 (\1> <^R35R+I]*K*. MWP525B' -B11I1H7.8 7NV;E?:Q#Y)A+1'M#TV'PO_QH'S\RVJ ZJ^8#_&@P M0@)_1CI)A2J9ZMM5'7R!3R5!!,VU]SSRM@\33>#VR U$LO3,GK MXB_GVNI+8,CAKS*+,RX+V>G:B.JIX;;9L3MGE6]90J[E],G;\(#,"85PQSNVQ(=RWF$:P,[QT*3K9!1_C< = M[6]9#9?3OFF -XE-.;VM[?''S&3ES+RYEV)4=0ZQC4F]0Q?$/.G+#V#E&9XR M:W CL%*L-O9\MZVES?N]6S@L '!A(6O4DP."'2VPEE['9L-K658KQP3V6X_F MG"38:[ C/AUTO!5DUHI''-T)0^L-;4".B_\%(5./HR)OK!GCO89X^3C&= MX*\PF4;5.0)R"N6HJ?(XY979K3Z93B!\X\J\_^Y46KGEL:C,7O')E$(FN#*[ MQJ=02GL889'1S#OG2MM==;'YUKRR[*Y"RZD;]@=K'M!5^,;2X"!+9X9S&'J2 M^ ]"O!K%=:"+;'XX5#V.XV 72?I@K'H8UZ'J!',X5#6,PU W$NI!>--C?2,] M@-;_;Q/@B05JPREFD>KXJ_>++79U*M-'/40S1>?,W&NG?JLU9_XTW1UG[ECN MM&?W:8_GA>'E=?5#_9?)G_X$4$L#!!0 ( #:""5=YV9%E,Q, (\] 0 5 M ;6YO=BTR,#(S,#8S,%]D968N>&UL[5U;<^.V%7[/KU#=EV1:6;8WUYUL M,O)MJ]:WL;UI\K0#DY"%+DDH "E;^?4%2(HB)0($)9 9 M^>7HIG<#7WI#)T0S>(ZHXV$:$=C[^N'ZF][OI_=7O2L4?'D"%/;.L1/Y, A[ M_=XD#*?O!X.7EY=#=XP"BKTH9!W20P?[@UZ_GS9_1B#@W_?.00A[[T^.3M[U MCWYD_ST>__#^VQ_>OSLZ//[^^Y-_'!V]/SK*5UZ+]NXAA60&W<.D38]Q\-Y;L/%* MT7OJ3* /KK 3D_?A(,?/ZQ/Q#C%Y'IP<';T;9+6$)?BG_J)8GW_5/S[IOSL^ M?*7N08^-1D#COA4Z613GO[IA5B%?^+M!\F-6=*WIEW=QV>.??OII$/^:%:6H MK"!K]'CP^_750PQ)GPUFR "&![]\U>LER 'B$.S!>SCNI7]^NA^M4X>"<. B M?Y"6&0#/8UW'+4P(' OY7[#$L?N.H_;W7,UP/H4?#BCRIQX\&&Q-$_L;!GQI M]%TX!I$7;DBAL)WFZ,4^0,'VY!::T4UMW'C?A_X3))N26M:&9CHGK#GB1$^P MGP&S(;62ED0T+PA>I99WYD,7.2C ,Q +4B[YCKY_=S0(P2L.L#\?Q.3?LW\^ M/X1,I')I?(8#E_4,7?8'D\/(9=^[V:_T=OP08N?+!'LN4PH7?T8HG!>9]5E_ M_457,5?:.F@8@Z6ZNH!.YQ."7Y% MC-QEU=MQIE!'3/*36,%3-9S:IZ2U^72&?1^%,06,7#;Q0T8^LZ,0I/HFUG:= MM#'#XI7-+1-&G3]E0@!LN;0T--W:''B(?!^0>2K?3E=)O7CE?T+%M:*C[?8X MSU;ND-+(G\96]B=&XRBXH"%?MFRBYA;N;5+B(P$!4PUL+M]!$H\>LR-CWF(N MTU*;X=4>1>VAO*8V]8F6C=JNR_D8T*?8-(IH_QF :<(EA*X_N'@-N37TY,&+ M@ ER$O=VA6A(UPTMNC#5UMIC')X,H!=2_@UOG'*F3V*&>3=5A#/;'"4:F_NP MA<*0$^A"=]$$;]V(*<:I7=#K8:= I,?]4UQB22M"QK]9(I9^L227@0)'[,]L M3#SP!+T/!Y*" X/D/@(VG:I(30J9)#,95R[-<1"K]E=4"7!I'0-,K-!Q7G 6 M5X@O+]M%HC\O?'@CTT;D.ZW-E;6"!LCE)BL.8EJN"Q[Z"K7KY4Q@.P$$TMLH MY!$M'@ 50;M6S@"Q2_U\!Q S:\[ %(7 DZ(LKV.$B?]%-/%H'K& NACM-PUA-^=SQX:=$(>&NS4!I>-$?N1Q"^(VG$#"J29PPJVJ M&1P%S":!\KFA7-^4U!LQ2QZZYQ%A*R[!/08[;YE?O$+B(+HTT\J$8JUV##![ MSXWL +H7@ 2,1"H=-D%A>\8H$98:!DG6D %V;V"8K(HK3$7V6K&, 2)%*YG3 M,PCCP_IZ[M]#]E,URPNRT#P@N'O9! B9=V4K M&&4;CINM_W57KK,L2YWJ/-IM>%O^EQ7GJHHVVCS#X:^[#,TRF M.,F=$1,E+-O!0&M](5LT(=5DF)U!&>7 ;#U1701(71K:"9):]+:^U!>AM!-Q M7-UP[$!$5ZR)..MJ^J&S03\%YL4*R'J_HL53">U;4!E=0S8YXV,#5P@\(8\A M"FG*IGL;,-W ?$;.6^#>X( L/IX"BFB5HZ*W#P-FI@X&9.Z.OO:-V.!L%B.' MK?\S0"?\W G['X_2S8#'IW;YMQ4Y*ULT:0"":V8IS:\!^0+#RRAPYT9)3$?D@I[/69RO94)AFQZU18IJS5W MC2$K1FH43*.0QGKW6#HG934L&1F:&;IJG,BJFI"#D(1HS+S[$-+;\3F<8HI" M^>$620UK!'D&]](?KB77R^I;LF).:J^8D^Z&Q!OQ^//Q/8W>)%FLO264=B $W[A@4W1#[010>3=0>["S=$[* MG%X[ 503:M5.<'$K;!LU83U.,KG6'E#6B[:ZVK(J7%2E!-8\7^MQ4520FH&Q M?N+4T(EUPL2E,)4%&'8*%D$\J-*B6@M6='@;7Z_3(@V$=!8E0V9F:?C%3A#M M,#5E!H:=N)F2YR?-K$E=9\;LF$ZJ?KCUZ4QZ[@QM/W#+SZ\4R%L3HBMQ6TD% M W'G-6ID"4&"PKK(IB3,D=DMB:70 M.7S&LX'#<^G(/*$W_; D-_WB\Z>'%=IR/YC92X9<,+ 5=T0O,8D/;M%'1E;%408=;9M8 =0(.Q'[0= [LCV(V<,(>-^!B8 ML*P1N<#6\\7K%"5'!_CC/\="25!25!N >3269Z1$$$I*:Z.H*/.*C%^SV<[7 MPA]L4931IUQ7&[75SLUM%2^EC:8 MRSJZ2-U'J3ZM6]L2Z"^8+F/T.=E%_8\X(;C&0(C;L$9)IJ\XU%)^BSKZ= AF MH(1L-5Y&841@MACOP#R.(I3JDJHZ'_. MRT:,U<)\D#G#EL(EW:=6R_:B]3"_ _O--86B@KMO)Q3*>Q+R ML&\V)<1SQT[^5:]-T!C_6$D'TB&6K<=6?@F#S> V)'PT$WGN&S, MPJD(-'46J+JJK2QB92?S&I699N%D9T*"L54EBSYV%BJU=54SUMG9ZVV;F3C5 M8=?. K:]QU&(VW;V=N :RZA.=+BS5P-O/R\D0>7.7B%<#Y6**+1>%'ZP#07% M:+?U"7_;/)%MZ(W%M?>K_M4E,*5*KO]I&D/84Q@K"KID&]R-?2%KQ=Q-K.7JBR$6 S'.+4_:. MN+#\;@DBHP]U;ZQO$Z7+@V2!JZ0"&^G*M Q/?#)U25XH;^+]Y0Q*\;HKEME/ MRKI=&;VD1)SDU).GPQE 'O?,F<#XR.J*CLXTUET3B^@21T1YN:P4-C64ZP&W-6R? M5K%=[FTES_?)QDY+^UV:Y_$_OT$:9J\;B@Z#:.U"VWS.GFCDTN8*^2C\%+B0 M%*S5NX@X$T85G[_GD#H$Q>9KV8S?IKDN#?M"Y66/9L3;GH\3$*0O6O+Q@NY( M8"R-:5:U<10RUXV%M(M#'%NV)H^*V!;NWNY;YL0G3!3 M:B$TU)7)$""3\2CUU=8XN\'!+%;&,1/T$8?\I;7E[V>8ACLG:8QLV](2FRR5LFHDOJ/#4D8_>9+@S)_T+T/.%(S"!A]DO\XWG^ M13G=6GY#*CIXA%-?KDD^:TICRH:E!U2J,ZS*@Z]95E6]W(G.HJ"^1*WH.E["D=5:S,D"A( M>(5U;3T8LK.%FM'H\ IH8V-<*/R+*0Z68J>TO$J3'PJ3J!%\K8=,M@B-8/86 MENI&5OT&Z1UV(JA\VE-[ZGD>SF("B9U(J8FVLE28,DYW0B;58[;#EP!LX,@J MY?=T#H@J%Z"8!M0Y]MJV[X192;N+W&9!M,:2H.P$V@ZMO&)R=O9. 76IO9I0 MUEF6&UR&>A+8[$36[+I;"2%V]A(&RW1 :8*@G>#:(?O.[AO42\35C%KWPS^;YOIJ!K*S#GRS*<::4>Z\I]I@5K)FJ#OK@)G* M8=:,_]OUVS9-;K;^?KV5!W4?(M\'9)X&4=:02F]/I/L+]DH:WE^P)VG? #C, MX\4^S%ZGN.*=<)K%MW[(:MC#@/1.$'F=76#"Y#4Y0R]N%[KERT'^Q)EB96UG M] 2W<0=L=?)K86G:H?@VBGH-&!B.CS!@FM=C% U=GRE*&O)=NQF4<5:O[OY< MT)LY%Z24+Z>@4_*H50@_ZY&09=/IA&*?N"M8=JH*I[.P*9D'64RHIDJS$Q4[ M=LVER]?.-#.=TZFF"=$Y/SZ;.D-*(S^)7GRB?&?Y@H;(CQ^*R.(4BS7WETIKUCF9=LUI M8#9GKF$XP2[V\/-\^$33AZKT*J4:/7<=T'M$OUP2"$?,;"&0ADU<'*?<[_[R MXI:03C65J8%>=+^3T":3QQBT:?==AY:[CP[SI'[#'FO&8YYC6Y))T/-N MJB M() 3L*/PMB<,Y 3L"KSG:(9<&+AM"X-"OUVZZ%;&%'_M57IW>C,=[K<$]UN" M.W%!W([?G&;/M0G[:['>P+58#>X0UX\D:?Y0(QBTK8.3([?&M(%TZ\V3YY%S$?.Z\<>2,C(XH?O[T+3:P? ME(:D?1?.VMD_-LT(LRY"(IU])J7V27BH]JE[)694VPO)&7E--#_@DRI_+>AQPZ2YC0%K'1.YV MD0ZIK"\O:X#HW*UITD3S]7(M+;Q5P2,0^*7%=DG4FKPF(3?XL;%%\Y<:BM9G M124#;-P1-&,RX\X#CMC,J2B\(V=[!%HX?U\H'S]$^6[";?"18$KO"'8@=.DE M\YX3G9$7"J6IA9H:U<9?[J[]&^9 \:<^-[6$-VW*MK?*;^!+_--&3Y,O*YMU MM.(K0!EA,575[E6QN!%)M)SUB]FR(;5B*R)M.4:UK1V=#7A8]Z"8$AK*$]N\;FP-#)?912#\N MCS-8BD&UB)?&302OGG9Y%51%-3*!KBX.K8=!]&2]5ASVMXY5/Q=<&K^Q$RX[ MXVJS43=6D9U5?BL8PM;(VTO,ER,F MW7\QE J\MI$48\0&UA]<\'H4L=5R$40^3![FOD*.+'"Q#3DCAP M(D(XYO*+_.1U#.S Q8_.EE(EX$!2038ITJ_Y/SPK_9?_ U!+ P04 " V M@@E7I6544N=8 F)00 %0 &UN;W8M,C R,S V,S!?;&%B+GAM;.V]?7/C MN)4W^O]^"MS96_O,U)5GNGMRD\QDDZ?4?NDX<5N.K9X\V=2M*9J$+.Y0I )2 MMC6?_N+@A01)@*1$@J"ZMVJF;4O 0X( N?U=_[S?[]N(O2,21HF\1^_>OOM MFZ\0COTD"..G/W[UZ>%L_G!^??W5__[3O_WG_W5VABZNKF_1+7Y!?12C"X2?[?!<8;.T#K+MC]^]]W+R\NW MP2J,TR3:973 ]%L_V7R'SLX$^7."/?@<77@91C^^>_/N^[,WOZ?_+=_^[L?? M_.['=S]\^\.[W__F_WGSYL09!]]RFA'EX,=(LO&:AC^F_AIOO)O$ M9]/[XU<*/Z^/)/HV(4_?O7OSYOOO\E[&%O#7F6QV!A^=O7UW]OW;;U_3X"M$ MGT:0DGW[W?_Y>// ^#RC3RBC MJX:_^M._(<27@R01OLOPMP M2*?Q[AW\<@:_,';I'S]?QG0B^WD0$)RFY_37!5DF+[&DR:;WQZ^:6G[7;XHK M+WUDR[1+SYX\;\OGB:,LE9\4$Q8?_'SEA>0G+]HI!T,Z?TPSXOE99>:=NCA@ MX=(C,3W[TCM,'M8>P2W3-S9WN?K7\7:7I3?X&4=O/^+-(R9MBZ_I<3@#FSAY MAEE]_^:WW[]A,X-/?CY/-AM,X @.?V7'Y\?4AQN6/X*0 W;9=GY/;YF /HPMCE/V'.:$ M>/$3AFO]_;YH"?%/-TW2WV;(K]_)UBWUZ@E^$P'(+'%A'(3/]U@.GDX\))=G#6L16LW%ZR$/GTH>/Y$,'L<2TPV M:>,IT]2C)P/M]^B1]Z2Y/KA@($F"ES"*3+.57SN86OG-8<+^8D5/6WI"8-/IW-S'^GZ52M/? M=A[),(GV]WB;D.IDFUI.Y'B[";W',*+BZ*Y+U(NI!A,GI)LBO'>XR, D>YD?-C*M_LMTGL[PC!QE>EO=]@K\4\ MCG=>=!W[!(:ZCID(EDJ[R55"KJG0!2:#.:A"]+[/O"=Z-2VH5I%Y,5B3>(_% M"D3[)'[($O\7W:MD9R#G#U4(JJ8KW=#8R2M#UPO6F K-.T)G1%; M;93L,6:-[G;$7\-L(R\V\74LM<'V[77,SN:4[2"/#D&/IPM0KB MX*$H6_GBZM=MB-8OAR&QW$XG5-2/!=L)\Y7M/NU2>^=G_M\Q* \XF#_33Y_P M/=Y0Q4U^"4KPVTZW004W)!RW-^$FS*B.@XGQ;KS J4]"ML]UEUDK2Z4?O-=SL-OE)O'O,3UX;WI"VX89S M[]$FH>]%2Q)ZT=SW"57?X6Z_(WCKA2 '@_$_O4NBT-_S?Y?X-7L?&0P O>B- M=(4];+PH>K]+PYB^A<8KJ]S*B07P&<<[*C'ZR5,<5MRHV3H)FLQB'3L[8(M9 MXEL.^W*;(:W#P<[/%'. V8=M;#O56X=K%E1:7*RNPI2^@G!W]+E^] 2G^"+< MT'?TFHIF)CO6 001-W*WNU"MQ/5GH3/ M=.VHINMCXVG=TG@TER^W$E[&P45='C2W<[&J8NL)95":&]@&-:UM4Y=3$N.% ML?<#;9CEEMW*X3*S&63,Z'SF(BDL<]CO$+E? QV1P@7JB]AF(D)9G" M!/VK8(#^\?,]/(?Y:UC=U>7OG!B?,DSOY8R;E1;9VGBHZ5HZD<#8'7;GD6RO MF(W2]WOU&\U2'T' F4K2J(M,(9CY(HQV=*DZQC++UH-I3\N79+E.=BF5)&^I MO)QA',^SCQ[Y!6?R0@ ;8YI'"IJ5JV-)C60@$-'X=_1Z\Z+_"K>-IFUMX]&D M#JZ9\1ODBGZFLV>8V[IPAF.2A:N0DH8HCPN\3=*P6;!KZN'BL C^>R?BPI8) M??A,GZ3+ZH7!=:SZY1^KDL$]_MO#CG4IXZUP M8.4O-W,%8;*%*\#HR3NLKW/O<6Y-.2SX:]J9$;TS(IQ&$8(92V03WL$1 K)Z MLTK?J>M(=])5& FSCO$F4IJX76?8#5=1\M)F,FGL,A%M1^>5FZ_HD0/6T*OP MN:^'KTQKI$/X 3_!^!]P\D2\[1H<-L9#U]QV3#5.*R%4OW6[Z^OA,-VW?T-? M%TSM'M,P"#VR5X(&&K0[9@>P, MZ,3F6B1#2%VL*>R[>S\7AGZ\PH2 , +FDZ7WJABT;XTY1&V]W+G 8''/DY@= M#'\/L_4Y50GH%(G))7]P=QO&@N4Z)*#A\W.-+BK=V?2N@_BU3A:"]O[3<=H) MHTO-[W:8V\Y(Q45^(([IW*)Y',R#31B'<"O!\HM(CD;-O5M?-\E5FMP YG9$.WB19);?!Y+LMO"@("V1GBKTC R$R)X8LV)&G8(+0P;L16[U M;L]AT[8=UTPK?MR$,:Z&Y#>W=;"V>;9O;D^XCN$(8$^[B"!H41P.I>)$A=AN M(W;<>9'4[95)MFE&'7L[\=W)M.#F:,CV]DX,'%3=*'*;X! W9;%HF[H)U&>Y MI!=8YI0>9FCMWO\$XQA:D]8J N;E*\#R"(W34E1#OSDYC(=9)G.?7M2$SB2A M6R3;@X:1 0_T4UV^Z1$$II82?(M?V%='90 7G5TF)[S?Y[_^.:0[BHK>>P:% MU6"PZMC9A<^_B^'0O84P/T.YC03P;-H<74I+QQ$L+>I;K:$3)[/6P=MNANO0 M<;CL_,V6;K_%ZGSQT_6%C./HG"ER0.\176SDG#[]IX14Q0E3*Y?OGDRF:7OS M\G;#)5)0]NF%)PAKTR?*+49Z@L)2P:&4 $PD\S)M2$QC7=,G_$W?N? 9\QNWT4+;O;\+66BUPG!#7+[Z;,- YN,BGH %< (3&^E 77JO MUP'X6UC\'1VY)03%U-Y]AO^-0/]NT J:>KB%#6H*#*PUI*_9&O8$%YL5BOTK:>@7K08(\SM)Y$JW&W# MM_<[I4BF)BSM)N0JBP.>DG&]B9N?$GHY,7\!"'T"IF-H2_KA$Q@MWX0E;X4\ MK: %V;C6U$D &%5G_)"[L/ VPNP)Q '5.*G&SXL3&*/ .G0=[ HT0GPMJ*Y1 M&-YUEU_7KL-9?Q*X5$,OXFB3.9:" 26U6Q^W4%K,^20SYTROLZFY(]T@Y-E M(*9Y"U:SR'*\V&*X@ R(0X*.,9LUNK%9#T\/ZN8G@-%_!50JC\$?/9^2H< M!^6!_15Q"2?/.&^Y^"T--AF;Z3R3CLI&.WRGOA. $6F[8_UW[FQ=G'H 4&TJ*;U]][B$VL<: M4:K69+CR!\=:N&6F8R&+\B7DH<:Z);VM!X6>G;3B]U_O)5!%Y!R"']+S#K.<=0&C<5DEV8 M"\*V4?WJ:FT^8<@=AI"3['H!FJMDQ@+:D1*,"I]C@"0UMSVU/&M^(-7?A>.5$!/#<5**_PHP2+.ZQ/1!K=)3.2?4#0A;=-5AQWC M1!>IJ2+- M=!TFK=SV5FJ=*+,R;(ZC(NLO+7H" 7P'YA;4=)GP7-K\>ZB <9MD_\"9>&B_ MXD ";!/E.9HB;D>>Q*A^] XYP,>0F9@W5;HK]>I&6^Q\?\)3#3YLX?PP&L[# M6. 5ZQ2ZPAI.S8[RT;,$[IR1!XW9,\&KM,Q+>MGNNJVUG< ME=T>X0"$G<@;+W.?*>80LTZ2F/[*2WEU*C]Z-!FW'J"N4*%3BTC-U3D>?,A M<]YUJPFLZ3$=\9;CM0W@NVDB-*U+^_ K>A+OC-97W-9Z)+O_QS &*Z<1M;[\ M_1164RTQW;0C&CI-,?KFD!2[^S#]Y8I@+(NNC9SAUS2\,XF2B7\=L\:;>IS2 MWBBG[8!OHD\#(:2UT8;VZ1%6F><;G-YV2F'-LB.0FW39.#RM#8E;V1KG%2QLYL=K^V=)I, ME85F+IK[3,VPID06]0Q,F@IK@-8!\1IQTWW>H>-8R;T8QHNNXP"__A6; RNJ M[9R(HPG)8)4*1'ACW+NNZ7!!V[EU4('4%["WRZ2"P9BR$"OV76GORN.QT;UC M:20K18I>Z"+OE[0Y/KI.41<2;K+[I344E+)V@U9#AU-2XW0Z-MUC'W&V3H(D M2IY:U9811C[U!=7#$HVQH(:1!SL<=)<X\M8[+1[KS M0,"&8'C=WNWWLG.!.+&>^$3&\"\M&6759/'(4X^M8QM)"2<># MRE3UH>@$=T;"=:14D<-^$OM0?%X%6%HFPZ1&6AEJ AC9C;$2AL8.IDTO?+S_ MZ)%?<':UBX/F:1L:#U=QII;-)735E!X@($@)7)XMA6$U[*2*4/%]H8E $(6M]_-Y1&=+>FAZ"Q3$:MB?M,+TWN M%4^VZHI$V)7,* ?C\!O!$T?:HA36J*;-O2>_H0=+ ?;LXM5Q0;> M,?:X8^=3>LKU<"3MV69OG(E6+Z10* M:T0W:N[CZFWND$8RB=R1NJ)]1_#6"Z'F%Z8;4FK84L'F J;Y41Q#;+ #Y/U] M&.']U?M[.A'SR:%I-<&,LRY8DDTA=,/1=[ X?]MY),,DVN?P]DK42IODU['S M"=[SREEA5?*KCS,:'M-5F%*MG&.#^=IZP::6$Q%.35!G5%[I:1R25": 6PW* ME6^*6M:V=>$8X:%L+2Z-P>0).<*V9!**5/)H+873I.9CH MHMCR\X)<9A&FH?4I[>#Z=7.?1-%50N!+^W>;.IB+VZ-4L>+@3*[.W=V R:_" MK*'^C]+ VE1 M*1-KEFLOEF556#JAM/$.?0T?.KS;B[G;'='082R0"PY.8 :Y*'WOU-S5*:M5 M -@"D/&JBJ3'0H"[XRX-/=ZD\7$,JW$ 5<@!AP4YF)75$D6N"9*V(@,*3$> M2H<3F)51H-5VLGXS&!,F0'0,'3^1/![- V:YR=^DUG M[S!)<("MTT#'!;/X"5:;UW _,!ZB6]\IP!_-=]DZ(0VX"$T]K,O 2^*![>!A MOWE,(HT,7/Y^L/?V XY_I4+4>4+H\V,7E?E=-;9U80G@,:CLR&#/JC%HV=3: MS;:L0L&VU-YLZG%*"D+7I ]7R28.$[=E]'FSX=C0V,7;)PH,-L23EYJX/?[O M/+(@+)"#W[O2@]1^#1A[#G;^_C5,4QS>4:(;S\>[# H"G2&6&SW65"U:SZ2N<; M.#A,Q\H@M">#398?]T7&K^E%[]R_S!Q00:^;B/X6/_WQ*QR?%<6'.+_T2DEV MI+TZVSG]=4&6R4O\<_282WTDB3!?'KHZ+R\OW[(5@L5Y]^;-]]_!U]\QBE_] MB5-#@AP">FA!$%#\S^^*H2<^ZN/_)A $G$ M:"*%*/JG)/O_V>.F]E+VXT220Y0>8@1'X4(''_V6WVK]'PFGB3A1]$].]C28 M4=\61@>]'7[>3+8 V0>N.B\*?^4:7CD,X-"9!R*HBI"$=B M8]4YR>E:W%M6.%)W5P-;]MX4@Q59A%GJDKO[L)B315Y.]\=39D[L2#H0@I&0 M' H][M'7,!H*XV]0P78QXBB'NI4PL(L06(P#T-N/7"]^K;%1D3HSI$P-O=\C MM9V8'F+S0\KEHDP1R3DB.4D$L_R"%EA]V_(UV(ZM+:GJS< M&1^\,(8HQ$7,JR,K**\'3Q^0M\7T@2SZ&@A_@^A-!;11LD(*]1EB2-TGP5G4 ME:EI<_,#YR;&3PS85KS#E"AP0T_5;9)Z$7 4CL)1D@0O810=^S!$]^E-4'V- M)SQ+]6T5-.R_DT=.=LO#6#*/9+4IO\=/80Q&("KZ1N XG>KT+^.@-OE+%H=O M?^9ET:P"\';D&UB5-1E5M%BA3RG3,W!V(ORH+RPC=9:LSG:4"<\.$VH27YZK MR>-2CGP4DAK*R2%.;]*3+ZE?XW'0*Y<,A=3S$ M!T1\Q%-= +VT 7R%X*1CUAX>TV#)_*@"=%T(Z::7&%BQ$4OZ:$4',,E/MJS% M@S,G-FK.%!!&DC*F>N_M->YH9B2&YN MI>3Y+\H #=_8MTJ,N28EWP&PZFEXMFCZE.@L#%'B6$.P)(+^RBGP2=%? M4,H&043,"ZT2@D(Q,ZHCH&T^-[A.DF)VLB?]U&<31"G,T)9,,(GEE,96OHQR M,O07[I]*D9P/HA-"])/^<00F]GGO(KJ.WH]X%8K8A\8((3X60_/U%&=W<8 )%3L1EJO +@.TE:NPI8.B MKR\?[NZ^F5E_74=:DV=,'I/"J?7T1)@Y0*Y)R#<+7QK@W-*9#CA\"=@P].#Q M?8/%/$+V+$Z'64C@'*://5MC],CMNI1=C#,44,YGZ&4=^FO*.6NP@LB,9Q:9 M(;IX/M5'"+..G&WYI%&&_77,:K7-D,=*4(BCWXOW,"C)9! 4R5-WD;>B&Q)M M6-(B6M%#)Q1"*WV8Z!'CF ZU#C'<(J +27+AAIY9A GL]+&3)VS-A#'P0XGD M;8D$623I,OU6H7P:_)1%@'PO$,D4/+3 )E.:-!,!N%$3B:YVV8Y@>>CUB%24 MLAT2(VF%1CY:+CN>,.?5B$:I(90%O!7G-[3.;U]H*;H>*QQF+$(]#HIB;7FV MBK,(.#%!I,R0G0K*'$%%X;/\$A98:YWGKYX8:T;?0;K;H@A_$0NB<8NSD<]: MMMVCV'9GFFTW*]92W7A>9>.%QN6**&_?6#S U,O"*/W\=XT: MR4B\\"TRY,/@%,=^)GWX*!N,"Q[&TO?.P64DU4[,I*E3'^%\*6^9-I^1RY\%AO-IA4@ KZ)Z=C\3#L-^&2JUK. MVI*BFMM^0+Z["3=A]@D,,$:KSP5.?1*R [FGI82?[;G!.H*QA?6GT2H6%#.P M98T8<5%J]E*V&&Q,](F;PAK$$J2,?/IK4;KYR\Z-F?K8;2:) U1-CA3$_-7G MO C,>1(<:\P0N>(ETHC11H(X NHGPY8F#[Y$?R:82XAE_A186+7J3<^<1$X- M*<$*8R0<^S) ID)BY4X/=C]1_]2J(]P'0[/ M7.FH$+D7EAS!9ES3 43%<]L1(_UG71<&99#(*'[+@PJ"K D>.&FRB.^18R$Z M&(+1$!ONA#E77Z)W;][]=@18"15J/2_'.A18ADHSI&"6HH1RS? %SQ$K=>Q'8. F3A]^Q'S=E@LY5-.@L]2#:-C(YH9#?O:6Z^YFA4WELMJ M,7,KV/F96I5M"!0V058-<[*83S<(!]+Q(&:NT+.-MC84!Y6DN2H;CG5?[J.D MTN=B5=0_[:D$?X^^+ER3:?B*J*";K:TZ)$=CM63IF%5-';/"UC%#68(>(=0^ M#&8H'QM$?SXZLW\XO(INZ'5_G>'-L7)/MYL(1D%L&)?7[M&\'G[UCL)P)=" MUU06A;G5@I2L5.Z1S[<66L%'879PD3^DI,.PD4Z488W/; =&#_H"^PP &P+/ M*5T4XPQ%@.]#W_I<@8<.I\JX(MV8'G>B>]PS_KRMQ=>QVG\ -TVPU\-IR "E M@89%WV"?:9948LMSE1NJ *AF"76Y@>H>1Q"YRFJ3L0?^J!C0^D*4%H.*I,/" M+B;&16Q@5(Q<^ K&)=!CB8D\@\O(0'(BIE_L)EKP9"L3S_?->+P M$AY[&?O##KEC-[\\#_- A#S4B9$]#69*+X+D")(ZRY%L_@EPI$WY*&4=C<5. MWZR/QA(X[$MX6W(/K?.L(S[?(L&H'@;.6K!W7 'K_F(?0#E1HQ9'7B3-SIAF MDUC.%=!9:^YQC%^\"(+DAPT^$819(L#)L*2>DHLRTL$,>;LL.2."KLVPBJ<4IJR6FAH88C/0DJ/T\1!)5JS\Z"!+ M3@F):$M&:](3+^=@B]F'C)Y-ZR#3,.\\DNV5H,GT_5[]IL].%RHLHZ.&A:9P MG96_M?4^V&>V; I5>++MNNOE7YS:Y.IJN"U'HJE"V 54_,/'IHYK"H0)@I/G MH%R=A)%P8=$=BAME(]4?RDP^%6LF6N8C7;XDRW6R2[TXN WI6F(<=ZGKWL^_ M^/8'Y&5G]/HY$V LN9J5PEC(DX.=-M/BA:.C(3D8;XB(41@(VIU$*Q M[!X?:14J$0SBZ:/1GWRM!.8=5>F]Z+_";?^D)EG$DY-$E*;U7*8AF&@JY3D* M*]*LQ_WI7'>^HI\=*S'D9D+AH!?&!49RXAQHK9VCL)%C^V"2A2NJ1F4 U7B! MMTD:]COY5(I@]!0T1[#Y#\B+^F#>>_$OJ,15DG-E44YE &?,W+E,Z O* A?H M9O/"X#I689@>J_:K>\A)IW/##Y@\AS[F&TD)?^AC#52F14445$R,1WUV?S_300H69 M=E8 [*Y8YFV:J;O)FC#-K%E8IH?D(A/+_,5D"UIV;^R&@KXB)*HCV 9VL,ID M&?FMPM3H8.)# Z-/G@%U^45TP7BPO$/Q4#/-. $9[EXWN!=0/=6>?(:HK!0- M7FDJ))\BHU'!XX&%D4^16W7?'L&R=9"\' 0"XJ[9^%0D )D77*3]XLH*?(G% M"N7$D:1N-72L4*:OPD@$9O:S P =$78YS>EJ-'ZK<];L(-C<5U'RTCLW0: MK: P0 %/52&C;+M^1^,$0>X4'JC M4#U^[K$:/Y>CYI'0QZ4*00*3HT^LHL;FJ M5?-1$*A8(@S"Q:J4E69KI2UA0 M(R0_BSH4?KPB^%#@J-B,YR^*8DI'Y1 %NLJ%/G.OK/4:6];X*MWBA,5(B"$L M)B?A%28$]&(("5MZKTK"R^W1A;4E51DG1^DB%4#NUF9E[8%9*CGZ)%\992BR M;RL4";"PP\Z3F%W,?P^S]?F.OM ;3/I"Y$,SFTEZNI[RT4<#)G.(HZMEO \?%:[C FL MISN?+-,=,ML#=Y&0MID_/KO==O"D7($/.*;3B>9Q, \V81R"M@LOK< ^ZW5* M"=H,::Y,74*KC1!)8X7!LGV)<^G5N+0I'NCJT2G*E10:E@E5FE8)V5PEA.5+ MI$M*OZ<77U^#KZ29YL+3,D%B!JS0&Y\#@DF,@%CM9)G*(I92VL^P5K-BL;)B ML5;Y8LW8:EF"CN!08@484;\D;4%.A1>RG*@]% ,E&\&H7.01?UZZAO]!>'KV M(@X714^2T =,#/H%W<3E#Y265-:*=G!Q7(3I-DF]B*K+NRUL>\H#W5TAE?,# MX>M(CBX'S)Q4[!]E:%1,BG\'QT+U,[5]/EL@\DK6OUR-^"F.&#O>%KYHJHL+( ML]H+.ZN^S3.VI@VO^,S\CGOF=]RZJ,NN4YXS=YO$?B_H4$8+"0#1@MK$)U]* MZF8(;T+F4'"O >QL_TABA'8>@-@"A27D)P$ M5I5(F3MR@?G/ZWC8]( \-T4. %E2#G(&K/'9]!1'B;VW7CZ]8O*^?,7$#T6T MA7-8+;6F^KQ24[T!:TLRP6-=_N?AU+9RRXJ!TA?[.(IL8FC(F-IE,O>IKD@H M5Y#=DNW!J9?!>M!/F76T'_X=H\ZC[UEZZU8,PW1/+,+7]A71T=PYN":])7E MY.79)WR%= 3^OD\E<^ F)#6 _@M<.EH09B MP1S#E9G_9!'P:(A8\1$CPG/)DX?LW21'EP8K9%@1>0BT)CUQ]=Q7)'"KTU:! MZ7KZQDM(>R,XN/M.W 6FGAZ6H7\ = ."QS@1T,-SICX>A3TH3WA&+TF?#V I MM.]ZLZ7GW&)UOOCI^D)";-DHT,D'@GL]6U-A('Z"5YZ->O;V!\IL'.!-Z%LN MS6F/6VD\R;ED0Q10:M+ *'[:+[IIC]62=%?F%QXE?07A"8/V[,7[__CWW[][ M^[L_I*/4K(0T87).S[>GA!QK_E(RC@F2M"8[:4.NM,V9U^0 64*UM_ABKQ;K M8'-N0N_ UJ;/*P72)TKU8S'SGJ>Q(";G;*T^8Z\YY[80/E=!99)3+1>< $IG M1$A:]K9%<8:(<+9[O$T([$7(>3T:H%"<(S)$+B>*.-7I\Z$Y%,=CIF19*>4Q MWR89+ISA?24-728SC%#RMX_BSK3&:3DEO1CD?PE^+9T$YVLP]8-D3\@>,',V M@/2U6-V#?7VQ^I1B%J/3\P3FHR FX/-QD,<& F&*P%#PRR[%/&;'6K%Z.\R* M32J89$J:8)(/ )DP; CXY1. Q<$HI\5C*9ZX]6F>):NS_&F.^3(.=[Y,>=;5 M.-KW7@2VX^E/60UF/8%)UP7@5*$IM#V1BVG1"./3LW3'Y"L6XPC*)L%K*F>% MSYC;)7ME-2GT>88&*HT@#:WV,YNL,5HR.BG<)HQ;O\2M7JS M0_2>SF,13SF>6LK);.)P@?>]2-KUF0R%OG_+/GWW!_2;'V9O?O/;V;O?_):U4/X4 M-$,>N -?)D5.?T?Z,T1);#'$S./(HIC<=]VCTI+SB"7+I0[N<>:%,0YDL2E% M-KW ]!@)CS5%2,(H+V.EBKV"]BGQ99+@@Q-D11$JZL_I:\V#^F8\/&FN)X/B ME<0@DO1!;.K 9\C#LH.MT& P4I0'($"Q0%_;\=Q>5KE-[_+3/ L,41V ME=REMK'!K/*KPUF9E3CV"HYM*DF7&TP@8HFJGB_96L2V]%/V)$G$:YC36XE>/>PX,S MUH+**;B;(%9SGB4PIRKOAB>YP7X%>]T2D\VQ"?$JKML>1>,"A_]%[#S6XSR+H\YY2K M"4DS),;Y$M=*?2?/6K)\'_?Z H%O1$3-FTIZ^MW#L"#P4^^99@/^30"W@;8;;QXV"^@7"\7]GG M1^.N%Z113IL#DBK43XNW,@"[PB#H.][ILJ48^E3Z,^7!>94'9\W2Q]37R\TV M2O88\^(3LBP%);58K7"1$-O3,"%'$:FO>8E4@"BG]Q ?26#4V3),6.)4*K62 M0U%Z)*], AS*$42"\VDQ6!(C#GB.MN+4$S!VA%YTM0.0B8]AA.ED8BSSY_LF M!DCR:,7HHXT< &W%"-:2!0;F3.S,@B-.%^6$\ZIT)\)0*+283'2IVE"E:\EA$ER:7,Z7-1@[\'5 /* D#<6\:V!\]LR$&_ MP&G 0F&><.R'.!TNTT 9A#M(U&'&3S>PRW,UU$ R[E49=Z@EIBT01!+XQS4> M5-H-$"J?[DG /SE=_(/PGN3?%O&>.H0G S[$+?[<'JGXDE21D%\F/'U3JLL&_#SE*'&0$4IWP#G_:IG&"_!<^MU- ;E1UEBVRB>&"0?;%L:"#.9K"AD<*!ATYCH2=$@>Q$&?Z M4$_#HQL=WJ]?-KD9LW"$#/(A&7(%55BHK??XB=7>C+-;;W/LZR-TU((6 F+3 MG;9&O[8^=_:BSWV?['"@%).G[SDSSR@?'7D!58YK,91ZE?+L.F8,4C\5JJ"M M8]LFSX5!D_&J$&2G-S=\J9]:DY6LLUJQ8C8\6VD1L2I$V>>W!HSBN>>Z5%G. M8+V]2@@.GV+.MK]?%DCL=''87Q'W@03_O>,%AGJ:\]M,^&)"2,X(*5-BKXDR M*53,:A33_S06LJ0MBM7RY6IERNIX^5"?_>8JZS/_LRH:I/5VMTKCJ^<97[U1 M_#'-&9+S3**[]9J/LYSP6D(> M/#%.RL>:L=JQ18@BD88OHZ/Z6G7SM/X\PFLD^^U@C%2]($QH&2->S5_C8,=B MUK0!*,S7*J)08*_Q*Z3(P5B"6Z,W[*R8!(O7,X;V<(>V#/#))U-*U&+3&0NB MUNG2E0($Y?K1VU)=C4^PB&&,+M,LW'!+K.('H(WE8GX G5\@S]!-QVJ^QKY, MQBDM_-A14@.'DDU]^J5S0);$9;[",YZOZ)\2,XI\H,WN*B+@N#^>B0[,RS**C,S(*,HC1F>9L MU75G!$"Y>?ONZ\=OD"1M:2L=C;[ 06L7J\+CS7&7(A M5=J)##_D<:U#.LB7,:9*.MA(:Z-Y>L4>E#!/[T4:]IVV" M>IX@D-/EZS;DR06]D!/ZXF 5T[ &K^!\J>CL'/"\>51)/S1"<"HP3X\<"IX_,Q!3&;R(U"W&&P6L MT#[[^G0@+Z=K$<>P HKP<0RR/2;0)VM RU>D60#^?6P;_X>9NOS M'3WV-YAS&T\T O<:X$FK M4+E4"J-M4F;Z61!V7!QOA!#1KH(F3_Y#"X(DV>DSHHG=%81%+B-*;+(C-]H- M;!]L2"&1@#07._P/[)$K2NC(Y\6'0>;D'SD4HF,A& S!:*?+M_IXW[UY][OA M.4E)5EAE/^"$RCW;=>A[T2"%"%2"UFH0#,J"NN(J+;N!/4?7X^("K[0P7F!I MR!0'NUKYB]?3ZA.ZUKODG(!?R0VB\6#$@J#2E*N8B_D"2-*7WM8]Q MD(+A.N0QAL^%VN0 M?6,ODMBKRN(L5J@8&6IOLK&1')Q+^Q)AKF0-LX8[[&9I2GY72C-5-XV7(@\ MZ90M5=Y$PZ^"#]&V9/_SIX.C"XJ:PG;=ADL M>7.+0-()%? ]>9L#II0UNDYC(/^F2A.E-SW"= M,OH]%HB9:D:GG A<5?E46"MU,HC-9J28'Z<+IT<^FU*QK)4RE.\XK\MPG*C/>Y4098L>6UZN*$C"9VE6O?*9\H":E">6E-O ;&G##-'Y MHF+"TEX.@=#JG+_4M2]91F)1IZBJ"/IT]!F""5HOEM(%J*QG74=3">()@\X- M5:*S&P;=.'4[QV)>!U,W7D'B+N B$BI$[_SJ6RBW,_R^V94X2F7=T1>H%+QF M0.IGR9A@>\^\5XO!;)TJI/3<"-V+PHQ91YF%=\#M-A!H+9":\K3U$9,THO MTL ;H#)V?J(H),A]N(/ZC2*.-BG:C"OXIU(M318=Y3$S1, M29$J(\/(\9V#P=A=H-*+O-ML/,*J3ZMK42R%QT*T>"6XS M;SC4R"1)3'_U>6(^?Q>&>;_I,*@8!Y4'DN_[J*^];<;+N@*$7D1[D49H7HE1 MOTB&[R84LYF,NTO.36.N$WE(?-(=E-_4+()N0&K 3O>F5S*EY+40:%$QTALW- 9DI^ M.Z"#WHUND;^.A0%RG*R]?+B)9.T-R'X92$.R.4K67H.APX99XR08:2I@ZY>, M-%_?)AE&O_EFQ'.^%[R#3MBP!M(D9HB0_(O/D8QA!/W.OB$30LWC.] M9ZJNL2 TXKYXV#VF/@FYUCC@!B_1/15^RA!@P,V6CKT&ZY3W1+! D?2>Z.]/ MD$3D,63F:O8";QM (;Y'G%.P#6]P# ")&M$F$5WOP_27*SK_ZYBN!KT4('!@.BZ M%#PSLGH9^LLNQNC[-S/T[LV[[[^XE5,/C%YH8=**K:YNRZ.P"=Q9%*GEZ!T] M]5F5(!)X(&-HK,,Q4A-#!-7_^/??OWO[NS^PK-QL;T$_!5GV'$0:3+8>R?80 M#MLC6U\E)4![+2;J#S'QLKY3F?T(F!WBQTT8XW?#((_(GXSDQ#EH@AQ1^4#+ MEV3TV@F*G-9K^A0RSSKDW6I2S@;/0FP M=QJD"RY8="S=''G2"@_-[9=BST-N5:HR+MEZ9OVP_-3CB*TGS@_,0*WDI.ZI M?"VH?V/]K9=1^E2 4^+T^^VV//(?Q%$U^M_Z9AN4&VTR TBD:O**Y3CB81E2 M]EZ)(I'PC7"LBI(.(P?L+S'9 /94 MW,=0:'AF0)MC;G'JI\194UZ%'9#QP@!TCF'.T74_XIZH3X(88M00)3?A MF6O,5B-,OW!64,4.=@V/86(O8S_UB-([8R^!0G&$JG7]V8B:.)CVU.O!:)8F MS2N6Y)D$2J"^B-U?)O?@"5JL/J4%T(WXKG2?2#5NJ QD-5,H+*:%B,@IR!)$ M8&9GR>IL!Q$9!="2;,(/NJB8H+7Z09-80+G?E?P593IY,L8R06Q&\#V=DXH; M))O4,K!&26R9T%*:4M9TZYF)]82-J*RGU[2>EA9O^9(LU\DNI6,O7^BKM%^N M"<;<^T@55OI)^(RA F7_T#1PN;/RFZ?)BGA7Z"A(#H/X.(@-)#W%^5"\U*B] MN,$QF*ZT<'CF#I(B?0D":OH'L:MI28+B M.$[_(8/+Z.'V$=,'%"11\M0[#*)WF(@^K(S=&\HTO]1EUL4QG7DB>,93U@L* M4'0.I_2NCEQBP)$$4XM6TI9XF*:;)HQR]JD4NJ MJ%R0YV)!*I'*EFXUG5WC\C7#5!D.^MDW*A>:L. D%4L'%F,QDP?GF0]G2QVP MQW"SJ4J.,8+-RC*?#8:K&7^>J?U">?E[^7XO0%1AKUT1*AWAV-_WB#U1SBQZ MMBG$44[=>E"*!>Y*J2LZIB9X^,JBJSQ=9/[LA1%HCE<)^0"%&9U=:T4)7Y%! MDT^-H?2QR7W^RUG2P_DZ>/DZ@"2UVF6 SO1D9SG8*5<]WV29S@O(]:#G&SC& MH.S6D,9YI1AHP%(T-C 0DQ3W=*@3XS2J,BFOJYQ)& &Q(9@^\8_3X[$BBASX M0"WJU@6&&:O.DK_,PC8%P4QI[5U.^QHA%>0T7J^F. *E48R-K#L!TY$2>49> MF5H8_UF]6K(]9C_@F.[(B.[N>0#.6M!RP;33+X!$4&4O;9FN_1"2@3DJU^/C M;,'KZ96(GPX[B@]/94?_E$;PY_7+H5* 3R:=0Z7,TV$.U307NPIQTY[N-Q+ MS:372X4_:EVQ$<&/[.=1\Y B.UGFMH$5IKHZZH$W=I:Y[36O.(<7CYD7QH 2 M).MY4"W4$ MW;/QLS8^.Y*B EI37$0&-W1@+^%DL2/FMJX9EH$2N2@@%U,2J M@/Y>M=5&]E=E'OSW3L33+!-(WXC],,*W."N@M9=)Q^H7?=V4Q5186(:<#,,? M5_'(Z9<'5089Q0LWA84L9<L,P4'INOK_;[+A1(,"KT \M6C8_)C'>?_3(+SB[VL5! MO_5GQ!"GAABY$1[ ,!R4;/4U-BP9W^HES$6@1DJ%"[#ITC_)CNXMKI6":YY7 M0-@10E]K)8"J;^C+FI\*XB8*=JP&'AV*GAI;R(S,*[K $0&?ZU">/#%YB'J' MV<_@$YB_S%_@OOV$EU'@/(P1CNANF<5[42^6<1U+J. 4B4D@,0MI@^"A)*(R MAU@L^R%S[M:J<@0:=I*R793-%(T!CJ]/_%$T!.G=729WF$!@),B3,+_T_;YG M=KXQ,TU54/*J=E0\$C/@HC:; \A(HZ3W.UDG8\Z;8;%FQ6IEQ6JM\M6:68(5 M*-(JF#K(9"Q\X66>>('ZY84H-,&'Y,F#8_I\:+)$QF/FT/RP6_R:+5]P],Q= M9$?7:CTD*P[!H(B/REV#KJK #+@0E0CJWUBZU*C"Y6,P1+(?%P2 M'%/:#4L?+HY#R:R(5G)LM(+"HZ$8O1IJ!E$\PG19A)Q M+4=C;% RB-$1<3W3G&X94W-^$,;[.\.;X MY.*^^^2?, 7$YC#%C)FC%Z@6NJD)=]*[&Q^=K1([:Q>K2CK:0(7#^+5"1;MJ M,0P<$Z(BHK+1"3VG"C'99![&&A6=?N#-4 R3H\- M+CV G1);9KSOB\*2&M+KF M.'TB2NA,DY*O"YP0>%U&ZG$WKLU[#A@.84;RDYJ\H95L9^,-R(?9R"54!*(X-GM"/B[*1]LUO+,%O+2N"(V710LG/W,U V"TN=?C8J@RO_7" MX *O,#V)94",C(?A]NLAXX7$>$@.*..$E# A/NC)+L(/?!%B%E18=]_BQA)1&G.()K9EOC:?^;20BK5Y66JPZ-T\O)[;,.JNQ=68D1I[$4"37-%/ MCI6T)37$R3&D%<0(3GKVZK$V)@N'QH?"7)8OR2CQL8QOJZ4/+7-="8;]?RT6 M'A.Y:G>8R$,C](^-/)>I=I18<7>$_L1G7_7/^T56Y!:RDT1,)="?.B<*LDG] M8/JMF3B4][F,8 M8?JBQG@0:=[>1E&V9/(?C0NH%RNQSBK;-G\-Q4=(/=*Q,\ BN*ZKW211= M)02^G)3- ^:%Q,0^]X54=Y+ X$WR4+P'RTXW)7R"'KS,WK!.HH!.B=< Z2EN MJB$A<+&H \B")V/(HK;8+$4:5O+FU5'^X]]__^[M[_X@6+9YE2:K,+LY/BB0 M$V 00%.<9>E=$=KD).>I:(P*LM+70.L;YIJ,=@$/QR?\M,PR$C[N,A9NG"4L M?@JRY^FQPFO_TU*:5+T&G445=_)!QHAS,DJR^I#U/('1_3M_*=QV2^/&/2\V$Q&N.(I0>X.Z["YU%J@POOEE7D<=M\5_P\OYN@ M"BE++.;)[EC*?J3 /9G2NA6^:3Q?>][NI M9EY;7G*]'O_,U\5V\*RB? XCO*O:[)@2_'",Z,1XNQ=02K*?/WJOX GH!_+) M:5@TAO:>:4E8XX3&"&B\W&RC9(_Q R;/H8\-1T$4B;2&Q0I @I_B\%=Z$K"7 MFI58&;+>M9P1$E-J"';,IP7]BHG)I$E>G6:<4,#)K&@I9'2WV7B$.35-U6KL MUWBYQ9D.0/HZ%L B!8#TD9L'S$%&9.U\& 59^Q1YK=J_&/[U5C+\"(6>):/> M"(RR[01 8SBX8,"[?.MRX[J*+29QQXZ6MUC 'A\)\:'DZRT2F$HA?3G^FDUQ MR3KO5%MZ3(H88!.H&@??9V^QQ%9+1\B(LL>^-IE&C\9A\P%_ IB\2_HR 8S6 ML:?2)XX!F).9ZG35^^(3!^>S.&?F,YYG'*=<;NP'+\+I_(E@IFP,XLF?9VC# ML=!S2,(41D&>',:66]\&<]+\GTF ]_Q(8-113MZVM]\&2@&JJ:BI;)$?\ ,L MB0?^]8?]YC&)C@65X300)S+!>9:0-BQ/EEVH'W#\ZWZ#SQ-"7RLFNPPB_@BR M]+[)Z=J2=X;B0&P1.7.%GFVA9B@.*M5GJVQ8C*KAE2"80,8.@UY/0*$FSTK[ M!9$&8J$4I:SP80U\73GIMP2O<9R&SYC')MWB;+%:>J_'WUD%11GN!)8?JE12 MJB?!BFJT*O-C-\S,>N5.9Z&]^D0*4\'.+VB%.Y2,M1@D5RXWU2]]I%9CRWJZ MR##3;ZJ%-?FY*P=5=?UG\@%8#Q4%C,);;].GYA8#:00:UBMF]9ELZ9J6,QY% M#;OSR((PM#9N^9!9K$,HEI0V6A".!1>(0SK/:3TI[LS*YI;R^ RD+[+/2]Z#RYR8)!U").'97)TYOXVQFB0]C2D ;F26P]$R_ B6V- M:6".U.W6_(@<"C1&8"6DX7 MB?D69:S8C+_(95=W90B3'TZH]WQ M8A($JT"V(OM%&4+59XM13I!1?7),(R-SXI>F[A%?CDA_;1E4M/C.3V(?;[,S MOM"B.VPGM=KI/ CHNJ3G]-<%628O<;YF26,SM@C?C3[Q6D9,\5AR\!.5@R[M M';-2.VH:V#"UG0(;^6R[O-3Z,>G-'C##)%;09N+F]*/R5F_K+ MH 4J*YTZ.'XJAH!# 1>I!APV;;G#J3AFVPIFSD4(W,+JLLA M@J,4I"+3FK3U<&%"TQV:3F0ZNAN2-&X':>TZD$+!TT\IZJ5W?I M2\>K_<$+8\C'7\00%[98\;!GIL7I5KNAN6M&DB1X":-(.VOQG>,IEE^Y>U!/ M%RMZ;+-\?=V\&SLXW-T2"C3'4N811M5];FCF^GQI2KO\1'4^?A)"D0&?-N4: M9M=SM)602T%*+3A.#_QMDGJ1\8WOUL/QL[RG\R AW,EZ+5'_J?DRZ4//M7@E MR]DPC'BM+%1J,:FS,']MBNI5[>>AII/+MVL>QSL DY> CPFANXH3)YQ<)40 M&50\!S71!P_'$Q1Y+$Q-HF[-2O$.U=Y(*Z-,:B_(S/?V#2!;.G_S&I)K\LQ" MYNO;$7\-$X^\6,O?D:1<;GNHS9/ _09[$$!EZ/FH0 '6-G!+>\?/4GDI! Y( M[06[VF4[@N5KIGN*!Q-QO8%[(@!2?E8XS)CM+@8$TY!'3^8NGD$U\ZZ#NC8? MJF^K6>+0-)O2Q/EB=YR^VGA25TK%Q7B/ 9E)?@D&@[?METT[#==Z30NZH]YX MTMS',4LR7HE#:>D8*+=P>0_F5S<:9RG/,BJN=)4+HM.W9QO 4K54B;+/*&IJXO=V:G8UL&7I3% M:DEOV!3P!F0M5>WMW-IK.J?=N5EAK+=R/>U#2KNL">YLP&\D,A4WI IQ>0_! M'J#B=/!'-O1S_78=*\4*N*#\2-\]YD?XX+ZLEK&<^G;I!Q MN"2A%\U]G^R\ M"$21"4-9Q42_,XV_';%:T:(X0*4KTJI4D6#$Q':<'$7!XJ$-$ MWIQ@3Z?UJ-\Y?AY%V!US".12Q3V.(".%P=JQM7U4A(K&N*1^%%T?1H6^T*). MN+:,D/"9+B=5_GVL/_.;6TX@>.!.%KR]J,B[QD:NUUSL5:$72_L,V]':E6]H M?ZIJ2Y<,#O8E/*] M$>20JM,N?>'<:,=3R+E%C@%> MA'9E5JM<>\ JT?P7/,M'Z__2-W6I$"Y?DN4ZV:54#KZE4G^&<=P% K"F+QY) MQ[DA1:3$W-%KUHO^*]R:_0ZZEA,0C+A.RN\U5E_=)!S5&KH.GL D"U>A#S"D MB]4%WB9IV""9-C1W?3X%_[T3 8[+A.X2IE'3E?;"X#I60SH>J_++/?[7+J1L M2"1Q_G 4O=PH#]D>TZ6\@+?"69F?%@CI.*-LCM3>U!!7G3 MDTE)TO'4O;=KM4?Z9L'PQR9'7S X=4#S:+!I=.GG_-Z["B-A#M/?=L7WTWD* ML&VNHN2ET:+4U'Z":IW.$SM?T3-+UG'JX](M$7)XI MHV0\X>2+>=@U>-_T1 M;FSH6G^MRR65KZ;SEI@K];:\+BTE?ATRMWM,PR#TR%X)-#&IM<;&KIG02F-U M"]9CU8*5AVX!#DDI$%^$[!OM959&F]*JZ#6WVR7TL7YY8IYF'D@"PQ.T/^'F;K$7K;0J!ENZFDM?,T';#";E5SHQ[@@C61<)T7C&,ZS6@>!_-@$\8A MW'_P1$0TD-D\T:FC\[=2ET.C7 KR?5LF EKY*B',T)TNZ<3,\9^#$';I?N>! M.45XA\'/:&KGVI)&]9Q*DFDM-;7\@=*2'CK1#MX\F;'[@22[+3Q)R$BFQQ$] MBP.A:B3Z/+0QQW=MNX%-R]T.+IFOG?/V-5>W;+=.=.[M^BVPGCC8!DMJ(9.DU(=?* MNS!-+I.Y3R4 0B>5T%V3[4'AR8 =^FDM$?SPWJ[W7%->_BU^85\=GM&?]YQ* M@L[[??[KGT.ZV:@&L&>KN,Y6FVFDS*.YLRRDJQV9+-_)B=;[XZ?I"AN]TRZ+JWM6Y\@,N M37).=]-30DHRC:')5%YLF8G6^%K+1DZ3BSP QT[%5&I;I?RU\^T@C#EYN4OP MA-6CIYK:3D',*/GK;I-,@49NU*[Y=7M0KB] W]]M=NQ69D8N334YLYF\%:NWSUV5Z"S.=%[-K0 MZGY6SD_MI?=Z'8"7C(6"TBDU!3$9&KNWNZC('S<)GYM):6IH[MKO4$BOQD#5 M:AOG2D=&50@I^\9&O88%YLT+JT M3:>F?349A(R-G9]VU43_#F]1:R?79]VQH6U-11J,L'[V1IO",@Y=Z^*GA%Z* MS.T#HJE $AK4"W+PZ!-(T6+9E2%/OFE"OJ^V%TJ=V_'?LYM<#)\G0<,3B'==&A9'?JX/J0 M*D*XF?]2)LYJCQ1#6]?2+%6 0IZI![(I4ZF?<.R'..UHJCN,@NLGUK??$.4'?97Q,6T'->B262Q,Y)K14%K MO9YGTHEM=K%TZ>C:GUI!/FJ\_8R-7>LV_AH'.Z9E:O4'I:Q)"HO.]UEAIV)0 MQX#+.H)OY5OW=:YN=8-X=, MDR[D&Y [;E9&L>U1%38;1IPX:J-7!\8QSH,BU2>EC)X0Q!W;\W188#E MAH$" ZS)[7XX%==2<#G8QGR1:AM.(YC A,MQ^2H""2&TEOX7&'2W(\@XMS>( M-&AVRR\(VV^5V[.MK?,LU>XUH*Z2W?'%,A0:+O'&I#BF HGI(*B-#5W??'U" M>OD)7T_0%2^6&CS, XI-1H7Q9C"%( TZ@C$P@W[GU*VOU.9FWN TI3?Y(OY MDC15P:VX#UP5B>HA.,-0=+0-P^.PGE-QPW$<%GIB*39SX5D+%G%>(Y VN$UB(O^$HD!IH]H_ MZ "?P6(9J[@-1MRU'$5/QU( 3N/V,+>>@/E$7L(Z#YJNS;2UCR8UL6/7:3"H MA%UWX$G3^F0T^WX:O6M-7L:":<9=@ MV*85.(B ZSU0,K; R]H>3@6M7$M)39:BCU[&9(MV9_@19)QOSCBEATC@=4RU M:FKOVHVAB410;PXU$D':7^JSL6;E[G/S V0[T&2F/[**V6V5QT_EH;S M3=TMWKI+^ZGHN#R6EB&.O3.[%AN:.]^&6CF9@V3V]9\U4)G 5C3]1-@ MI/2.U/WZ+4T=>E<^AC%8@/4E44I?3FV5H3:(3\*M&LK21^K;T#I,;=V[3C,PW4-,R\U^%QM MM:.:95W?C%5?EM'7IV_IVI(&=D^Z[$D9!KG!P]WR_G5_$YAHE$UW& 7_^*#1$OE4:N);=U0C)8 MQJ*DB#ZG0]/.:2Y!;CM52KD(>/1E4H&V35EX'ONN]$[(X]CL*;,SS%2*];W0 MI[A?KJGR>5R]O@[]78MFA6D9--(6$Z"YM?.W=$"# ]VE'W&V3H(D2IZ:%37[ MPWY."ZM'7K.^L/IA79XQNJN:X:<$'.U/?]$?V'4JWI/W>P66Y(K@?^T@T[Y# MT1=3MU-])63V'+<5SY^],();[RHA'P!X8M#WH&4LEYN_NG?5(F5P(BX3/GYJ0?$!;3VL/+6VT'/X%'GN0 M/I49\/ZC1W[! MV=4N#AJFKV_IM 9;+5M2Z.8I/9) TA-(8#G$O( !$]A?BN6E)F8-1]KY]CRZ MSOS[?9.[:A#"SHVQ[$X"K+-G3"5H3P,IU]9V@F9RG37_ELK!RQ<S]2?FL/-#!6.HKLU/:'UM9VJWT_%+,(M MXIIL1IZ^V GOM2.-4Y7FV3\_\>A2GF9B+KHQ$/U37:J;1KRQWE0=+PO;SHM5 MQ?W0)7J^6\]3?>KU&+CZ&6AMD G>_I=4KLHPN[CXK)<)MXUWO?*-!$Y\AS"C M;UZA@,%VV-@CFF$FXLH%B*%N3MMRRRD$(BD:50'%;PQ"TK9VC+_RESMUNL6G MTRRM:09::^PPA2.B+=MJ:BE6=5O#'<%;+X1"F9CN7&EDD#8&+O :'LT1E%R> M3N_OPPCOK][?TZD;CJ5Z$]>;K"4CLPMXKS$4=##BCA?I;SN/9)A$^[Q&BA(; MU2BM=NOI>@\,YX*R)ZW6!ID 9MQ5F/I>Q $/_5WI%&MH-D$QVX3C2*6H/K8U M0<)U_'^EG !HD+Z.+6U#U\XL'F;9Y(8JM3C5H^2 NIXC>7H;1W=>FX!)0EH) MJ*'P4H=N+N4GQ?62%Z(TR%'FIJ?Z M2ON?LDBJX2 E]:OE"5D5Q?3J4Z1X0"B[$7^_-=H&# M"$R0V3R\]C 6*]TF9TO(14Y1CZYI7W;O[5"3.$^>]>"5M2]='\R'H+^'S[V2 M]22-4[W*96H0?7!,_TN9F+5<>[$LW<62?Z55?=#+_<"Q7>^J6@W#CA?\-*X; M!GC#@4L,:#CJEZZW'I'8'>!A[L9("W=*O2O;?K MO0+",P>:NMB1/)A"8"(I84(RA$A_B!U,Q3';GR 6ZI(^B@W5]+5/L-S":9&W MC(>ORL@N*-20SI$9M>#06WNTFF:6X])JGUWGIF(:Z;Q$SR >[Q-R$'1,)TZ MNL:\J8*JS7?9.B$F!)6&Y@X%]27QP%+RL-\$I$Z[=J7+@^%#SC^ESHXD]>W,$OZ&I^[U>A=9N*F3=T-SUB60[:OY>XQ=7-Y MO/\U3%,>W&2!X91O:3_U(\88$Z(-3AP\\7:XX5T?.W$6 M!F&T@V0?4=J'JIB\TB8.>%V>%UT[%TS^YW<%CS?TMS_]F_R$_@-U>__T_P-02P,$% @ -H()5U\3 MCX0V)@ U-(" !4 !M;F]V+3(P,C,P-C,P7W!R92YX;6SM76USX[B1_IY? MX9O[DM2=Q_.RV=W9RB0EO\WY8EN.K=DD]V6*)B&)&8I4 %*V]MGT]'3QW+KA]^?'01.+B,W68 P/CD]FSLY>7E[?>U ]1%"0Q_B!Z MZT:+LY/3TVSX"P@<\N\GETX,3G[Y\.[#Q]-W/^/_F[S_Z9[=+^_>%;I%RS7T9_/XY/?N'TY(+_SM, 1!L#ZY]D,G='TG.'G*/_K? M)S>A^_9D% 0GCZ07.GD$", 5\-ZF8P9X!K\$^31>D?\+?3S;]&*V('\[S9N=DG\Z??_A]./[MZ_(>W."5R-$]-L" M'\F;OU;:OWRDK=]_^O3IC/ZZ:8K\NH9XV/=G_[B[?:+S/,4K%&/4P)L__^[D M)(4#1@%X!-,3\M^OCS>E01; \UT_C%8.74^R .]^_/CN+'9>HS!:K,](I[-' M_#_?.;,\,&!N-T5+-"9=R.9[S= M]6_"&$!_L=ECI96XS$B]S>H1K$"8X/^XT2ST6TR&/4!O<[AV?/BK$R3@#CCD M[Y15)*?!':.WF6#=MO!C^FVJZ? F'\ZPB>H#V?D(C-3;K*BZ.G>H5"^66+S; M" U_D'[G(J_;10;H;0[W(";[Y@. 3W-L9$A.@-';!#W\@'>,%K(B,:)>G39Q MG@/IV0F,9()^:S4WX?$TZ[I6DQ,9R@2I&WD>W?=+_W@)8L<7.Q.I^HA&FTD= M!*W&[F[F#6J$N%"\) #$+H=PC85OM(@2ZJ 8+9

O4QN=NNXVEA:5$,J3,# MB>'4/R4F:$5UC+7?1TS 8KO$U),YGGY%8(00H"T?04".BK>8)<"M[SS[ 9X2 M$.2M/FDP"\D[)TX@I7+C90EG_8'8XO-]Z#JZ\S[O[KQ[R**"H?NS8)+%PH'K MS,LT7E+Z2 0$'U6V3+ZO.MKS*YK0J%AC5Z_DCRU%I-78_7@-\0F1KE[H CJWPDJWQ*L_BC3Z$]1M M^:W&UN6%4#=M^8%90;!YS?5W\^Z)B<'<()'K*&F]'/GQ(SPISSRN>O F=50 M4_Z]-VRP"/@1YB^/I!AP0"JWZXV\:RRR3O!/X,!K_"^(0^!NRYY)3/$1([+8 MMG,R)] AR2M/Z\5S%-205OZ]"%@F0K M\,#K7\&:2=UNN\[)NT@@+'$Z6VR937O"\-H/ +S 'YQ%D(U@N55/I#TMG" X M3Y ? E0GJW6M>B+M:@'@# OC%QB]Q'-BZ#LA&[WZUGT)"3Z[1R$U'ZD)A<9) M3)*DB"YA2PRO4U_+/P=!T 1MJ5&/(G.?+)X!Y,I+UJ0GHB;.ZXV'%8D_]=-< MOP8*6>U[(A<;\IBK4/8?; F#]TQ2Z]IJ(_.#!)D?>B;S O]Q#"?12]A$9*%E MOR32])\Q?(#1RB=YF@UT[C;OE]B'".N\X/_\Y47D-9):;MR]B4&^#('#(*WT M<^?$D/SBX&$>A6R]6&G2U_:7VE>/8!E!XE(B'%5K^7.;]W9&^5OBP!C 8)U2 MP#FA[+;L[Y".S7Q$O3"--%::]K3H-Z$;0?Q!NK%1'7)!XH=PS15D?J_>2,>+ MZJ27%)S8R?B10W-M\\Z)?0(N"?:LWW]XGA#/5@V!E2:]$77UZLZ=< 881];: M9B7BBEZZ$2P3ZD W'Q/_L>(^+%]XR%J<+6G^]ZD[]P,O[SV%T:+.VY9_+:IQ M?IU$T /P\YL?/I'[+DOH1V0BG]]@JR1!F)!HF7I'R6]@"C S>+?IQ)DD4OHP M$R% 6YH+Q(Y?+D/BC^\.#PF&2S!'Y/WA(E+Q0N:8?#AT3$INSQR5CX>'RHZ7 M-4?BA\-#HM[!FP/RQT,%I.)4SA'Y\? 08?NQ.\[Z M'(\#M%.Y$8(,EQ\/T&H5"4?D\!R@"5L7],CA.$#KM1IJR<$X0*.U(<23(W.P M1FQM-"E'Y6 MV=K@58[* 5JSS%A9CLG!&K.LX%P.S,%:M?6!P!R6 S1NRV'' M#(B?#M":K88\1^,SUO=,;2&TJ[O5X$6GJ MH&>*6H).9XZS3/,V0!"C_%^V"1S9/VRG5+C6C^WOM'Q"_8TEJ:Y[9J&TF5)V MJ9Q/_$XC#6367#%LPIO900/Y!<\RO3/*(+K23!M#9-N7$%_LMM5 =.$6_RCT MI)E%N+O>J8DM"J>##LYWT)S49<#_(5BNG "02@UQ7CV%*PY"?77(B.L2VQ<] M.&M2):D^$;*AL0ZR-S>4'QS?NPDOG*4?.T%!Z["FT-Q1PW2^1)'WX@>[]Q$K M/VL@[3(SULBA:0$FSFM!*.\!BU.:>FF8R ,$2[SD68D(+(SC>(YMW*+>9TQ& MI*?\A*J7\LF_$!F#";:-2WJ^O1^$DBX26*J%4E6H3I^Q"2A%@ M)AE/,=^P-9'4*,J6YR9\@)$+$"(UX?%9BFCU2[ "0;1<,%:DJ8N&1=CEA_LH M=+DBP.F@PX2>1S"> +BX"5< Q:7"L[O&/V 3_"TK@BVS:A0LG]1G6S M%:W]%"9R^C+C:")\)#'#AR#L.]"O_';* KIOMT^FAP?#>7!:WP@K!ZZ-OU4 MTL3V^TI;;=J#JS9,]-*T],YH\_FW<0N3< #+]YH% VP+C8C[<(O@5%VFEL-3 M[XFO\DO%"V@Y+K*^W2)B/.>IY;!Q_?@E01/ST'8!UPK Y\@4P)H=[2599+B M+>>JMEN=N!!G +ZW%D 9_27BL;<6].+!9$LAV3;Z@BG"!\US M%V>R%)=]^$G :VXK;**QT6W] TOUM2*#D9%^T0=XAE]%?*!+, >Q[SK;=]N. M]Q(UWIC#2S*&E$Z/QJ+S!_I*\.KKOQH MIYY0\VRSS:_;A]OQK_0X70B6DC#I4&RU-+"[F5>#><9JK>46TPJ$";C&O$Y\ M&82,O_OQ_")!,2817KVZ04)8E9S$\/]Y['N(;4;2>0$C?R"]8:W8[95=I,Q# MWX6X-WEN'','EI#LLSO4B??3<84;A!BS -,R\A9^2*O]DPI*]5,1[:635[9Y M&TU<4FAI G.+,K4.8FEM+8#B%#+J.63JRVI+7;>&[O%65UYL/ELW=-(PC7L0 M-_)SN8T&(O/H>GZ&.7>0[S*(K6]K -&7?I#$S,,TJ[4&PO\.2 0(>*,59M)9 M5F!T/*T8K+Q5D!O#G$EFL(LZ$61'&8* ?WO_3IL^;+K;)!Z+';HLATN"VSC(6NXI%>(I MX;.OY6"UX:BBL=*)%]F<2+\4+]6__T(D:1C*0/NYR-PTLZJ#+I/1^@JKJV- MS7T\QBGQN>5P'L\PG?GLZ8GS6QF,2'% MEII2F=-&6BJ,9A2DZ!)^C$)Z_^?59]9:YO;1.8DZAA'/)C?K%8T=<"^CA>.' MK&AK;5N=*X%E$=S@/S;RT+;AL;ZN1%KX'4B?R63%@';::2G>+A9S-B*JS*A: MQD69WT?+)');"TTB!G44[6>';KD+XBZC.^?>^*S/"E$ZJA8"UL&[*'@Q/,+E.)%] MRQ.L!,6)&2!4BLMPI:G!FW%DHEZ<)9;?&1?G M1G%?BN6025@+RQ')^]^(KK4NHBD]*P\L@BT/601CE 5#K. M#U&:A#E >&O=89VD7Z:6[E7H#0J>&N];)SF6=>B8G35#'D:[#J*7P528P;)/ M:'Z T#F_#JU9T[X0Q@ X7Q-@@K M-KS'B'J>O)_Z,2><6FA@CIRE#]DHD#/>0)UH_$L?+2/D!.-IZ3$>OE:O[Z0[ M=8BXLO!N&8#2L6<2J5&,G7Q*5Y3X?-C;7]Q,= MP(CI/:2O(^:O2=:^DB@\5:'!S%&G-7;OWH:SELW,6>>>>A>?A"%@/L'$VNS$ M!] PO4N 3V:N3W4"_G, ,C_):!'!V/^-IUB$NBK;\*H"L?.H=/:VYJ8 0"88 MV>,]I?>?JCNCPM'-$<$:0V1O2T9+W4ML[9*]>1P^.0'@63DB/8S8&>3L?_'^ M.BZ+3*? Q:>3_"SRB$_5XY"P$_E_HMQ6> TP\H]X":#OQM@0P3]@"2K_0Z$E MGF]:8BDW4K_ *%F2%TQ]Y-*7@; H;@L$:_*-!=&]XVGE :VJYA;MJN/.S#ZL5G]9>,. 1:9.&9UU(:=?(H8&LQI5 M8[M2.3"(O_VH/1#5/BRQJ<2W9U#@4)(@.0&#G3B\M!/*=@CE//BE;)E]?.26 MP]H^#K3S4O3&"7^8@ DX]&MU)<.=;CF(7;KA*[D3-;YKR^&5]WV7BS*V.H2*SB*M[+;\$H&;_[D8?'R;T@I9 MFY"/4D!-U+!]V05B@2C+^;>=E: \/F8YRHKV.*Z18?EU(C5[G R['R:@DCN7 M3"#8\I+W?>U;W."T4HQ-M Y4'VN;?'ZVBK_LEF1 ;-OVFXUJMCB9<'PG@!Z. M1I;+)+"<>V452M^Y"IV\DV(.K_<*?UO-K?02L7$E2TQ>@F\_=G/5V-3;M()+ M(!Q0[N,A&!WW; FW!!%*(*#/D6A:F/2+!>XF"W4;1J* M3#>\C=L@RZ*]M=1JYI+6),7"W77+L>0"2KR+?% 2?.WXD%;%NL,G'?SWTF44 MTX5X0_QV/DTW9[E=-(AK'?XWX3*)T9; )IF5&T.WX(HL6E%:)1&R7V1)CK.? MNI_PN>R"'LIF -LA8#""RYF"L#TM-X:FEV8:"6R2;(F MY;#OJ+JUA1KF*"5?[8OS@>B303X'*?06H?Y'!ZL WT<6^20!9S764=-BAI4GTV.VUBUK#(I1R:MBSME_( M./&FARCPAW1*SO*>297QC/*FLG#L#AJ$#YM8/AI/=XA:I__;)(F"G;4M^258@2"BMX(4ARRYE$EM/8RZ,CVXB>\ZP03B M'8+>)W$"XF_*+J/F5TM$Y&+_\32PU2U " ":FBPH(;P>ZDKC+98.20:^&/]Z M!(G>&B#_2LJ37*'8Q[8(LV353B,M5;=>"GLNQ'96$KII5%!F MEY >1E^DO)"\(#:WYGZZ#PO-AF/QN"!JIUE>V$ .-+X5:/F]0SFH!*U-RR_& M2+*7F#%K>>Z_'&8<6[F3)/VAX=3>>N\BS7Z8\.UW<.@B4WYP. J=0?K(BS<> M*>DS41\W*0]FO^"9\<MA3<.,76D6PY+CH>04C^Y<^ E:,ZR'OZ$O: AB,(BMW3IP0 M8>4"LL](NC5?ZRSK3OG-T^QRSWU-._T2SU MQ;&+[S)D)7#$E+2"@;7"<;58!M$:@"< 5[X+ZB'[TXT"LN.;'JTRDAE"S2?VO-5WM\1/<6I?X^A0J)MMPN MZ!)TY7K#\L!T/P*PCQKJ(\IM; +VR//\=(K%FBL@=OQ@*);>P=0"R@/%I/37 M-E:C"]%J^L<'3LM=*LE!36'&I;#\CUV#P!K.<;^4W4U0&6! M\JU.ZLX/ (JC$-R!>!YY=+<53MNL[:Q%U5+KY 'S^'H"'6RSN-1V.%\7?QF] M^JRT88D!-$_O,EHX/NL=]IJ&RO:,O_H( ?\!VW +QP5)3))X+J+;V+L#BV< MZS:1IBY&I"R+%2JKZV $^3LBB+4-N(G!@LWHP@,HXYPO(/P-V_L7$5Q&:=53 M-LLPV^K>0.4T9]GP$%=.EELA\GJ:!62N!@\(L++FWUAFC7K9>HB:-#H_[:A> MC \.-'%M)KX#6>XK$Q!.]M9GX0&J(:UMZP@LO\A 7G9;+F'T2O-,-UW'T$1 M%0MT0@<9UG'+OMPXO%B%!(::###^'A=?^56 G>M&]?]: M:_TJ&5(#!'=8\:_O'/@=Q-=)Z/$GQVBLDZW/UYL__H\/(/$0KF^)?Y#C+1#L M;$@Q7%2ED>M$D!MCH"JIZ9RL]AO&%/,8Q?G>2R?'2N,4ZJM7:@O,>0W!OQ,0 MNCP'GTA/AJP(VF@IL9GP MNNJ0$0!C?^J[Y!+:>'H)EA'R8^Y,>#V,$?(:0U]*YNOZ&R(Q'Z0EYH,A7MX] M;\3L49HKG^2,7^/L(LYSVJ MY6C>:3A3DTE4>PX^0MW>+.*9!(>"J\I]Z,-1_I7:ZMQSJ^4U M+/O!6(T"[Z,TIK&U6TS-]4^"S>Y@2&4ALOSD0G'(2WT3Z&CJ([1#?VFW MPD&\E#U&XV$IZ_,U4:G<*V$JQNYU*_W?!\96BG]0=W<81E[BQ@5,V+=YF&VU MJ"6L3JY>EWZ:AWV)%?Y[IB*J::H,P"(:V]1Y%H2N/^;LW,!@85B8Q]#]LE'$((7)R"[GL0F6>RE#.:Z M#UUEIQGN=B[;VQ#HK["ZQO2Y8#Q-JY%,HI1@B85@CV',YFA&_8F(5!/ TGB= MQ-CRV0AC7D^F=B]IZJ/+MR-T[B9^FN*)U_ZXC+I3=*D$).\D:BFH0H=9 E(# M)UH*C_BQN:F6Z.ZV9CE@^]=C99P:+<>-?UC>"");8BW'1^FIO+F$D_2N8BG\ MTG8(<1=8'M-4;H]4 KP M@5S(PHJ*&A?(QZ>P6U^0]_;[@CD R4U6/^%_!V1_ MX(&R+.#)]&R#FO&')C MI6%)#V-()@G96(B+_1$SET3R2*F;;CMM[]@@:U^S-/C2$6[IQFJYBUY?5)7HUY^C_XI$_U3W#?7<[,^51V8S\GFAEPGJ+DMHF! 4Z=_F8![ MS(>3%Q"LTL X\Z9FV^$,GCI9FLE+M.>,\U%,GRC^ILRAGC^.X9.]CI*]I+@X MC.E3]5]YSR-F]K7T,LL3.!=O;JX:?J03IMY M,L?2[C96XN^VY4@A:G$=O:L*L*TUYXX^6#7(;JS%HU-6(:"I57ITTJJ#-+5] MCYY8A8A2D]/R;,#>$-VQY(]^6C6P=N2OM2B&T/)HDL'ZLQ)8/Z6PAF!&LQSM M +8IJO7)H@C"%I&G.'*_/^,)8\@6) LZ73-#RV]*G&8? B>\=Q;\BI [C905 M6,$6]F0>)<@)O'Q)0H[Q#X MQM/":_)

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end